Pyrazolo[1,5-a]pyrazine derivatives as BTK inhibitors

JP2023549360A5Active Publication Date: 2024-11-15BIOGEN MA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023528245
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-13
Filing Date
2021-11-12
Publication Date
2024-11-15
Estimated Expiration
2041-11-12

AI Technical Summary

Technical Problem

There is a need for effective inhibitors of Bruton's tyrosine kinase (Btk) to address various human diseases in oncology, neurology, and immunology, particularly in conditions like X-linked agammaglobulinemia and autoimmune disorders, as current treatments are inadequate.

Method used

Development of pyrazolo[1,5-a]pyrazine derivatives represented by specific chemical formulas (I', I, II, etc.) that act as Btk inhibitors, potentially modulating Btk activity and providing therapeutic benefits.

Benefits of technology

The compounds effectively inhibit Btk activity, offering potential therapeutic benefits in treating autoimmune disorders, inflammatory diseases, and cancers by modulating Btk signaling pathways.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022104079000001
    Figure 2022104079000001
  • Figure 2022104079000002
    Figure 2022104079000002
  • Figure 2022104079000003
    Figure 2022104079000003
Patent Text Reader

Abstract

Compounds of formula (I'): TIFF2023549360000758.tif5974 or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein; and methods of using and making same.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] Cross-reference of related applications This application claims the filing date benefit of U.S. Provisional Application No. 63 / 113,515, filed November 13, 2020, under 35 U.S.C. 119(e), the entire contents of which , incorporated herein by reference.

[0002] Certain agents that inhibit Bruton's tyrosine kinase (Btk) are provided, as well as methods of making and using such agents. [Background technology]

[0003] Protein kinases are a large multigene family of over 500 proteins that play important roles in the development and treatment of many human diseases in oncology, neurology and immunology. Tec kinases are divided into five members: Tec (a tyrosine kinase expressed in hepatocellular carcinoma), Btk (a Bruton's tyrosine kinase), and Itk (an interleukin-2 (IL-2)-induced T-cell kinase; also known as Emt or Tsk). It is a non-receptor tyrosine kinase consisting of Rlk (resting phase lymphocyte kinase; also known as Txk), Bmx (bone marrow tyrosine kinase gene on the X chromosome; also known as Etk)), and is mainly expressed in hematopoietic cells. However, Bmx and Tec expression has been detected in endothelial cells and hepatocytes. Tec kinases (Itk, Rlk and Tec) are expressed in T cells and are all activated downstream of the T cell receptor (TCR). Btk is a downstream mediator of B cell receptor (BCR) signaling that is involved in regulating B cell activation, proliferation, and differentiation. More specifically, Btk contains a PH domain that binds phosphatidylinositol (3,4,5)-trisphosphate (PIP3). Binding of PIP3 induces Btk to phosphorylate phospholipase C (PLCy), which hydrolyzes PIP2 to produce two second messengers, inositol trisphosphate (IP3) and diacylglycerol (DAG). These activate the protein kinase PKC, which in turn induces further B cell signaling. Mutations that impair Btk enzyme activity result in XLA syndrome (X-linked agammaglobulinemia), a primary immunodeficiency disorder. Given that Tec kinase plays an important role in both B cell and T cell signaling, Tec kinase is a target of interest in autoimmune disorders.

[0004] Therefore, effective inhibitors of Btk are greatly needed in the art. [Summary of the invention]

[0005] One embodiment of the present invention provides a compound represented by formula (I'): [ka] or a pharmaceutically acceptable salt thereof, in which: Het is phenyl, 5-6 membered heteroaryl or N-(C 1 -C 3 alkyl)pyridonyl; X 0 is N and 1 is C and 2 is N and 4 is N or X 0 is CR 0 and X 1 is C and 2 is N and 4 is N or X 0 is CR 0 and X 1 is N and 2 is C and 4 is N or X 0 is CR 0 and X 1 is N and 2 is C and 4 is CH or X 0 is CR 0 and X 1 is C and 2 is N and 4 is CH, R 0 is H, halo, methyl, halomethyl, cyclopropyl, CN or phenyl; R 1 is H or C 1 -C 3 Alkyl, C 1 -C 3 -alkoxy, C 1 -C 3 haloalkyl or a 4- to 7-membered monocyclic oxygen-containing heterocycle, R 3 is H or halo, X 3 is absent, CH 2 ,C.H. 2 CH 2 ,O,O-CH 2 *, O-CH 2 CH 2 *,NH,N(CH 3 )-*, CH 2 N(CH 3 )-* or NH-CH 2 *, where "*" is R 2 indicates the point of attachment to X 3 is absent, CH 2 or CH 2 CH 2 , then R 2 is the bicyclic core or X via the ring nitrogen atom 3 a 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle that is attached to (“N-attached”) 3 is CH 2 ,C.H. 2 CH 2 ,O,O-CH 2 *,NH,N(CH 3 )-*, CH 2 N(CH 3 )-* or NH-CH 2 *, then R 2 is X via the ring carbon atom 3 (“C-bonded”) a 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle; a 4- to 7-membered monocyclic or bicyclic oxygen-containing heterocycle; 3- to 12-membered monocyclic or bicyclic carbocyclyl, or 5- to 6-membered heteroaryl, X 3 is O-CH 2 -CH 2 *, then R 2 X via the absent ring carbon atom 3 a 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle attached (“C-attached”) to C 1 -C 3 an alkyl group, where R 2 is absent, then X 3 is R 4 is directly connected to R 2 N-bonded 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle, 4- to 7-membered oxygen-containing heterocycle, 3- to 12-membered monocyclic or bicyclic Carbocycle, 5-6 membered heteroaryl, and C 1 -C 3 The alkyl group is R 4 optionally substituted with a group represented by R 10 further substituted with 1 to 3 groups represented by, provided that when the N-bonded 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle contains two ring nitrogen atoms, R 2 Optionally, the N-bonded 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle represented by R 5 N-substituted with a group represented by, optionally R 10 further substituted with 1 or 2 groups represented by A C-bonded 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle is R 5 N-substituted with a group represented by, optionally R 10 further substituted with 1 to 3 groups represented by R 4 teeth, [ka] and R 5 teeth, [ka] and Each R 6 are independently H, CN, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, N(R a ) 2 or CH 2 N(R a ) 2 , where each R a are independently H, C 1 -C 3 alkyl or C 3 -C 6 cycloalkyl, Each R 6 ’ is independently H, C 1 -C 3 Alkyl, C 1 -C 3 haloalkyl or C 3 -C 6 cycloalkyl, Each R 7 are independently H, C 1 -C 2 Alkyl, C 1 -C 2Fluoroalkyl or C 3 -C 6 cycloalkyl, R 8 is H or C 1 -C 3 is alkyl, Each R 10 halo, C 1 -C 3 alkyl or C 3 -C 6 cycloalkyl, R 11 is H or N(R 12 ) 2 and Each R 12 is independently H or C 1 -C 3 is alkyl, R 13 is CN or F, R 14 is a halo, each n is independently 0 or 1, each p is independently 1 or 2, q is 1 or 2.

[0006] Another embodiment of this invention is a compound of formula (I): [ka] or a pharmaceutically acceptable salt thereof, in which:

[0007] Het is phenyl, 5-6 membered heteroaryl or N-(C 1 -C 3 alkyl)pyridonyl;

[0008] X 0 is N and 1 is C and 2 is N and 4 is N or X 0 is CR 0 and X 1 is C and 2 is N and 4 is N or X 0 is CR 0 and X 1 is N and 2 is C and 4 is N or X 0 is CR 0 and X 1 is N and 2 is C and 4 is CH or X 0 is CR 0 and X 1 is C and 2 is N and 4 is CH,

[0009] R 0 is H, halo, methyl, halomethyl, cyclopropyl or CN;

[0010] R 1 is H or C 1 -C 3 Alkyl, C 1 -C 3 -alkoxy, C 1 -C 3 haloalkyl or a 4- to 7-membered monocyclic oxygen-containing heterocycle,

[0011] X 3 is absent, CH 2 ,C.H. 2 CH 2 ,O,O-CH 2 *, NH or NH-CH 2 *, where "*" is R 2 indicates the point of attachment to

[0012] X 3 is absent, CH 2 or CH 2 CH 2 , then R 2 is the bicyclic core or X via the ring nitrogen atom 3 a 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle that is attached to (“N-attached”) 3 is CH 2 ,C.H. 2 CH 2 ,O,O-CH 2 *or NH-CH 2 *, then R 2 is X via the ring carbon atom 3 (“C-attached”) a 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle, a 4- to 7-membered monocyclic oxygen-containing heterocycle, or a 3- to 12-membered monocyclic oxygen-containing heterocycle is a monocyclic or bicyclic carbocyclyl,

[0013] R 2 N-bonded 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle, 4- to 7-membered oxygen-containing heterocycle, and 3- to 12-membered monocyclic or bicyclic heterocycle represented by Carbocycle is R 4 optionally substituted with a group represented by R 10 further substituted with 1 or 2 groups represented by

[0014] A C-bonded 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle is R 5 N-substituted with a group represented by, optionally R 10 further substituted with 1 or 2 groups represented by R 4 teeth, [ka] and R 5 teeth, [ka] and

[0015] Each R 6 are independently H, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, N(R a ) 2 or CH 2 N(R a ) 2 , where each R a are independently H or methyl;

[0016] Each R 6’ are independently H, C 1 -C 3 alkyl or C 1 -C 3 is haloalkyl,

[0017] Each R 7 are independently H, C 1 -C 2 alkyl or C 1 -C 2 is a fluoroalkyl;

[0018] Each R 10 is F or methyl,

[0019] R 11 is H or N(R 12 ) 2 It is. Alternatively, R 11 is H or NH 2 and

[0020] Each R 12 is independently H or C 1 -C 3 is alkyl or R 12 is H or NH 2 and

[0021] R 13 is CN or F,

[0022] each n is independently 0 or 1;

[0023] each p is independently 1 or 2,

[0024] q is 1 or 2.

[0025] The invention also provides a pharmaceutical composition comprising at least one compound described herein or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.

[0026] Another embodiment of the invention is a method of treating a disorder responsive to Btk inhibition in a subject, comprising: an effective amount of at least one compound described herein, or a pharmaceutically acceptable salt thereof; A method comprising administering to a subject.

[0027] The invention also includes the use of at least one compound described herein, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disorder responsive to Btk inhibition. Also provided is a compound described herein, or a pharmaceutically acceptable salt thereof, for use in treating disorders responsive to Btk inhibition.

[0028] Other features or advantages will be apparent from the following detailed description of some embodiments, and from the appended claims. [Form for carrying out the invention]

[0029] A compound described herein, or a pharmaceutically acceptable salt thereof, may have activity as a Btk modulator. In particular, a compound described herein or a pharmaceutically acceptable salt thereof may be a Btk inhibitor.

[0030] In a first embodiment, the compound of the invention is represented by formula (I'), or a pharmaceutically acceptable salt thereof, wherein the variables are as described above. .

[0031] In a second embodiment, the compound of the invention is represented by formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables are as described above.

[0032] In a third embodiment, for the compound of formula (I') or (I), or a pharmaceutically acceptable salt thereof, R 11 is H or NH 2 and the remaining variables are as described in the first or second embodiment.

[0033] In a fourth embodiment, the compound of the invention has formula (II): [ka] or a pharmaceutically acceptable salt thereof. The variables in formula (II) are as described for formula (I') or (I) in the first or second embodiment.

[0034] In a fifth embodiment, the compound of the invention is represented by formula (I'), (I) or (II), or a pharmaceutically acceptable salt thereof, wherein formula (I '), (I) and (II) (R 1 ) q -Het- is [ka] selected from. The remaining variables in formulas (I), (I') and (II) are as described in any one of the first to fourth embodiments.

[0035] In a sixth embodiment, the compound of the invention has formula (III): [ka] or a pharmaceutically acceptable salt thereof. The variables in formula (III) are as described for formula (I') or (I) in the first or second embodiment.

[0036] In a seventh embodiment, the compound of the invention is represented by formula (I'), (I), (II) or (III), or a pharmaceutically acceptable salt thereof, wherein ,X 0 is N and 1 is C and 2 is N and 4 is N or X 0 is CH and X 1 is C and 2 is N and 4 is N or X 0 is CH and X 1 is N and 2 is C and 4 is N or X 0 is CR 0 and X 1 is N and 2 is C and 4 is CH or X 0 is CH and X 1 is C and 2 is N and 4 is CH and X 3 is absent, O, O-CH 2 *, NH or NH-CH 2 *, where "*" is R 2 indicates the point of attachment to X 3 is absent, then R 2 is the bicyclic core or X via the ring nitrogen atom 3 a 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle that is attached to (“N-attached”) 3 is O, O-CH 2 *or NH-CH 2 *, then R 2 is X via the ring carbon atom 3 (“C-attached”) a 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle, a 4- to 7-membered monocyclic oxygen-containing heterocycle, or a 3- to 12-membered monocyclic oxygen-containing heterocycle is a monocyclic or bicyclic carbocyclyl of R 2 N-bonded 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle represented by, 4- to 7-membered monocyclic oxygen-containing and 3- to 12-membered monocyclic or bicyclic ring The carbocyclic ring in the formula is R 4 optionally substituted with a group represented by R 10 A C-bonded 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle further substituted with 1 or 2 groups represented by R 5 N-substituted with a group represented by, optionally R 10 is further substituted with one or two groups represented by, and the remaining variable groups are represented by formulas (I'), (I), (II) described in any one of the first to sixth embodiments. ) and (III).

[0037] In an eighth embodiment, the compound of the invention has formula (IV), (V), (VI), (VII) or (VIII): [ka] or a pharmaceutically acceptable salt of any of the foregoing, wherein the variables are as described in any one of the first to seventh embodiments.

[0038] In a ninth embodiment, the compounds of the invention have formulas (I'), (I), (II), (III), (IV), (V), (VI), (VII) and (VIII). or a pharmaceutically acceptable salt thereof, in which X 3 is a combination and R 2 is a 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle attached to the bicyclic core via the ring nitrogen atom, and R 2 The monocyclic or bicyclic 4- to 12-membered nitrogen-containing heterocycle represented by R 4 optionally substituted with a group represented by R 10 is further substituted with a group represented by Alternatively, R 2 is a 4- to 7-membered monocyclic nitrogen-containing heterocycle attached to the bicyclic core via the ring nitrogen atom, and R 2 A 4- to 7-membered monocyclic nitrogen-containing heterocycle represented by R 4 optionally substituted with a group represented by R 10 is further substituted with a group represented by The remaining variable groups are formulas (I'), (I), (II), (III), (IV), (V), (VI), ( VII) or (VIII) as described.

[0039] In a tenth embodiment, the compounds of the invention have formulas (I'), (I), (II), (III), (IV), (V), (VI), (VII) and (VIII). or a pharmaceutically acceptable salt thereof, in which X 3 is a combination and R 2 is a 7- to 10-membered bicyclic nitrogen-containing heterocycle attached to the bicyclic core via the ring nitrogen atom, and R 2 A 7- to 10-membered bicyclic nitrogen-containing heterocycle represented by R 4 optionally substituted with a group represented by R 10 and the remaining variables are as described in any one of the first to ninth embodiments.

[0040] In an eleventh embodiment, the compounds of the invention have formulas (I'), (I), (II), (III), (IV), (V), (VI), (VII) and (VIII). or a pharmaceutically acceptable salt thereof, in which R 2 A 7- to 10-membered bicyclic nitrogen-containing heterocycle represented by R 4 optionally substituted with a group represented by R 10 is azaspiro[2.4]heptanylene further substituted with a group represented by, and the remaining variables are as described in any one of the first to tenth embodiments.

[0041] In a twelfth embodiment, the compounds of the invention include (I'), (I), (II), (III), (IV), (V), (VI), (VII) and (VIII). represented by any one or a pharmaceutically acceptable salt thereof, in the formula 3 is a combination and R 2 is a 4- to 7-membered monocyclic nitrogen-containing heterocycle attached to the bicyclic core via the ring nitrogen atom, and R 2 A 4- to 7-membered monocyclic nitrogen-containing heterocycle represented by R 4 optionally substituted with a group represented by R 10 The remaining variables are as described in any one of the first to ninth embodiments.

[0042] In a thirteenth embodiment, the compounds of the invention include (I'), (I), (II), (III), (IV), (V), (VI), (VII) and (VIII). or a pharmaceutically acceptable salt thereof, where R 2 The 4- to 7-membered monocyclic or bicyclic nitrogen-containing heterocycle represented by R is azetidinylene, pyrrolidinylene, piperidinylene, azapanylene or oxazapanylene, respectively 4 optionally substituted with a group represented by R 10 The remaining variables are as described in any one of the first to ninth embodiments.

[0043] In a fourteenth embodiment, the compound of the invention has formula (IX), (X), (XI), (XII), (XIII) or (XIV): [ka] or a pharmaceutically acceptable salt of any of the foregoing, wherein the variables are as described in the thirteenth embodiment.

[0044] In a fifteenth embodiment, the compounds of the invention have formulas (I'), (I), (II), (III), (IV), (V), (VI), (VII), (VIII). , (IX), (X), (XI), (XII), (XIII) or (XIV), in which R 6 and R 6 ’ is independently H, CH 3 or CH 2 Cl, p is 2, and the remaining variables are as described in any one of the first to fourteenth embodiments.

[0045] In a sixteenth embodiment, the compounds of the invention have formulas (I'), (I), (II), (III), (IV), (V), (VI), (VII), (VIII). , (IX), (X), (XI), (XII), (XIII) or (XIV), in which R 4 is CH 2 NHC(O)C≡CH, CH 2 NHC(O)CH=CH 2 ,N(CH 3 )C(O)C≡CH, NHC(O)CH=CH 2 , NHC(O)C≡CH or NHC(O)CH=CHCH 2 Cl, and the remaining variables are as described in any one of the first to fifteenth embodiments.

[0046] In a seventeenth embodiment, the compounds of the invention have formulas (I'), (I), (II), (III), (IV), (V), (VI), (VII), (VIII). , (IX), (X), (XI), (XII), (XIII) or (XIV), in which R 4 is CH 2 NHC(O)C≡CH, CH 2 NHC(O)CH=CH 2 ,N(CH 3 )C(O)C≡CH or CH 2 NR 7 C(O)CH=CHCH 2 Cl, and the remaining variables are as described in any one of the first to fifteenth embodiments.

[0047] In an eighteenth embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). , where X 3 is O, O-CH 2 *, O-CH 2 CH 2 *, NH, NH-CH 2 *, N(CH 3 ), or CH 2 N(CH 3 )-* and R 2 is X via the ring carbon atom 3 a 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle that is bonded to (“C-bonded”); R 5 N-substituted with a group represented by, optionally R 10 The remaining variable groups are as described in any one of the first to eighth embodiments.

[0048] In a nineteenth embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). , where X 3 is O, O-CH 2 *, NH or NH-CH 2 * and R 2 is X via the ring carbon atom 3 is a 4- to 12-membered nitrogen-containing heterocycle that is bonded (“C-bonded”) to R 5 N-substituted with a group represented by, optionally R 10 The remaining variables are as described in any one of the first to eighth embodiments.

[0049] In a twentieth embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). represented by one of X 3 is O or O-CH 2 *, and the remaining variables are as described in any one of the first to eighth, eighteenth, and nineteenth embodiments.

[0050] In a twenty-first embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). , where R 2 A C-bonded 4- to 12-membered nitrogen-containing heterocycle represented by is a 4- to 7-membered monocyclic heterocycle optionally containing one ring oxygen or one ring sulfur atom; It is a 10-membered fused bicyclic ring, an 8-12-membered spiro ring, or a 7-10 bridged bicyclic ring, and R 2 A C-bonded 4- to 12-membered nitrogen-containing heterocycle represented by R 5 N-substituted with a group represented by, optionally R 10 The remaining variable groups are as described in the 1st to 8th and 18th to 20th embodiments.

[0051] In a twenty-second embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). , where R 2 The C-bonded 4- to 12-membered nitrogen-containing heterocycle represented by is azaspiro[3.3]heptanylene, azaspiro[3.5]nonanylene, azaspiro[4.4]nonanylene, azaspiro[3.4]octanylene, azetidinylene, pyrrolidinylene, Piperidinylene, azapanylene, diazepanylene, morpholinylene, octahydrocyclopenta[c]pyrrolilene, oxazapanylene, azabicyclo[3.2.0]heptanylene, azabicyclo[2.2.1]heptanylene, azabicyclo[3.1.1]heptanylene, azabicyclo[3.2.1]octanylene , azabicyclo[4.2.0]octanylene, azatricyclo[4.1.1.03,7]octylene, azabicyclo[3.2.0]heptanylene, azabicyclo[2.1.1]heptanylene, azabicyclo[2.1.1]hexanylene, azabicyclo[3.1.0]hexanylene , 2λ 2 -Azaspiro[3.4]octylene or octahydrocyclopenta[c]pyrolene, R 2 A C-bonded 4- to 12-membered nitrogen-containing heterocycle represented by R 5 N-substituted with a group represented by, optionally R 10 The remaining variables are as described in any one of the first to eighth and eighteenth to twenty-first embodiments. R 2 An exemplary 4- to 12-membered nitrogen-containing heterocycle represented by [ka] [ka] In the formula, "**" is 3 ``***'' indicates the attachment point to R 5 , where R 2 Optionally, each group represented by R 10 is further substituted with 1 to 3 groups represented by

[0052] In a twenty-third embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). R 2 C-bonded 4- to 12-membered nitrogen-containing heterocycles represented by are azetidinylene, pyrrolidinylene, piperidinylene, azapanylene, oxazapanylene, azabicyclo[3.2.1]octanylene, azatricyclo[4.1.1.0 3,7 ]octylene, azabicyclo[3.2.0]heptanylene, azabicyclo[3.1.0]hexanylene, 2λ 2-Azaspiro[3.4]octylene or octahydrocyclopenta[c]pyrene, R 2 A C-bonded 4- to 12-membered nitrogen-containing heterocycle represented by R 5 N-substituted with a group represented by, optionally R 10 The remaining variables are as described in any one of the first to eighth and eighteenth to twenty-first embodiments. R 2 An exemplary 4- to 12-membered nitrogen-containing heterocycle represented by [ka] can be mentioned. R 2 Optionally, the nitrogen-containing heterocycle represented by R 10 and '**' is further replaced with 3 ``***'' indicates the attachment point to R 5 , where R 2 Optionally, each group represented by R 10 further substituted with one or two groups represented by

[0053] In a twenty-fourth embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). , where X 3 , R 2 The stereochemical configuration of the ring carbon atoms in the C-bonded 4- to 12-membered nitrogen-containing heterocycle represented by is R. Or X 3 , R 2 The stereochemical configuration of the ring carbon atoms in the C-bonded 4- to 12-membered nitrogen-containing heterocycle represented by is S. The remaining variables in formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) are and as described in any one of the 18th to 23rd embodiments.

[0054] In a twenty-fifth embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). is represented by one of R 6 and R 6’ are independently H, CH 3 or CH 2 Cl, p is 2, and the remaining variables are as described in any one of the first to eighth and eighteenth to twenty-fourth embodiments.

[0055] In a twenty-sixth embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). is represented by one of R 5 is SO 2 CH=CH 2 , S.O. 2 CH=CHCH 3 , S.O. 2 CH=CHCH 2 Cl, SO 2 C≡CH, SO 2 C≡CCH 3 , S.O. 2 C≡CCH 2 Cl, COCH=CH 2 , COCH=CHCH 3 , COCH=CHCH 2 Cl, CO-C≡CH, CO-C≡CCH 3 , CO-C≡CCH 2 Cl, COCF=CH 2 , COCF=CHCH 3 , COCF=CHCH 2 Cl, [ka] The remaining variable groups are as described in the first to eighth and eighteenth to twenty-fifth embodiments.

[0056] In a twenty-seventh embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). is represented by one of R 5 is SO 2 CH=CH 2 , S.O. 2 CH=CHCH 3 , S.O. 2 CH=CHCH 2 Cl, SO 2 C≡CH, SO 2 C≡CCH 3 , S.O. 2 C≡CCH 2 Cl, COCH=CH 2 , COCH=CHCH 3 , COCH=CHCH 2 Cl, CO-C≡CH, CO-C≡CCH 3 or CO-C≡CCH 2 It is Cl. Alternatively, R 5 is SO 2 CH=CH 2 , S.O. 2 CH=CHCH 3 , COCH=CH 2 , COCH=CHCH 2 Cl, CO-C≡CH or CO-C≡CCH 3 It is. The remaining variables in formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) are and as described in any one of the 18th to 25th embodiments.

[0057] In a twenty-eighth embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). , where X 3 is O, O-CH 2 *, NH or NH-CH 2 * and R 2 is a 3- to 12-membered monocyclic or bicyclic carbocyclyl, a 4- to 7-membered monocyclic or bicyclic oxygen-containing heterocycle, or a 5- to 6-membered heteroaryl; 2 A 3- to 12-membered monocyclic or bicyclic carbocycle, a 4- to 7-membered monocyclic or bicyclic oxygen-containing heterocycle, and a 5- to 6-membered heteroaryl represented by R 4 optionally substituted with a group represented by R 10 The remaining variable groups are as described in any one of the first to eighth embodiments.

[0058] In a twenty-ninth embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). , where X 3 is O, O-CH 2 *, NH or NH-CH 2 * and R 2 is a 4- to 7-membered monocyclic or bicyclic oxygen-containing heterocycle or a 5- to 6-membered heteroaryl, and R 2 4- to 7-membered monocyclic or bicyclic oxygen-containing heterocycle and 5- to 6-membered heteroaryl represented by R 4 optionally substituted with a group represented by R 10 The remaining variable groups are as described in any one of the first to eighth embodiments.

[0059] In a 30th embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). , where R 2 The 4- to 7-membered monocyclic or bicyclic oxygen-containing heterocycle represented by is oxabicyclo[3.1.1]heptanylene or tetrahydro-2H-pyranylene, respectively, R 4 optionally substituted with a group represented by R 10 5-6 membered heteroaryl is further substituted with 1 or 2 groups represented by R 4 optionally substituted with a group represented by R 10 is pyridinylene further substituted with 1 to 3 groups represented by, and the remaining variable groups are as described in any one of the first to eighth and twenty-ninth embodiments.

[0060] In a 31st embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). is represented by one of R 2 teeth, [ka] selected from Each is R 4 optionally substituted with a group represented by R 10 and the remaining variables are as described in any one of the first to eighth and twenty-ninth embodiments.

[0061] In a 32nd embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) , where X 3 is O, O-CH 2 *, NH or NH-CH 2 * and R 2 is a 3- to 12-membered monocyclic or bicyclic carbocyclyl; R2 A 3- to 12-membered monocyclic or bicyclic carbocycle represented by R 4 optionally substituted with a group represented by R 10 and the remaining variables are as described in any one of the first to eighth embodiments. Or X 3 is O or O-CH 2 *is. In another alternative, X 3 is O. The remaining variables in formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) are As described in any one of the embodiments.

[0062] In a 33rd embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) is represented by one of R 2 is phenylene, C 3 -C 7 Cycloalkylene or C 6 -C 9 Bicyclic saturated carbocycle, R 2 Phenylene, represented by C 3 -C 7 Cycloalkylene and C 6 -C 9 A bicyclic saturated carbocycle is R 4 optionally substituted with a group represented by R 10 The remaining variables are as described in any one of the first to eighth and twenty-eighth to thirty-second embodiments.

[0063] In a 34th embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). is represented by one of R 2 is R 4 optionally substituted with a group represented by R 10 phenylene or C further substituted with 1 or 2 groups represented by 4 -C 7 cycloalkylene, and the remaining variables are as described in any one of the first to eighth, thirty-second, and thirty-third embodiments.

[0064] In a 35th embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). , where X 3 is O, and the remaining variables are as described in any one of the first to eighth and twenty-eighth to thirty-fourth embodiments.

[0065] In a 36th embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). is represented by one of R 2 is phenylene, cyclobutylene, cyclohexylene, cyclopentylene, cyclopropylene, bicyclo[3.3.1]heptylene, bicyclo[2.2.1]heptanylene, bicyclo[4.1.0]heptanylene or bicyclo[2.1.1]hexanylene , each of which is R 4 optionally substituted with a group represented by R 10 and the remaining variables are as described in any one of the 1st to 8th and 32nd to 35th embodiments.

[0066] In a 37th embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) is represented by one of R 2 is R 4 optionally substituted with a group represented by R 10 phenylene, cyclobutylene, cyclohexylene or bicyclo[3.3.1]heptylene further substituted with one or two groups represented by As described in the embodiments.

[0067] In a 38th embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) is represented by one of R 2 teeth, [ka] In the formula, "**" is 3 ``***'' indicates the attachment point to R 4 , where R 2 Optionally, the group represented by R 10 further substituted with one or two groups represented by The remaining variables in formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) are and as described in the 32nd to 35th embodiments.

[0068] In a 39th embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) is represented by one of R 2 teeth, [ka] , where R 2 Optionally, the group represented by R 10 The remaining variables are as described in any one of the 1st to 8th or 32nd to 35th embodiments.

[0069] In a fortieth embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). is represented by one of R 6 and R 6 ’ is independently H, CN, CH 3 ,C.H. 2 Cl, CF 3 , cyclopropyl or CH 2 N(R a ), and the remaining variables are as described in any one of the 1st to 8th and 32nd to 39th embodiments.

[0070] In a 41st embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). is represented by one of R a is -CH 3 and cyclopropyl, and the remaining variables are as described in any one of the first to eighth and thirty-second to fortieth embodiments.

[0071] In a 42nd embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). is represented by one of R 6 and R 6’ are independently H, CH 3 or CH 2 Cl, and the remaining variable groups are as described in any one of the first to eighth and thirty-second to thirty-ninth embodiments.

[0072] In a 43rd embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). is represented by one of R 4 is NHC(O)CH=CH 2 ,N(CH 3 )C(O)CH=CH 2 ,NHC(O)CH=CHCH 3 ,N(CH 3 )C(O)CH=CHCH 3 ,N(CH 3 )C(O)CH=CHCN, NHC(O)C≡CH, N(CH 3 )C(O)C≡CH, N(H)C(O)C≡CCH 3 ,N(CH 3 )C(O)C≡CCH 3 ,N(CH 2 CH 2 F)C(O)CH=CH 2 ,N(CH 2 CH 2 F)C(O)CH=CHCH 3 ,N(CH 2 CH 2 F)C(O)C≡CH, N(CH 2 CH 2 F)C(O)C≡CCH 3 ,C.H. 2 N(CH 3 )C(O)CH=CH 2 ,N(CH 2 CHF 2 )C(O)CH=CH 2 ,N(CH 3 )C(O)CH=CHCH 2 Cl, NHC(O)CH=CHCF 3 ,N(CH 3 )C(O)CH=CHCF 3 , NHC(O)C≡C-cyclopropyl, NHC(O)CH=CHCH 2 N(CH 3)-Cyclobutyl, N(CH 2 CHF 2 )C(O)CH=CHCH 2 N(CH 3 ) 2 , N(cyclopropyl)C(O)CH=CH 2 ,N(CH 3 )C(O)CH 2 Cl,N(CH 3 )CH 2 CN, [ka] CH 2 NHC(O)CH=CH 2 , or CH(CH 3 )NHC(O)CH=CH 2 It is. The remaining variables in formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) are and as described in any one of the 32nd to 41st embodiments.

[0073] In a 44th embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). R 4 is NHCOCH=CH 2 ,N(CH 3 )COCH=CH 2 , NHCOCH=CHCH 3 ,N(CH 3 )COCH=CHCH 3 , N(H)COC≡CH, N(CH 3 )COC≡CH, N(H)COC≡CCH 3 ,N(CH 3 )COC≡CCH 3 ,N(CH 2 CH 2 F) COCH=CH 2 ,N(CH 2 CH 2 F)COCH=CHCH 3 ,N(CH 2 CH 2 F)COC≡CH or N(CH 2 CH 2 F) COC≡CCH 3 It is. Alternatively, R 4 is NHC(O)C≡CH 、 NHC(O)C≡CCH 3 , NHC(O)CH=CH 2 ,N(CH 3 )COCH=CH 2 ,N(CH 3 )COC≡CCH 3 or N(CH 2 CH 2 F) COCH=CH 2 It is. The remaining variables in formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) are and as described in any one of the 32nd to 42nd embodiments.

[0074] In a 45th embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). , where X 3 , R 2 The stereochemical configuration of the ring carbon atoms in the C-bonded 3- to 12-membered carbocycle represented by is R. Or X 3 , R 2 The stereochemical configuration of the ring carbon atoms in the C-bonded 3- to 12-membered carbocycle represented by is S. The remaining variables in formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) are and as described in any one of the 32nd to 44th embodiments.

[0075] In a 46th embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). , where X 3 and R 4 is the trans orientation. Or X 3 and R 4 is the cis orientation. The remaining variables in formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) are and as described in any one of the 32nd to 44th embodiments.

[0076] In a 47th embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). , where X 3 is O-CH 2 CH 2 * and R 2 is R 4 optionally substituted with a group represented by R 10 C further substituted with one or two groups represented by 1 -C 3 is an alkyl group, or R 2 is absent and X 3 is R 4 connected directly to. The remaining variables in formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) are As described in the embodiments.

[0077] In a 48th embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). is represented by one of R 2 is **-CH 2 -***,**-CH 2 CH(CH 3 )-***, where "**" is 3 "***" represents the connection point to R 4 Represents the point of attachment to. The remaining variables in formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) are and as described in any one of the forty-seventh embodiments.

[0078] In a 49th embodiment, the compound of the invention has formula (I'), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII). is represented by one of R 4 is N(CH 3 )C(O)CH=CH 2 and the remaining variables are as described in any one of the first to eighth, forty-seventh, and forty-eighth embodiments.

[0079] In a fiftieth embodiment, the compounds of the invention have formulas (I'), (I), (II), (III), (IV), (V), (VI), (VII), (VIII). , (IX), (X), (XI), (XII), (XIII) or (XIV), in which R 1 is H or C 1 -C 3 Alkyl, C 1 -C 3 It is a fluoroalkyl or a 4- to 7-membered monocyclic oxygen-containing heterocycle. Alternatively, R 1 H, CH 3 , CH(CH 3 ) 2 ,CHF 2 , oxetanyl or tetrahydrofuranyl. Formula (I'), (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), The remaining variables in (XII), (XIII) or (XIV) are as described in any one of the first to forty-ninth embodiments.

[0080] In a 51st embodiment, the compound of the invention has the formula (I'), (I), (II), (III), (IV), (V), (VI), (VII), (VIII) , (IX), (X), (XI), (XII), (XIII) or (XIV), in which R 1 H, CH 3 , CH(CH 3 ) 2 ,CHF 2 , C.F. 3 , oxetanyl, or tetrahydrofuranyl, and the remaining variables are as described in any one of the first to forty-ninth embodiments.

[0081] In a 52nd embodiment, the compounds of the invention have formulas (I'), (I), (II), (III), (IV), (V), (VI), (VII), (VIII). , (IX), (X), (XI), (XII), (XIII) or (XIV), in which R 0 H, F, CN, CH 3 , C.F. 3 , cyclopropyl, or phenyl, and the remaining variables are as described in any one of the first to fifty-first embodiments.

[0082] In a 53rd embodiment, the compound of the invention has the formula (I'), (I), (II), (III), (IV), (V), (VI), (VII), (VIII) , (IX), (X), (XI), (XII), (XIII) or (XIV), in which R 0 H, F, CN, CH 3 or CF 3and the remaining variables are as described in any one of the first to fifty-first embodiments.

[0083] In a 54th embodiment, the compounds of the invention have formulas (I'), (I), (II), (III), (IV), (V), (VI), (VII), (VIII) , (IX), (X), (XI), (XII), (XIII) or (XIV), in which R 7 H, CH 3 ,C.H. 2 CH 3 ,C.H. 2 CHF 2 and cyclopropyl, and the remaining variables are as described in any one of the first to fifty-third embodiments.

[0084] In a 55th embodiment, the compounds of the invention have formulas (I'), (I), (II), (III), (IV), (V), (VI), (VII), (VIII). , (IX), (X), (XI), (XII), (XIII) or (XIV), in which R 8 is H or CH 3 and the remaining variables are as described in any one of the first to fifty-fourth embodiments.

[0085] In a 56th embodiment, the compounds of the invention have formulas (I'), (I), (II), (III), (IV), (V), (VI), (VII), (VIII). , (IX), (X), (XI), (XII), (XIII) or (XIV), in which R 10 is F, Cl, CH 3 or cyclopropyl with formula (I'), (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X ), (XI), (XII), (XIII) or (XIV) are as described in any one of the first to fifty-fifth embodiments.

[0086] In a 57th embodiment, the compounds of the invention have formulas (I'), (I), (II), (III), (IV), (V), (VI), (VII), (VIII). , (IX), (X), (XI), (XII), (XIII) or (XIV), in which R 14 is Cl, and the remaining variables are as described in any one of the first to fifty-sixth embodiments.

[0087] In a fifty-eighth embodiment, the compound has the formula: [ka] or a pharmaceutically acceptable salt thereof, in which R 0 is H, halo or cyclopropyl, and X 3 is O or O-CH 2 * and R 2 is a 4- to 7-membered monocyclic or bicyclic saturated carbocyclyl, and R 2 A 4- to 7-membered monocyclic or bicyclic saturated carbocyclyl represented by R 4 optionally 1 or 2 R 10 or R 2 is X via the ring carbon atom 3 is a 7- to 9-membered bicyclic nitrogen-containing heterocycle that is bonded to (“C-bonded”); R 5 optionally 1 or 2 R 10 further substituted with R 4 is N(R 7 )C(O)C≡CCH 3 , N(R 7 )C(O)CH=CH 2 and R 5 is C(O)CH=CH 2 and R 7 H, C 1 -C 2 alkyl, or C 1 -C 2 Haloalkyl, R 10 is C 1 -C 3 It is an alkyl.

[0088] In a 59th embodiment, the compound of the invention is represented by formula (XV), wherein 3 is O and the remaining variables in formula (XV) are as described in the 58th embodiment.

[0089] In a sixtieth embodiment, the compound of the invention is represented by formula (XV), in which R 2 is cyclobutylene, cyclohexylene, cyclopentylene or bicyclo[2.1.1]hexanylene, each of which R 4 optionally 1 or 2 R 10 is further replaced by The remaining variables in formula (XV) are as described in the 58th or 59th embodiment.

[0090] In a 61st embodiment, the compound of the invention is represented by formula (XV), wherein R 2 teeth, [ka] , where R 2 Optionally, the group represented by R 10 further substituted with one or two groups represented by The remaining variables in formula (XV) are as described in the 58th or 59th embodiment.

[0091] In a 62nd embodiment, the compound of the invention is represented by formula (XV), wherein R 2 is azabicyclo[3.2.1]octanylene, azabicyclo[3.1.1]heptanylene or azabicyclo[3.2.0]heptanylene, each of which is R 5 optionally 1 or 2 R 10 is further replaced by The remaining variables in formula (XV) are as described in the 58th or 59th embodiment.

[0092] In a 63rd embodiment, the compound of the invention is represented by formula (XV), In the formula, R 2 teeth, [ka] , where "**" is 3 ``***'' indicates the attachment point to R 5 indicates the point of attachment to R 2 Optionally, each group represented by R 10 further substituted with one or two groups represented by The remaining variables in formula (XV) are as described in any one of the 58th to 62nd embodiments.

[0093] In a sixty-fourth embodiment, the compound of the invention is represented by formula (XV), wherein R 7 H, CH 3 or CH 2 CHF 2 It is. The remaining variables in formula (XV) are as described in one of the 58th to 63rd embodiments.

[0094] In a sixty-fifth embodiment, the compound of the invention is represented by formula (XV), wherein R 10 is CH 3 It is. The remaining variables in formula (XV) are as described in any one of the 58th to 64th embodiments.

[0095] The present invention also includes both neutral forms and pharmaceutically acceptable salts of the compounds disclosed by way of example.

[0096] As used herein, the term "alkyl" refers to a fully saturated branched or unbranched hydrocarbon moiety. Unless otherwise specified, alkyl contains 1 to 6 carbon atoms, or 1 to 3 carbon atoms. Representative examples of alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl, Not limited to these.

[0097] As used herein, the term "alkoxy" refers to a fully saturated branched or unbranched alkyl moiety attached through an oxygen bridge (i.e., --O--C 1-4 an alkyl group, where C 1-4 Alkyl is as defined herein). Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, and the like. In some embodiments, the alkoxy group has about 1-4 carbons, more preferably about 1-2 carbons.

[0098] The number of carbon atoms in a group is herein defined as "C x-xx ” prefix, where x and xx are integers. For example, “C 1-3 "Alkyl" is an alkyl group having 1 to 3 carbon atoms.

[0099] "Halogen" or "halo" can be fluoro, chloro, bromo or iodo.

[0100] The term "haloalkyl" or "halo-substituted alkyl" refers to an alkyl group having at least one halogen substitution. The terms "fluoroalkyl" or "fluorosubstituted alkyl" refer to an alkyl group having at least one fluorine substitution.

[0101] "Heterocyclyl" or "heterocycle" is a saturated or partially unsaturated monocyclic or bicyclic (e.g., fused, bridged, or spiro ring system) ring system containing from 4 to 12 rings. having ring members, at least one of which is a heteroatom, and up to four (e.g., 1, 2, 3, or 4) of which may be heteroatoms, where a heteroatom are independently selected from O, S and N, C can be oxidized (e.g., C(O)), N can be oxidized (e.g., N(O)) or quaternized, and S is optionally Can be oxidized to sulfoxides and sulfones. In some embodiments, when a "heterocyclyl" or "heterocycle" described herein contains both N and O, the "heterocyclyl" or "heterocycle" is an N-containing heterocycle. It is considered that

[0102] The 4-12 membered heterocyclyl can be a 4-7 membered monocyclic heterocyclyl, or a 7-12 membered bicyclic heterocyclyl that is fused, bridged or spiro. Examples of 4- to 7-membered monocyclic heterocyclyl include oxetanyl, thietanyl, azetedinyl, pyrrolidinyl, tetrahydrofuranyl, thiolanyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, dioxolanyl, dithiolanyl, Examples include, but are not limited to, oxathiolanyl, piperidinyl, tetrahydropyranyl, thianyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, dithianyl, trioxanyl, trithianyl, azepanyl, oxepanyl, thiepanil, dihydrofuranyl, imidazolinyl, and dihydropyranyl.

[0103] A "fused ring system" has two rings having 8 to 12 members (ring atoms) and sharing two adjacent ring atoms. A fused bicyclic heterocyclyl has a 4-7 membered heterocyclyl fused to a 4-7 membered heterocyclyl or a 3-7 membered non-aromatic carbocyclyl. Examples include cyclopentapyrrolidinyl, cyclopentapiperidinyl, cyclopentaazapanyl, cyclohexapyrrolidinyl, cyclohexapiperidinyl, cyclohexaazapanyl, cycloheptapyrrolidinyl, cycloheptapiperidinyl , cykheptazapanil, pyrrolopyrrolidinyl, pyrrolopiperidinyl, pyrroloazapanil, furanopyrrolidinyl, furanopiperidinyl, furanoazapanil, pyranopyrrolidinyl, pyranopiperidinyl, pyranoazapanil, and the like.

[0104] A "bridged bicyclic ring system" (also referred to herein as "bridged bicyclic") is defined as two rings having 7 to 10 members (ring atoms) and sharing three adjacent ring atoms. has. Bridged bicyclic heterocyclyls include 5-7 membered heterocyclyls or 5-7 membered heterocyclyls that share 3 ring atoms with a 5-7 membered non-aromatic carbocyclyl. Examples of nitrogen-containing bridged bicycles include azabicyclo[2.2.1]hepanthyl, azabicyclo[3.2.1]octanyl, azabicyclo[3.3.1]nonanyl, diazabicyclo[2.2.1]hepanthyl, diazabicyclo[3.2.1]octanyl and Diazabicyclo[3.3.1]nonanyl is mentioned. Examples of oxygen-containing bridged bicyclics include oxobicyclo[2.2.1]hepanthyl, oxobicyclo[3.2.1]octanyl, oxobicyclo[3.3.1]nonanyl, oxa-azabicyclo[2.2.1]hepanthyl, oxa-azabicyclo Mention may be made of [3.2.1]octanyl and oxa-azabicyclo[3.3.1]nonanyl.

[0105] A "spiro ring system" (also referred to herein as a "spirocycle") has two rings having 8 to 12 members (ring atoms) and sharing one ring atom. Spirobicyclic heterocyclyl includes a 4-7 membered heterocyclyl or a 4-7 membered heterocyclyl that shares one atom with a 4-7 membered non-aromatic carbocyclyl. Examples of 8-12 nitrogen-containing spiro ring systems include 3,4-azabicyclooctanyl, 4,4-azabicyclononanyl, 3,5-azabicyclononanyl, 3,6-azabicyclodecanyl, Mention may be made of 4,5-azabicycloundecanyl, 3,7-azabicycloundecanyl, 4,6-azabicycloundecanyl and 5,5-azabicycloundecanyl. Examples of 8-12 oxygen-containing spiro ring systems include 3,4-oxobicyclooctanyl, 4,4-oxobicyclononanyl, 3,5-oxobicyclononanyl, 3,6-oxobicyclodecanyl, Mention may be made of 4,5-oxobicycloundecanyl, 3,7-oxobicycloundecanyl, 4,6-oxobicycloundecanyl and 5,5-xobicycloundecanyl.

[0106] Examples of 4- to 12-membered nitrogen-containing heterocycles include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azepanyl, oxepanyl, imidazolinyl, cyclo Pentapyrrolidinyl, cyclopentapiperidinyl, cyclopentaazapanil, cyclohexapyrrolidinyl, cyclohexapyrrolidinyl, cyclohexaazapanyl, cycloheptapyrrolidinyl, cycloheptapyrrolidinyl, cycloheptaaza Panil, pyrrolopyrrolidinyl, pyrrolopiperidinyl, pyrroloazapanil, furanopiperidinyl, furanoazapanil, pyranopyrrolidinyl, pyranopiperidinyl, pyranoazapanyl, azabicyclo[2.2.1]hepanthyl, azabicyclo[3.2.1] Octanyl, azabicyclo[3.3.1]nonanyl, diazabicyclo[2.2.1]hepanthyl, diazabicyclo[3.2.1]octanyl, diazabicyclo[3.3.1]nonanyl, 3,4-azabicyclooctanyl, 4,4-azabicyclooctanyl Nanyl, 3,5-azabicyclononanyl, 3,6-azabicyclodecanyl, 4,5-azabicyclodecanyl, 3,7-azabicycloundecanyl, 4,6-azabicycloundecanyl and 5 ,5-azabicycloundecanyl. Examples of 4- to 7-membered nitrogen-containing heterocycles (optionally containing one ring oxygen or one ring sulfur atom) include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothinyl, Mention may be made of azolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azepanyl, oxepanyl and imidazolinyl.

[0107] Examples of 4- to 7-membered oxygen-containing heterocycles include oxetanyl, tetrahydrofuranyl, oxazolidinyl, isoxazolidinyl, dioxolanyl, oxathiolanyl, tetrahydropyranyl, morpholinyl, dioxanyl, oxepanyl, dihydrofuranyl, and dihydropyranyl. It will be done.

[0108] "Heteroaryl" refers to an aromatic 5- to 6-membered monocyclic ring system having 1 to 4 heteroatoms independently selected from O, N, and S; , N can be oxidized (eg, N(O)) or quaternized, and S can optionally be oxidized to sulfoxides and sulfones. Examples of 5- to 6-membered monocyclic heteroaryls include pyrrolyl, furanyl, thiophenyl (or thienyl), imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, furazanyl, oxadiazolyl, thiadiazolyl, dithiazolyl, triazolyl, tetrazolyl, pyridinyl. , pyranyl, thiopyranyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazinyl, thiazinyl, dioxynyl, dithiinyl, oxathianyl, triazinyl, tetrazinyl, and the like, but are not limited to these. In one embodiment, the heteroaryl is a 5-membered heteroaryl. Examples of 5-membered heteroaryls include pyrazolyl, oxazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadizolyl, 1,2,3-thiadiazolyl, 1,3 ,4-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, and tetrazolyl.

[0109] "Carbocyclyl" is a saturated or partially unsaturated monocyclic or bicyclic (e.g., fused, bridged, or spiro ring system) ring system having from 4 to 12 ring members; All of which is carbon. The term "carbocyclyl" includes cycloalkyl, cycloalkenyl, and aromatic (ie, aryl) groups. "Cycloalkyl" refers to a fully saturated monocyclic hydrocarbon radical of 3 to 7 carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclopentyl; "cycloalkenyl" refers to a fully saturated monocyclic hydrocarbon radical of 3 to 7 carbon atoms; refers to an unsaturated non-aromatic monocyclic hydrocarbon group of carbon atoms, including cyclopentenyl, cyclohexenyl and cyclopentenyl. Exemplary aromatic carbocyclyl groups include phenyl.

[0110] A fused bicyclic carbocyclyl has a 4- to 7-membered carbocyclyl fused to a 3- to 7-membered non-aromatic carbocyclyl. Examples include decahydronaphthalene, octahydro-1H-indene, octahydropentalene, decahydroazulene, decahydro-1H-annulene, bicyclo[4.2.0]octane, bicyclo[3.2.0]heptane, and the like.

[0111] Bridged bicyclic carbocyclyls include 5-7 membered non-aromatic carbocyclyls and 5-7 membered non-aromatic carbocyclyls that share three ring atoms. Examples of bridged bicyclic carbocycles include bicyclo[2.2.1]hepantyl, bicyclo[3.2.1]octanyl, bicyclo[3.3.1]nonanyl.

[0112] The suffix "il" added to the end of a chemical name indicates that the specified moiety is attached to the molecule at a point. The ``ene'' suffix added to the end of a chemical name indicates that the specified moiety is attached to the molecule at two points. Examples include azetidinylene, pyrrolidinylene, piperidinylene, azapanylene or oxazapanylene, which indicates that the azetidine, pyrrolidine, piperidine, azapane or oxazapane is attached to the rest of the compound at two points.

[0113] In the context of a nitrogen-containing heterocycle, "N-bonded to a bicyclic core" means that a nitrogen-containing heterocycle is connected to the core via its ring nitrogen atom. [ka] It means that it is connected to. In the context of a nitrogen-containing heterocycle or carbocycle, "C-bonded to a bicyclic core" means that the nitrogen-containing heterocycle or carbocycle is attached to the core via a ring carbon atom. [ka] It means that it is connected to.

[0114] A nitrogen-containing heterocycle is "N-substituted" if the ring nitrogen atom is substituted.

[0115] When a compound provided herein is sufficiently basic or acidic to form a stable, non-toxic acidic or basic salt, the preparation and preparation of the compound as a pharmaceutically acceptable salt; administration may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids that form physiologically acceptable anions, such as tosylate, methanesulfonate, acetate, citrate, malonate. acid salt, tartrate, succinate, benzoate, ascorbate, alpha-ketoglutarate, or alpha-glycerophosphate. Inorganic salts may also be formed and include hydrochlorides, sulfates, nitrates, bicarbonates, and carbonates.

[0116] Pharmaceutically acceptable salts are prepared using standard procedures well known in the art, for example, by combining a sufficiently basic compound, such as an amine, with a suitable acid that yields a physiologically acceptable anion. It can be obtained by reacting with Alkali metal (eg, sodium, potassium or lithium) or alkaline earth metal (eg, calcium) salts of carboxylic acids can also be produced.

[0117] Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts from inorganic bases can include, but are not limited to, sodium, potassium, lithium, ammonium, calcium or magnesium salts. Examples of salts derived from organic bases include alkylamines, dialkylamines, trialkylamines, substituted alkylamines, di(substituted alkyl)amines, tri(substituted alkyl)amines, alkenylamines, dialkenylamines, trialkenylamines, Substituted alkenylamine, di(substituted alkenyl)amine, tri(substituted alkenyl)amine, cycloalkylamine, di(cycloalkyl)amine, tri(cycloalkyl)amine, substituted cycloalkylamine, disubstituted cycloalkylamine, trisubstituted cyclo Alkylamines, cycloalkenylamines, di(cycloalkenyl)amines, tri(cycloalkenyl)amines, substituted cycloalkenylamines, disubstituted cycloalkenylamines, trisubstituted cycloalkenylamines, arylamines, diarylamines, triarylamines, heteroaryls amines, diheteroarylamines, triheteroarylamines, heterocycloalkylamines, diheterocycloalkylamines, triheterocycloalkylamines, or mixed diamines and triamines, wherein at least two of the substituents of the amine are different. Primary, secondary, such as those which may be alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, or heterocycloalkyl, etc. Mention may be made, without limitation, of salts of secondary or tertiary amines. Also included are amines in which two or three substituents together with the amino nitrogen form a heterocycloalkyl group or a heteroaryl group. Non-limiting examples of amines include isopropylamine, trimethylamine, diethylamine, tri(isopropyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethylaminoethanol, trimethamine, lysine, arginine, histidine, caffeine. , procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamine, theobromine, purine, piperazine, piperidine, morpholine, or N-ethylpiperidine. Other carboxylic acid derivatives may be useful, such as carboxamides, including carboxamides, lower alkyl carboxamides, or dialkyl carboxamides, and the like.

[0118] The compounds described herein, or their pharmaceutically acceptable salts, can contain one or more asymmetric centers within the molecule. According to this disclosure, any structure that does not specify stereochemistry includes all of its various stereoisomers (e.g., diastereomers and enantiomers) in pure or substantially pure form, as well as mixtures thereof. (racemic mixtures, enantiomeric enriched mixtures, etc.). Methods for preparing such optically active forms (e.g., racemic resolution by recrystallization techniques, synthesis from optically active starting materials, chiral synthesis, or chromatographic separation methods using chiral stationary phases) are Well known in the technical field.

[0119] When a specific stereoisomer of a compound is designated by name or structure, the stereochemical purity of that compound is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% %, 95%, 97%, 99%, 99.5% or 99.9%. "Stereochemical purity" means the weight percent of the desired stereoisomer relative to the total weight of all stereoisomers.

[0120] When a specific enantiomer of a compound is designated by name or structure, the stereochemical purity of that compound is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99%, 99.5% or 99.9%. "Stereochemical purity" means the weight percent of the desired enantiomer relative to the total weight of all stereoisomers.

[0121] When the stereochemistry of a disclosed compound is named or depicted by a structure, and the named or depicted structure encompasses multiple stereoisomers (e.g., diastereomeric pairs), inclusion It is understood that one of the included stereoisomers or any mixture of included stereoisomers is included. Additionally, the stereoisomers named or depicted are at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99% stereoisomerically pure. , 99.5% or 99.9%. Stereoisomeric purity refers to the weight percent of the desired stereoisomer encompassed by its name or structure relative to the total weight of all stereoisomers.

[0122] When a disclosed compound is named or depicted in a structure without stereochemistry and the compound has one chiral center, the name or structure includes the compound in pure or substantially pure form. It should be understood that single enantiomers of, and mixtures thereof, such as racemic mixtures of compounds and mixtures in which one enantiomer is enriched relative to its corresponding optical isomer, are included.

[0123] If a disclosed compound is named or depicted in a structure without stereochemistry and, for example, if the compound has at least two chiral centers, then the name or structure may include pure or substantially one stereoisomer in pure form, and mixtures thereof (mixtures of stereoisomers, and stereoisomers in which one or more stereoisomers are enriched compared to the other stereoisomer(s)) It should be understood that mixtures etc.) are included.

[0124] The disclosed compounds may exist in tautomeric forms, and mixtures and separate respective tautomeric forms are also contemplated. Additionally, some compounds may exhibit polymorphism.

[0125] In one embodiment, the invention provides compounds disclosed herein that are deuterated, in which case any or more positions occupied by hydrogen are This can include enrichment with deuterium in excess of a certain degree. For example, one or more hydrogen atoms are replaced with deuterium at an abundance at least 3340 times greater than deuterium's natural abundance of 0.015% (i.e., at least 50.1% deuterium introduced), and at least 3500 times ( 52.5% deuterium loading on each specified deuterium atom), at least 4000 times (60% deuterium loading), at least 4500 times (67.5% deuterium loading), at least 5000 times (75% deuterium loading) Hydrogen), at least 5500 times (82.5% deuterium introduced), at least 6000 times (90% deuterium introduced), at least 6333.3 times (95% deuterium introduced), at least 6466.7 times (97% deuterium introduced) , at least 6600 times (99% deuterium introduction), or at least 6633.3 times (99.5% deuterium introduction) greater abundance. In one embodiment, hydrogen is present in its natural abundance at all positions. A compound described herein, or a pharmaceutically acceptable salt thereof, may exist in tautomeric forms, and mixtures and separate respective tautomeric forms are also contemplated.

[0126] Another embodiment is a pharmaceutical composition comprising at least one compound described herein or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

[0127] The compounds described herein, or their pharmaceutically acceptable salts, may be used to reduce the activity of Btk, or to modify the properties and / or behavior of Btk, such as stability, phosphorylation, kinase activity, or other proteins. may be used to influence interactions with others in other ways.

[0128] In some embodiments, the invention provides methods of reducing Btk enzyme activity. In some embodiments, such methods include contacting Btk with an effective amount of a Btk inhibitor. Accordingly, the invention further provides a method of inhibiting Btk enzymatic activity by contacting Btk with a Btk inhibitor of the invention.

[0129] One embodiment of the invention includes a method of treating a disorder responsive to Btk inhibition in a subject, comprising: an effective amount of at least one compound described herein, or a pharmaceutically acceptable salt thereof; The method includes administering to a subject.

[0130] In one embodiment, the invention provides a method of treating autoimmune disorders, inflammatory diseases, and cancer in a subject in need thereof, comprising: an effective amount of at least one of the methods described herein; A method is provided comprising administering a compound or a pharmaceutically acceptable salt thereof to a subject.

[0131] The term "autoimmune disorder" refers to diseases or disorders that involve inappropriate immune responses to natural antigens, such as acute disseminated encephalomyelitis (ADEM), Addison's disease, alopecia areata, and antiphospholipid antibody syndrome (APS). ), autoimmune hemolytic anemia, autoimmune hepatitis, bullous pemphigoid (BP), celiac disease, dermatomyositis, type 1 diabetes mellitus, Goodpasture syndrome, Graves' disease, Guillain-Barre syndrome (GBS), Hashimoto's disease, idiopathic thrombocytopenic purpura, lupus erythematosus, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polymyositis, primary biliary cirrhosis, Sjögren's syndrome, side Including cephalic arteritis and Wegener's granulomatosis. The term "inflammatory disease" refers to diseases or disorders involving acute or chronic inflammation, such as allergies, asthma, prostatitis, glomerulonephritis, pelvic inflammatory disease (PID), inflammatory bowel disease (IBD), e.g. including Crohn's disease, ulcerative colitis), reperfusion injury, rheumatoid arthritis, transplant rejection, and vasculitis. In some embodiments, the invention provides methods of treating rheumatoid arthritis or lupus. In some embodiments, the invention provides methods of treating multiple sclerosis.

[0132] The term "cancer" refers to diseases or disorders that involve abnormal growth and / or proliferation of cells, such as glioma, thyroid cancer, breast cancer, lung cancer (e.g., small cell lung cancer, non-small cell lung cancer), gastric cancer, Gastrointestinal stromal tumors, pancreatic cancer, cholangiocarcinoma, ovarian cancer, endometrial cancer, prostate cancer, renal cell carcinoma, lymphoma (e.g., anaplastic large cell lymphoma), leukemia (e.g., acute myeloid leukemia, T-cell leukemia, chronic lymphocytic leukemia), multiple myeloma, malignant mesothelioma, malignant melanoma, and colon cancer (eg, frequent microsatellite unstable colon cancer). In some embodiments, the invention provides methods of treating leukemia or lymphoma.

[0133] As used herein, the terms "subject" and "patient" may be used interchangeably and include a mammal in need of treatment, such as a companion animal (e.g., dog, cat, etc.), a domestic animal (e.g. , cows, pigs, horses, sheep, goats, etc.) and experimental animals (eg, rats, mice, guinea pigs, etc.). Typically, the subject is a human in need of treatment.

[0134] As used herein, the term "treating" or "treatment" refers to obtaining a desired pharmacological and / or physiological effect. The effect may be therapeutic, including partially or substantially achieving one or more of the following results: partially or completely reducing the extent of the disease, disorder or syndrome. ameliorating or ameliorating clinical symptoms or indicators associated with a disorder; or delaying, inhibiting, or reducing the likelihood of progression of a disease, disorder, or syndrome.

[0135] An effective dose of a compound provided herein, or a pharmaceutically acceptable salt thereof, administered to a subject can be from 10 μg to 500 mg.

[0136] Administration of a compound described herein, or a pharmaceutically acceptable salt thereof, to a mammal includes any suitable delivery method. Administering a compound described herein, or a pharmaceutically acceptable salt thereof, to a mammal includes administering a compound described herein, or a pharmaceutically acceptable salt thereof, to the mammal. Topically, enterally, parenterally, transdermally, transmucosally, by inhalation, intracisternally, epidurally, intravaginally, intravenously, intramuscularly, subcutaneously. This includes intradermal or intravitreal administration. Administering a compound described herein, or a pharmaceutically acceptable salt thereof, to a mammal may include metabolizing the compound described herein into the compound described herein in or on the mammal's body. or a pharmaceutically acceptable salt thereof, topically, enterally, parenterally, transdermally, transmucosally, by inhalation, intracisternally, or epidurally. This also includes intravaginal, intravenous, intramuscular, subcutaneous, intradermal, or intravitreal administration.

[0137] Accordingly, the compounds described herein, or their pharmaceutically acceptable salts, may be administered systemically, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. can be done. They may be enclosed in hard-shell or soft-shell gelatin capsules, compressed into tablets, or combined directly with food in the patient's diet. For therapeutic oral administration, a compound described herein, or a pharmaceutically acceptable salt thereof, may be combined with one or more excipients to form an ingestible tablet, buccal tablet, troche, capsule, or elixir. It may be used in the form of , suspension, syrup, or wafer. Such compositions and preparations should contain at least about 0.1% of active compound. The percentages of compositions and preparations may, of course, vary and may conveniently be from about 2 to about 60% by weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions can be such that an effective dosage level will be obtained.

[0138] Tablets, troches, pills, capsules, etc. may contain: binders such as tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; corn starch, potato starch, alginic acid, etc. a lubricant such as magnesium stearate; or a sweetening or flavoring agent such as sucrose, fructose, lactose or aspartam.

[0139] The active compound may be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salt can be prepared in water, optionally mixed with a non-toxic surfactant.

[0140] Exemplary pharmaceutical dosage forms for injection or infusion may include sterile aqueous solutions or dispersions or sterile powders containing the active ingredients adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions. In all cases, the final dosage form should be sterile, fluid, and stable under the conditions of manufacture and storage.

[0141] Sterile injectable solutions can be prepared by incorporating the active compounds in the required amount in the appropriate solvent in various combinations with other ingredients enumerated above, as required, followed by filtered sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, preferred methods of preparation may be vacuum drying and lyophilization, whereby any additional desired ingredients previously contained in the sterile-filtered solution are added. A powder of the active ingredient can be obtained.

[0142] Exemplary solid carriers can include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina, and the like. Useful liquid carriers include water, alcohols or glycols or blends of water and alcohols / glycols in which effective levels of the compounds described herein, or pharmaceutically acceptable salts thereof, are present. and can optionally be dissolved or dispersed using non-toxic surfactants.

[0143] Useful doses of the compounds described herein, or pharmaceutically acceptable salts thereof, can be determined by comparing their in vitro activity and in vivo activity in animal models. Methods of extrapolating effective doses in mice and other animals to humans are known in the art, see, eg, US Pat. No. 4,938,949, which is incorporated by reference in its entirety.

[0144] The amount of a compound described herein, or a pharmaceutically acceptable salt thereof, required for use in therapy will vary depending on the particular salt selected, as well as the route of administration, and the amount being treated. It also depends on the nature of the condition and the age and condition of the patient, and is ultimately at the discretion of the attending physician or clinician. However, in general, doses may range from about 0.1 to about 10 mg / kg body weight per day.

[0145] The compounds described herein, or pharmaceutically acceptable salts thereof, are conveniently administered in unit dosage forms containing, for example, 0.01 to 10 mg, or 0.05 to 1 mg of active ingredient per unit dosage form. I can do it. In some embodiments, doses of 5 mg / kg or less may be suitable.

[0146] The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals.

[0147] The methods of the present disclosure include a compound described herein or a pharmaceutically acceptable salt thereof, and a compound described herein or a pharmaceutically acceptable salt thereof, or a compound described herein or a pharmaceutically acceptable salt thereof. A kit may be included that includes instructional materials that can explain administering to a cell or subject a composition comprising a compound or a pharmaceutically acceptable salt thereof. This can be done using kits known to those skilled in the art, e.g., prior to administering a compound described herein or a pharmaceutically acceptable salt thereof or a composition thereof to a cell or subject. or a pharmaceutically acceptable salt thereof or a solvent (eg, sterile) for dissolving or suspending the composition. In some embodiments, the subject can be a human.

Example

[0148] The invention is illustrated by the following examples, which are not intended to be limiting. Abbreviations and acronyms used herein include: ABPR means Automatic Back Pressure Regulator, Ac 2 O means acetic anhydride, ACN means acetonitrile, Aq. means aqueous solution, Ar means argon, Bn means benzyl, Boc means tert-butoxycarbonyl, Boc 2 O means di-tert-butyl dicarbonate, BPin means pinacolatobolone, B 2 pin 2 means bispinacolate diboron, br means broad t-BuOH means tert-butanol, n-BuLi means n-butyllithium, ℃ means degrees Celsius, CHCl 3 means chloroform, CDCl 3 means deuterochloroform, C.O. 2 means carbon dioxide, Cs 2 C.O. 3 means cesium carbonate, CsF means cesium fluoride, CuI means copper iodide, δ means chemical shift, d means double line, dd means double double line, ddd means double double line double line, DCM means dichloromethane, DIEA or DIPEA means N-ethyldiisopropylamine or N,N-diisopropylethylamine, DEA means diethylamine, deg means degree DIAD means diisopropyl azodicarboxylate; DME means 1,2-dimethoxyethane, DMF means N,N-dimethylformamide, DMSO means dimethyl sulfoxide, DMSO-d 6 means hexadeuterodimethyl sulfoxide, DPPA means diphenylphosphoryl azide, Et means ethyl Et 2 O means ether, EtOH means ethanol, EtOAc means ethyl acetate, Eq. means equivalent, g means gram h means time HATU means O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HBr means hydrogen bromide, HCl means hydrochloric acid, HCO 2 H means formic acid, Hept means heptane, HFIP means hexafluoroisopropanol, 1 H NMR means proton nuclear magnetic resonance, H 2 O means water H 2 S.O. 4 means sulfuric acid, HMPA means hexamethylphosphoramide, HPLC means high performance liquid chromatography, Hz means Hertz, IPA or iPrOH means isopropanol, J means coupling constant, K 2 C.O. 3 means potassium carbonate, kg means kilogram, KHMDS means potassium hexamethyldisilazide, KOAc means potassium acetate, KOH means potassium hydroxide, KOt-Bu means potassium tert-butoxide, K 3 P.O. 4 means tripotassium phosphate, K 4 Fe(CN) 6 ·3H 2 O means potassium hexacyanoferrate(II) trihydrate; L means liter LCMS means liquid chromatography mass spectrometry, m means multiplet, M means mole, MBPR means manual back pressure regulator, Me means methyl MeB(OH) 2 means methylboronic acid, MeCN means acetonitrile, MeOH means methanol, MeOH-d 4 means deuteromethanol, mg means milligrams, MgSO 4 means magnesium sulfate, MHz means megahertz, mins means minutes mL means milliliter, mmol means millimoles, MMPNO means methylmorpholine N-oxide, mol means moles, MS m / z means mass spectral peak, N 2 means nitrogen, NaOt-Bu means sodium tert-butoxide, NaH means sodium hydride, NaHCO 3 means sodium bicarbonate, NaHMDS means sodium hexamethyldisilylazide, NaIO 4 means sodium periodate, NaOH means sodium hydroxide, Na 2 S 2 O 3 means sodium thiosulfate, Na 2 S.O. 4 means sodium sulfate, NEt 3 means triethylamine, NFSI means N-fluorobenzenesulfonimide, N.H. 3 means ammonia, N.H. 4 Cl means ammonium chloride, N.H. 4 OH is ammonium hydroxide, N.H. 4 OAc is ammonium acetate, NIS means N-iodosuccinimide, OsO 4 means osmium tetroxide, P(cy) 3 means tricyclohexylphosphine, Pd 2 (dba) 3 means tris(dibenzylideneacetone)dipalladium(0), Pd(dppf)Cl 2 means [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), Pd(dtbpf)Cl 2 means [1,1'-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II), PEPPSI-IPr or Pd-PEPPSI-IPr means [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II) dichloride, Ph means phenyl, POCl 3 means phosphoryl chloride, Pyr means pyridine, q means quartet, Rf means delay factor, Rt means retention time, RT means room temperature, RuPhos means 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl, s means single line, sat. means saturated, SCX means strong cation exchange, SFC means supercritical fluid chromatography, SiO 2 means silicon dioxide, Si-SPE means silica solid phase extraction, t means triple line, td means triple double line, t-BuONa means sodium tert-butoxide, TEA means triethylamine, TFA means trifluoroacetic acid, THF means tetrahydrofuran, TLC means thin layer chromatography, T 3 P means propanephosphonic anhydride; μL means microliter, μmol means micromoles, μW means microwave, v / v means volume per volume, Xphos means 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl, Xphos G3 is (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II ) means methanesulfonate.

[0149] [ka] Synthesis of 1-(1-methyl-1H-pyrazol-4-yl)ethan-1-one (2). [ka] Sulfuric acid (4.78 g, 2.61 mL, 0.08 eq., 48.7 mmol) was added to a mixture of 1-methyl-1H-pyrazole (50.0 g, 1 eq., 609 mmol) and acetic anhydride (112 g, 104 mL, 1.8 eq., 1.10 mol) at room temperature. added. The mixture was heated at 150° C. for 7 hours, then cooled to room temperature overnight. The reaction mixture was poured into ice and the pH of the resulting solution was adjusted to 10 with 20% aqueous NaOH, then extracted with DCM and the organic phase was dried over sodium sulfate and concentrated. This gave 1-(1-methyl-1H-pyrazol-4-yl)ethan-1-one (36.8 g, yield 49%). 1 H NMR (300 MHz, CDCl 3 ) d 7.80-7.96 (m, 2H), 3.91 (s, 3H), 2.39 (s, 3H).

[0150] Synthesis of 2-bromo-1-(1-methyl-1H-pyrazol-4-yl)ethan-1-one (3). [ka] In a round bottom flask, 1-(1-methyl-1H-pyrazol-4-yl)ethan-1-one (36.8 g, 1 eq., 296 mmol) was dissolved in dichloromethane (700 mL). Ethanol (175 mL) and pyridinium tribromide (94.7 g, 1 eq., 296 mmol) were added portionwise at 15°C. The mixture was stirred from 0°C to room temperature overnight. The mixture was confirmed by TLC (heptane:EtOAc 4:6) and HPLC. Once the addition was complete, the reaction was quenched with water. The layers were separated and the organic phase was dried over sodium sulfate and concentrated to give the product as a brown solid. The solid was suspended in a mixture of DCM and heptane, warmed to 50°C and cooled again to room temperature. The product precipitated and was isolated by filtration (28.8g). Further solid precipitated from the mother liquor (7.43g). A total of 36.2 g (60% yield) of the title product was isolated as a brown solid. ESI-MS (M+H) + : 205.1.

[0151] Synthesis of diethyl 1-(2-(1-methyl-1H-pyrazol-4-yl)-2-oxoethyl)-1H-pyrazole-3,5-dicarboxylate (5). [ka] In a round bottom flask, 2-bromo-1-(1-methyl-1H-pyrazol-4-yl)ethan-1-one (60.6 g, 1 eq., 298 mmol) was dissolved in DMF (900 mL) and 1H- Diethyl pyrazole-3,5-dicarboxylate (69.6 g, 1.1 eq., 328 mmol) and cesium carbonate (126 g, 1.30 eq., 388 mmol) were added. The reaction was stirred at room temperature overnight. The reaction mixture was diluted with water and extracted with DCM. The organic layer was dried over sodium sulfate and concentrated. The crude product was suspended in heptane:EtOAc 1:1 (50-100 mL) and filtered. The solid was washed once with EtOAc and once with heptane to give the product (68.5g) as a white solid. The mother liquor was concentrated and purified by column chromatography (120 g silica, heptane:EtOAc gradient 0-100%) to give a separate portion of the product (9.7 g). A total of 78.2 g (78% yield) of product was isolated as a white solid. ESI-MS (M+H) + : 335.2.

[0152] Synthesis of ethyl 4-hydroxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate (6). [ka] Diethyl 1-(2-(1-methyl-1H-pyrazol-4-yl)-2-oxoethyl)-1H-pyrazole-3,5-dicarboxylate (15.0 g, 1 eq., 44.9 mmol) was added to a Berghoff reaction vessel. ), ethanol (150 mL) and ammonium acetate (10.4 g, 3.0 eq., 135 mmol) were charged. The mixture was heated at 130° C. for 24 hours, after which complete conversion was observed by HPLC (sample was taken after the reactor was cooled to room temperature again). The reaction mixture was filtered off, washed with water, and air dried to give the product (11.8 g, 92%) as a white solid. This reaction was carried out batchwise using a total amount of 78.2 g of starting material to obtain a total amount of 66.6 g of product (92% yield). ESI-MS (M+H) + : 288.3.

[0153] Synthesis of 4-hydroxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylic acid (7). [ka] In a round bottom flask, add ethyl 4-hydroxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate (66.6 g, 1.0 eq., 232 mmol). Suspended in methanol (1.2L), 1M sodium hydroxide (27.9g, 696mL, 3.0eq, 696mmol) was added at room temperature. The mixture was stirred at room temperature overnight. The mixture was acidified to pH 2 with concentrated HCl and then filtered (filtration was very slow and difficult). The solids were washed with MeOH, transferred to a round bottom flask and stripped with acetonitrile. The product obtained was found to be a mixture of methyl ester and salt (92.8 g, max. 232 mmol). The solid was divided into two parts and the hydrolysis was repeated. In a round bottom flask, add methyl 4-hydroxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate (46.0 g, 1.0 eq., 116 mmol). Suspended in methanol (1.2L), 1M sodium hydroxide (13.9g, 348mL, 3.0eq, 348mmol) and 10mL of water were added at room temperature. The mixture was stirred at room temperature overnight. The mixture was neutralized to pH 7 with concentrated HCl and then filtered (filtration remained difficult). The solids were washed with acetonitrile, dioxane, transferred to a round bottom flask, and stripped with acetonitrile to remove the 4-hydroxy-6-(1-methyl-1H-pyrazole-4- yl)pyrazolo[1,5-a]pyrazine-2-carboxylic acid batch 1 (71.0 g, maximum 116 mmol, batch 1) was obtained. The same procedure was repeated for the second batch of methyl esters. In this case, once the conversion was complete, the reaction mixture was acidified to pH5. This results in 4-hydroxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylic acid (60.0 g, up to 116 mmol, batch 1) containing many salts. ) was obtained. ESI-MS (M-H) + : 258.0.

[0154] Synthesis of 6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-ol (8). [ka] Preheated sulfolane (0.24 kg, 0.19 L, 30 equivalents, 2.0 mol) was placed in a 3-necked flask and heated to 50°C. Then 4-hydroxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylic acid (41.8 g, 1.0 eq., 68 mmol) and a few drops of concentrated sulfuric acid was added little by little. The reaction mixture was heated at 350° C. (external, gentle reflux of sulfolane) and conversion was checked every hour. After 4 hours, the reaction mixture was cooled to room temperature, diluted with DCM, 3L heptane(fr1), 6L heptane:EtOAc 1:1(fr2-3), 6L EtOAc(fr4-5), 4L DCM. (fr6), purified by filtration through a short plug of silica, eluting with 6 L of DCM:MeOH 9:1 (fr7-8). The product (containing by-product 8a) (2.88 g, 20%) was isolated from fr7 as a brown solid. ESI-MS (M-H) + : 214.1.

[0155] Synthesis of 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine. [ka] In a round bottom flask, 6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-ol (2.88 g, 1.0 eq., 13.4 mmol) was dissolved in POCl 3 (32.8 g, 19.9 mL, 16 eq., 214 mmol) and the reaction was heated at 80° C. overnight. The mixture was diluted with acetonitrile, concentrated, the residue was suspended in DCM, and the mixture was dissolved in saturated NaHCO 3 and brine, dried over sodium sulfate, and concentrated. The crude product was purified by column chromatography (DCM:EtOAc / NEt 3 Purification by 5% gradient (0-25%) gave the product (1.35 g, 43%) as a yellow solid. ESI-MS (M+H) + : 234.0.

[0156] [ka] Synthesis of 7-chloro-5-(methylthio)imidazo[1,2-c]pyrimidine hydrochloride (11). [ka] In a round bottom flask, 6-chloro-2-(methylthio)pyrimidin-4-amine (150 g, 1 eq., 854 mmol) was dissolved in 1,4-dioxane (300 mL) and 2-chloroacetaldehyde (220 g, 0.18 L) was dissolved in 1,4-dioxane (300 mL). , 1.5 eq., 1.28 mol) were added. The mixture was stirred at 100°C. After 2 hours, a solid precipitated in the reaction mixture and after 3 hours, the reaction was checked by HPLC and the conversion was found to be complete. The reaction mixture was cooled to room temperature overnight. The suspension was cooled to 0° C. and the solid was filtered off to give the product (151 g, 75%) as a yellow solid. ESI-MS (M+H) + : 200.1.

[0157] Synthesis of 7-chloroimidazo[1,2-c]pyrimidin-5(6H)-one (12). [ka] In a 3-neck flask, 7-chloro-5-(methylthio)imidazo[1,2-c]pyrimidine hydrochloride (52.2 g, 1 eq., 221 mmol) was suspended in MeOH (200 mL). A solution of potassium hydroxide (55.9 g, 4.5 eq., 996 mmol) in water (520 mL) was added slowly. The reaction was heated under reflux for 3 hours and then checked by HPLC-MS. Starting material disappeared. The reaction was cooled to room temperature overnight. The mixture was acidified to pH 6 with 1M HCl and the resulting suspension was filtered. The solids were washed with MeOH, then transferred to a round bottom flask, suspended in ACN, and then concentrated. The product 7-chloroimidazo[1,2-c]pyrimidin-5(6H)-one (28.55 g, 76%) was obtained in pure form as a white solid. ESI-MS (M+H) + : 170.1.

[0158] Synthesis of 7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5(6H)-one (13). [ka] In a 3-necked flask, 7-chloroimidazo[1,2-c]pyrimidin-5(6H)-one (40.0 g, 1 eq., 236 mmol), 1-methyl-4-(4,4,5,5-tetra Methyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (73.6 g, 1.5 eq., 354 mmol) and X-phos (11.2 g, 0.10 eq., 23.6 mmol) in 2-propanol (1.8 L). and 2M aqueous potassium phosphate solution (150g, 0.35L, 3.0eq, 708mmol) was added. Mixture N 2 Purge for 15 min with Pd 2 (dba) 3 (10.8g, 0.05eq, 11.8mmol) was added and the mixture was refluxed overnight. The reaction was checked by HPLC-MS and analysis showed that the conversion was nearly complete. Pd 2 (dba) 3 (5.0g) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (25.0g) and stirred the mixture once more. Refluxed overnight. HPLC-MS showed complete conversion. The reaction mixture was filtered to remove palladium residue. The organic solvent was evaporated and the residue was partitioned between water and a 1:1 mixture of heptane:EtOAc. A white solid precipitated in both the organic and aqueous layers. The mixture was filtered off. The solid was washed with water, ethyl acetate and acetonitrile and dried under vacuum to give the product (32.8g). The filtrate layers were separated. The organic phase was discarded and the aqueous layer was cooled on an ice bath. The solution was treated with concentrated HCl to pH 6 while stirring and the resulting fine precipitate was collected and added to HCl. 2 O and Et 2 Washing with O and drying under vacuum gave a separate portion of the product (9.0 g). A total of 41.8 g (82%) of product was obtained as a yellowish solid. ESI-MS (M+H) + : 215.0.

[0159] Synthesis of 5-chloro-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidine. [ka] In a round bottom flask were 7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5(6H)-one (41.8 g, 1 eq., 194 mmol), anhydrous DCM (300 mL). and DIPEA (126g, 0.17L, 5eq, 971mmol). After 5 min, the mixture was cooled to 0 °C and POCl 3(89.3g, 54.1mL, 3eq, 583mmol) was added dropwise over 5 minutes. The mixture was allowed to warm to room temperature, diluted with DCM (150 mL), and then stirred at room temperature for 24 hours. The suspension was diluted with hexane and the solid was collected by filtration (66.0g). The collected solids were suspended in DCM:DIPEA (5:1, 500 mL). The mixture was stirred for 30 min, then NaHCO 3 A saturated aqueous solution was added and the mixture was stirred for 1 hour. The mixture was filtered through Celite, then the layers were separated and the aqueous layer was extracted three times with DCM. The organic layer was dried over sodium sulfate and concentrated. The product 5-chloro-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidine (22.5 g, 50%) was obtained as a yellow solid. ESI-MS (M+H) + : 234.0.

[0160] [ka] Synthesis of 4-methoxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine [ka] 6-bromo-4-methoxypyrazolo[1,5-a]pyridine (8.0 g, 35 mmol) and 1-methyl-4-(4,4,5,5- In a solution of tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (8.8 g, 42 mmol), K 2 C.O. 3 (9.74g, 70.5mmol) and Pd(dppf)Cl 2 (1.29g, 1.76mmol) and the reaction mixture was 2 The mixture was stirred at 90°C for 2 hours. Reaction mixture with H 2 Diluted with O (80 mL) and extracted with EtOAc (100 mL x 2). The combined organic phase was 2 S.O. 4 and filtered. The filtrate was concentrated under vacuum and the residue was purified by column chromatography on silica gel (PE / EtOAc=1 / 1-0 / 1) to give 4-methoxy-6-(1-methyl-1H-pyrazole- 4-yl)pyrazolo[1,5-a]pyridine (8.0g) was obtained as a white solid. 1HNMR (400 MHz, CDCl 3 ) δ: 8.27 (s, 1H), 7.86 (d, J=1.6 Hz, 1H), 7.74 (s, 1H), 7.61 (s, 1H), 6.62 (s, 1H), 6.47 (s, 1H), 4.00 (s, 3H), 3.97 (s, 3H)

[0161] 1.Synthesis of 6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-ol [ka] A solution of 4-methoxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine (15 g, 65.7 mmol) in aqueous HBr (100 mL, 48%) was prepared at 120 °C. Stirred for 48 hours. The reaction mixture was concentrated under vacuum and the residue was dissolved in saturated NaHCO 3 to pH 8 and extracted with EtOAc (3 x 80 mL). The combined organic layer was diluted with Na 2 S.O. 4 and filtered. The filtrate was concentrated to give the crude product, which was purified by column chromatography on silica gel (DCM / MeOH=20 / 1-10 / 1) to give 6-(1-methyl-1H-pyrazole-4 -yl)pyrazolo[1,5-a]pyridin-4-ol (13.0 g, 92% yield) was obtained as a gray solid. LCMS m / z = 215.0 (M+H)+

[0162] 2.Synthesis of 6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl trifluoromethanesulfonate [ka] DIPEA (87.58 g, 678 mmol) and N-phenyl-bis(trifluoromethanesulfonimide) (72.63g, 203mmol) was added and the reaction was stirred at 20°C for 20 hours. Reaction mixture with H 2 Diluted with O (500 mL) and extracted with EtOAc (3 x 350 mL). The combined organic layer was diluted with Na 2 S.O. 4 and filtered. The filtrate was concentrated under vacuum and the crude was purified by column chromatography on silica gel (PE / EtOAc=20 / 1-1 / 1) to give 6-(1-methyl-1H-pyrazol-4-yl). 10 g of crude pyrazolo[1,5-a]pyridin-4-yl trifluoromethanesulfonate (32.0 g, 68% yield) as a yellow solid was obtained. LCMS m / z = 347.1 (M+H)+

[0163] C. Synthesis of Examples 1-236 Example 1: 1-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy-1-piperidyl]prop-2-yn-1- on. [ka]

[0164] Synthesis of tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxypiperidine-1-carboxylate [ka] A solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (664 mg, 3.30 mmol) in dry DMF (10 mL) was cooled in an ice bath. Sodium hydride (396 mg, 9.90 mmol, 60% purity) was then added in four portions with stirring. Stirring in the ice bath was continued for 45 minutes, during which time a pale yellow suspension formed. To this mixture was added 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (701 mg, 3.00 mmol) in one batch, and the mixture instantly turned brownish-orange. It turned into color. Stirring at room temperature was continued overnight. The mixture was diluted with EtOAc and then water was carefully added. The mixture was transferred to a separatory funnel and the phases were separated. The aqueous phase was extracted one more time with EtOAc and the combined organic phases were washed with brine and Na 2 S.O. 4 dried, filtered and evaporated under vacuum. The residual material was purified with a 10g Si-SPE column: Rt=0.18, heptane / EtOAc=1 / 1 to give tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5- a]pyrazin-4-yl]oxypiperidine-1-carboxylate (1.30 g, 98% yield, 90% purity) was obtained as a sticky yellow gum. LCMS: m / z = 399.0 (M+H + ).

[0165] Synthesis of 6-(1-methylpyrazol-4-yl)-4-(4-piperidyloxy)pyrazolo[1,5-a]pyrazine [ka] tert-Butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxypiperidine-1-carboxylate (1.17g, TFA (6.70 g, 58.8 mmol, 4.5 mL) was added to a solution of 2.94 mmol) at room temperature with stirring. Stirring was continued overnight. Dilute the mixture with MeOH and transfer the product to 2M NH on a 10g SCX column. 3 -MeOH and purified by elution with 6-(1-methylpyrazol-4-yl)-4-(4-piperidyloxy)pyrazolo[1,5-a]pyrazine (890 mg, 96% yield, 95% purity). ) was obtained as a pale yellow solid. LCMS: m / z = 299.0 (M+H + ).

[0166] Synthesis of 1-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy-1-piperidyl]prop-2-yn-1-one [ka] 6-(1-methylpyrazol-4-yl)-4-(4-piperidyloxy)pyrazolo[1,5-a]pyrazine (30 mg, DIPEA (26 mg, 201 μmol, 35 μL) was added to a solution of 101 μmol) at room temperature with stirring. T3P (128 mg, 201 μmol, 50% purity) was then added with stirring. Stirring was continued overnight. The mixture was diluted with EtOAc and washed with water. The organic phase was dried over Na2SO4, filtered and the filtrate was evaporated to dryness. This material was dissolved in DMSO, filtered through a syringe filter, and preparative HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-50%B(0.2%NH 41-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4 -yl]oxy-1-piperidyl]prop-2-yn-1-one (12.6 mg, 95% purity, 34% yield) was obtained as a white solid. LCMS: m / z = 351.0 (M+H + ). 1 H NMR (500 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.20 (s, 1H), 7.98-8.04 (m, 2H), 6.83-6.92 (m, 1H), 5.55-5.69 (m, 1H) ), 4.57 (s, 1H), 3.95-4.06 (m, 1H), 3.88 (s, 3H), 3.72-3.86 (m, 2H), 3.50-3.61 (m, 1H), 2.12-2.20 (m, 1H) ), 2.02-2.11 (m, 1H), 1.82-1.91 (m, 1H), 1.73-1.81 (m, 1H).

[0167] Example 2: 1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)piperidin-1-yl)prop- 2-en-1-one [ka]

[0168] A 20 mL screw top vial was charged with 6-(1-methylpyrazol-4-yl)-4-(4-piperidyloxy)pyrazolo[1,5-a]pyrazine (30 mg, 101 μmol) and THF (1 mL). Acryloyl chloride (12 μL, 151 μmol) was then added with stirring and a milky white suspension was instantly formed. Triethylamine (28 μL, 201 μmol) was then added with stirring. After stirring for 5 minutes at room temperature, the volatiles were evaporated leaving a white solid. This material was dissolved in DMSO, filtered through a syringe filter, and preparative HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-50%B(0.2%NH 4 1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a ]pyrazin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one (24.9 mg, purity 95%, yield 67%) was obtained as a white solid. LCMS: m / z = 353.0 (M+H + ). 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.75 (d, J =1.22Hz,1H),8.21(s,1H),8.01-8.03(m,2H),6.86-6.88(m,1H),6.83-6.90(m,1H),6.12( brdd,J = 2.44, 16.48 Hz, 1H), 5.67-5.73 (m, 1H), 5.60 (ddd, J =3.97,7.63,11.60Hz,1H),3.85-3.97(m,2H),3.89(s, 3H), 3.39-3.69(m, 2H), 1.98-2.21(m, 2H), 1.59-1.91 (m, 2H).

[0169] Example 3: 6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl)piperidin-4-yl)oxy)pyrazolo[1,5-a]pyrazine [ka]

[0170] 6-(1-Methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl)piperidin-4-yl)oxy)pyrazolo[1,5-a]pyrazine, 2- It was prepared in the same manner as in Example 2 except that chloro-ethane-sulfonyl chloride was substituted. Substances were analyzed by preparative HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-55%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to give 6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl)piperidine-4 -yl)oxy)pyrazolo[1,5-a]pyrazine (4.9 mg, 95% purity, 12% yield) was obtained as a white solid. LCMS: m / z = 389.0 (M+H + ). 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.75 (d, J =1.22Hz,1H),8.20(s,1H),8.02(d,J = 2.44 Hz, 1H), 8.01 (s, 1H), 6.89 (dd, J =10.38,16.48Hz ,1H),6.85(d,J = 3.05 Hz, 1H), 6.20 (d, J =9.77Hz,1H),6.16(d,J = 17.09 Hz, 1H), 5.49 (ddd, J =3.66,7.63, 11.29Hz,1H),3.88(s,3H),3.37-3.54(m,2H),3.18(m,2H),2.10-2.24(m,2H),1.79-1.96(m,2H).

[0171] Example 4: (R)-1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)piperidine-1- il)prop-2-en-1-one [ka]

[0172] (R)-1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)piperidin-1-yl)prop- 2-en-1-one was prepared as in Example 2 except starting from (R)-tert-butyl 3-hydroxypiperidine-1-carboxylate. Substances were analyzed by preparative HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-50%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to give (R)-1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1 ,5-a]pyrazin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one (23.1 mg, purity 95%, yield 67%) was obtained as a white powder. LCMS: m / z = 353.0 (M+H + ). 1 HNMR(500MHz,DMSO-d 6 ) δ 8.76 (s, 1H), 8.28-8.33 (m, 1H), 8.14-8.22 (m, 1H), 7.97-8.03 (m, 1H), 6.67-6.77 (m, 1H), 6.52-6.97 (m , 1H), 5.92-6.15 (m, 1H), 5.42-5.74 (m, 1H), 5.19-5.40 (m, 1H), 3.88 (s, 3H), 3.59-4.27 (m, 4H), 1.47-2.22 (m, 4H).

[0173] Example 5: (R)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl)piperidin-3-yl)oxy)pyrazolo[1,5-a] pyrazine [ka]

[0174] (R)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl)piperidin-3-yl)oxy)pyrazolo[1,5-a]pyrazine, ( Prepared as in Example 3 except starting with R)-tert-butyl 3-hydroxypiperidine-1-carboxylate. Substances were analyzed by preparative HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-55%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to produce (R)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl )piperidin-3-yl)oxy)pyrazolo[1,5-a]pyrazine (8.9 mg, purity 95%, yield 22%) was obtained as a white powder. LCMS: m / z = 389.0 (M+H + ). 1 H NMR (500 MHz, DMSO-d 6) δ 8.78 (s, 1H), 8.21 (s, 1H), 8.03 (d, J =1.83Hz,1H),8.02(s,1H),6.84(d,J = 2.44 Hz, 1H), 6.78-6.88 (m, 1H), 6.11 (s, 1H), 6.08 (d, J =6.10Hz,1H),5.38(ddd,J = 3.66, 7.17, 10.53 Hz, 1H), 3.88 (s, 3H), 3.74 ( br dd, J =3.66,12.21Hz,1H),3.46(brd, J = 18.31 Hz, 1H), 3.21-3.29 (m, 1H), 3.11 (ddd, J =3.36,8.09,11.75Hz,1H), 2.05(ddd,J = 3.66, 8.39, 12.36 Hz, 1H), 1.89-1.98 (m, 1H), 1.79-1.88 (m, 1H), 1.71 (tdd, J =4.04,8.47,17.01Hz,1H).

[0175] Example 6: (S)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl)piperidin-3-yl)oxy)pyrazolo[1,5-a] pyrazine [ka]

[0176] (S)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl)piperidin-3-yl)oxy)pyrazolo[1,5-a]pyrazine, ( Prepared as in Example 3 except starting with S)-tert-butyl 3-hydroxypiperidine-1-carboxylate. Substances were analyzed by preparative HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-55%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to produce (S)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl )piperidin-3-yl)oxy)pyrazolo[1,5-a]pyrazine (8.0 mg, purity 95%, yield 18%) was obtained. LCMS: m / z = 389.0 (M+H + ). 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.78 (s, 1H), 8.21 (s, 1H), 8.03 (d, J =1.83Hz,1H),8.02(s,1H),6.84(d,J = 2.44 Hz, 1H), 6.79-6.86 (m, 1H), 6.11 (s, 1H), 6.08 (d, J =6.10Hz,1H),5.38(tt,J = 3.59, 7.10 Hz, 1H), 3.88 (s, 3H), 3.74 (dd, J =3.36,11.90Hz,1H),3.48(brs, 1H), 3.21-3.29 (m, 1H), 3.11 (ddd, J =3.36,8.09,11.75Hz,1H),2.05(ddd,J = 3.97, 8.24, 12.21 Hz, 1H), 1.89-1.98 (m, 1H), 1.80-1.89 (m, 1H), 1.65-1.76 (m, 1H).

[0177] Example 7: (R)-1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)piperidine-1- il)prop-2-yn-1-one [ka]

[0178] Synthesis of (R)-tert-butyl 3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxypiperidine-1-carboxylate [ka] A solution of (R)-tert-butyl 3-hydroxypiperidine-1-carboxylate (221 mg, 1.10 mmol) in dry DMF (3 mL) was cooled in an ice bath. Sodium hydride (132 mg, 3.30 mmol, 60% purity) was then added in two portions with stirring. Stirring in the ice bath was continued for 45 minutes, during which time a pale yellow suspension formed. To this mixture, 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (234 mg, 1.00 mmol) was added in one batch, and the mixture instantly turned orangeish. It turned brown. Stirring at room temperature was continued overnight. The mixture was diluted with EtOAc and then water was carefully added. The mixture was transferred to a separatory funnel and the phases were separated. The aqueous phase was extracted one more time with EtOAc and the combined organic phases were washed with brine and Na 2 S.O. 4 dried, filtered and evaporated under vacuum. The residual material was purified with a 10g Si-SPE column: Rt=0.22, heptane / EtOAc=1 / 1 to give (R)-tert-butyl=3-[6-(1-methylpyrazol-4-yl)pyrazolo[ 1,5-a]pyrazin-4-yl]oxypiperidine-1-carboxylate (390 mg, 88% yield, 90% purity) was obtained as a colorless viscous gum. LCMS: m / z = 399.0 (M+H + ).

[0179] Synthesis of (R)-6-(1-methylpyrazol-4-yl)-4-(3-piperidyloxy)pyrazolo[1,5-a]pyrazine [ka] (R)-tert-Butyl 3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxypiperidine-1-carboxy in dry DCM (3 mL) TFA (2.23 g, 19.58 mmol, 1.50 mL) was added to a solution of Lato (390 mg, 979 μmol) at room temperature with stirring. After stirring overnight at room temperature, the mixture was diluted with MeOH and the product was transferred to 2M NH on a 5g SCX column. 3 -MeOH and purified by elution with (R)-6-(1-methylpyrazol-4-yl)-4-(3-piperidyloxy)pyrazolo[1,5-a]pyrazine (270 mg, 88% yield). , purity 95%) was obtained as a colorless gum. LCMS: m / z = 299.0 (M+H + ).

[0180] (R)-1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)piperidin-1-yl)prop- Synthesis of 2-yn-1-one [ka] A solution of (R)-6-(1-methylpyrazol-4-yl)-4-(3-piperidyloxy)pyrazolo[1,5-a]pyrazine (30 mg, 101 μmol) in DMF (1 mL) was added with propiol. Acid (7.0 mg, 101 μmol, 6 μL) was added followed by DIPEA (26 mg, 201 μmol, 35 μL) at room temperature with stirring. T3P (128 mg, 201 μmol, 50% purity) was then added with stirring. Stirring at room temperature was continued overnight. The mixture was diluted with EtOAc and washed with water. organic phase with Na 2 S.O. 4 and filtered. The filtrate was evaporated under vacuum and the residual material was redissolved in DMSO. Substances were analyzed by preparative HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-50%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to give (R)-1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1 ,5-a]pyrazin-4-yl)oxy)piperidin-1-yl)prop-2-yn-1-one (20.6 mg, purity 95%, yield 55%) was obtained as a white powder. LCMS: m / z = 350.1 (M+H + ). 1 HNMR(500MHz,DMSO-d 6 )δ8.75-8.77(m,1H),8.02(d,J = 1.83 Hz, 1H), 8.00-8.27 (m, 2H), 6.76-6.77 (m, 1H), 5.26-5.49 (m, 1H) , 4.13-4.61 (m, 1H), 3.90-4.33 (m, 1H), 3.88 (s, 3H), 3.70-3.84 (m, 1H), 3.44-3.62 (m, 1H), 3.15-3.30 (m, 1H), 1.53-2.18 (m, 4H).

[0181] Example 8: (Z)-4-chloro-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy) Piperidin-1-yl)but-2-en-1-one [ka]

[0182] (Z)-4-chloro-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)piperidine-1- Synthesis of yl)but-2-en-1-one [ka] A 20 mL screw top vial was charged with 6-(1-methylpyrazol-4-yl)-4-(4-piperidyloxy)pyrazolo[1,5-a]pyrazine (30 mg, 100 μmol) and DMF (1 mL). (Z)-4-Chlorobut-2-enoic acid (15.5 mg, 120 μmol) was then added with stirring and a milky white suspension was formed instantly. HATU (57.7 mg, 150 μmol) was then added and the mixture was stirred at room temperature for 5 minutes. DIPEA (35 μL, 201 μmol) was then added with stirring. Stirring at room temperature was continued overnight. The mixture was diluted with EtOAc and washed with water. organic phase with Na 2 S.O. 4 and filtered. The filtrate was evaporated under vacuum, the residual material was dissolved in DMSO and purified by preparative HPLC (Waters XSelect CSH C18, 5 μm, 19 mm × 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-55%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to give (Z)-4-chloro-1-(4-((6-(1-methyl-1H-pyrazol-4-yl) ) pyrazolo[1,5-a]pyrazin-4-yl)oxy)piperidin-1-yl)but-2-en-1-one (17.8 mg, purity 95%, yield 42%) was obtained as a white powder. Ta. LCMS: m / z = 400.1. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.76 (s, 1H), 8.21 (s, 1H), 8.00-8.03 (m, 2H), 6.88 (d, J =1.22Hz,1H),6.84-6.87(m,1H),6.65-6.72( m,1H),5.61(ddd,J = 3.66, 7.48, 11.44 Hz, 1H), 4.38 (dd, J =1.22,6.71Hz,2H),3.89(s,3H),3.44-3.69(m,4H) ,2.00-2.17(m,2H),1.67-1.86(m,2H).

[0183] Example 9: 1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azetidin-1-yl)prop- 2-en-1-one [ka]

[0184] Synthesis of tert-butyl 3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazetidine-1-carboxylate [ka] A solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (191 mg, 1.10 mmol) in dry DMF (3 mL) was cooled in an ice bath. Sodium hydride (132 mg, 3.30 mmol, 60% purity) was then added in two portions with stirring. Stirring in the ice bath was continued for 45 minutes, during which time a pale yellow suspension formed. To this mixture, 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (234 mg, 1.00 mmol) was added in one batch, and the mixture instantly turned orangeish. It turned brown. Stirring at room temperature was continued overnight. Dilute the mixture with EtOAc and then carefully add water. The mixture was transferred to a separatory funnel and the phases were separated. The aqueous phase was extracted one more time with EtOAc and the combined organic phases were washed with brine and Na 2 S.O. 4 dried, filtered and evaporated under vacuum. The residual material was purified with a 10g Si-SPE column: Rt=0.0.18, heptane / EtOAc=1 / 1 to give tert-butyl=3-[6-(1-methylpyrazol-4-yl)pyrazolo[1, 5-a]pyrazin-4-yl]oxyazetidine-1-carboxylate (380 mg, 97% yield, 95% purity) was obtained as a colorless viscous gum. ESI-MS (M+H) + : 371.0.

[0185] Synthesis of 4-(azetidin-3-yloxy)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine [ka] tert-Butyl 3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazetidine-1-carboxylate (380 mg, TFA (2.34 g, 20.5 mmol, 1.57 mL) was added to a solution of 1.03 mmol) at room temperature with stirring. Stirring was continued overnight. Dilute the mixture with MeOH and transfer the product to 2M NH on a 10g SCX column. 3 -MeOH and purified by elution with 4-(azetidin-3-yloxy)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (250 mg, 85% yield, 95% purity). %) as a white solid. ESI-MS (M+H) + : 271.0.

[0186] 1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azetidin-1-yl)prop-2-ene- Synthesis of 1-one [ka] 1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azetidin-1-yl)prop-2-ene- 1-one was prepared similarly to Example 2. Substances were analyzed by preparative HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-45%B(0.2%NH 4 1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a ]pyrazin-4-yl)oxy)azetidin-1-yl)prop-2-en-1-one (20 mg, purity 95%, yield 64%) was obtained as a white powder. LCMS: m / z = 325.0. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.82 (s, 1H), 8.24 (s, 1H), 8.06 (d, J =2.44Hz,1H),8.03(s,1H),6.90-6.92(m,1H),6.38(dd,J = 10.38, 17.09 Hz, 1H), 6.11-6.17 (m, 1H), 5.70 (dd, J =2.44,10.38Hz,1H),5.62(tt,J = 4.27, 6.71 Hz, 1H), 4.83 (br dd, J =6.71,9.16Hz,1H),4.52(brdd,J = 7.02, 11.29 Hz, 1H), 4.37 (brdd, J =3.66,9.77Hz,1H),4.08(brdd,J = 3.66, 11.60 Hz, 1H), 3.89 (s, 3H).

[0187] Example 10: (Z)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(prop-1-en-1-ylsulfonyl)azetidin-3-yl)oxy) Pyrazolo[1,5-a]pyrazine [ka]

[0188] (Z)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(prop-1-en-1-ylsulfonyl)azetidin-3-yl)oxy)pyrazolo[1, 5-a]pyrazine was prepared similarly to Example 9 except that (Z)-prop-1-ene-1-sulfonyl chloride was used instead of acryloyl chloride. Substances were analyzed by preparative HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-55%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to give (Z)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(prop- 1-en-1-ylsulfonyl)azetidin-3-yl)oxy)pyrazolo[1,5-a]pyrazine (10 mg, 95% purity, 28% yield) was obtained as a beige solid. LCMS: m / z = 374.0. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.82 (s, 1H), 8.23-8.27 (s, 1H), 8.06 (d, J =2.44Hz,1H),7.98-8.04(s,1H),6.87-6.92(m,1H),6.72- 6.84(m,2H),5.42-5.56(m,1H),4.31-4.45(m,2H),3.92-4.04(m,2H),3.88(s,3H),1.95(d,J = 4.88 Hz, 3H).

[0189] Example 11: (R)-1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)pyrrolidine-1- il)prop-2-en-1-one [ka]

[0190] Synthesis of tert-butyl(3R)-3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxypyrrolidine-1-carboxylate [ka] A solution of tert-butyl (3R)-3-hydroxypyrrolidine-1-carboxylate (193 mg, 1.03 mmol) in dry DMF (3 mL) was cooled in an ice bath. Sodium hydride (136 mg, 3.40 mmol, 60% purity) was then added in four portions with stirring. Stirring in the ice bath was continued for 45 minutes, during which time a pale yellow suspension formed. To this mixture, 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (240 mg, 1.03 mmol) was added in one batch, and the mixture instantly turned orangeish. It turned brown. Stirring at room temperature was continued overnight. The mixture was diluted with EtOAc and then water was carefully added. The mixture was transferred to a separatory funnel and the phases were separated. The aqueous phase was extracted once more with EtOAc and the combined organic phases were washed with brine, dried over Na2SO4, filtered and evaporated under vacuum. The residual material was purified on a 10 g Si-SPE column with heptane / EtOAc=1 / 1 to give tert-butyl(3R)-3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5- a]pyrazin-4-yl]oxypyrrolidine-1-carboxylate (345 mg, 83% yield, 95% purity) was obtained as a sticky colorless gum which, upon further drying, gave a sticky white It turned into a foamy substance. ESI-MS (M+H)+: 395.0.

[0191] Synthesis of 6-(1-methylpyrazol-4-yl)-4-[(3R)-pyrrolidin-3-yl]oxy-pyrazolo[1,5-a]pyrazine [ka] tert-Butyl (3R)-3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxypyrrolidine-1-carboxylate in DCM (5 mL) (326 mg, 849 μmol) was added TFA (1.93 g, 17 mmol, 1.30 mL) at room temperature with stirring. Stirring was continued overnight. Dilute the mixture with MeOH and transfer the product to 2M NH on a 10g SCX column. 3 -MeOH and purified by elution with 6-(1-methylpyrazol-4-yl)-4-[(3R)-pyrrolidin-3-yl]oxy-pyrazolo[1,5-a]pyrazine (230 mg, yield 91% purity, 95% purity) was obtained as a sticky pale yellow gum. ESI-MS (M+H)+: 285.0.

[0192] (R)-1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)pyrrolidin-1-yl)prop- Synthesis of 2-en-1-one [ka] (R)-1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)pyrrolidin-1-yl)prop- 2-en-1-one was prepared similarly to Example 2. Substances were analyzed by preparative HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-45%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to give (R)-1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1 ,5-a]pyrazin-4-yl)oxy)pyrrolidin-1-yl)prop-2-en-1-one (27.9 mg, purity 95%, yield 74%) was obtained as a white solid. ESI-MS (M+H)+: 339.0. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.78 (s, 1H), 8.21-8.26 (m, 1H), 8.03 (d, J =1.83Hz,1H),8.00-8.02(m,1H),6.84(brd, J = 1.22 Hz, 1H) , 6.54-6.69 (m, 1H), 6.12-6.20 (m, 1H), 5.81-5.94 (m, 1H), 5.64-5.73 (m, 1H), 3.89 (s, 3H), 3.82-4.11 (m, 1H), 3.65-3.78 (m, 1H), 3.43-3.59 (m, 2H), 2.19-2.47 (m, 2H).

[0193] Example 12: (R)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl)pyrrolidin-3-yl)oxy)pyrazolo[1,5-a] pyrazine [ka]

[0194] (R)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl)pyrrolidin-3-yl)oxy)pyrazolo[1,5-a]pyrazine, chlorinated Prepared as in Example 11 except that acryloyl was replaced with 2-chloro-ethane-sulfonyl chloride. Substances were analyzed by preparative HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-50%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to produce (R)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl )pyrrolidin-3-yl)oxy)pyrazolo[1,5-a]pyrazine (6.6 mg, purity 95%, yield 16%) was obtained as a white solid. ESI-MS (M+H)+: 375.0. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.78 (s, 1H), 8.22 (s, 1H), 8.03 (d, J =2.44Hz,1H),8.00-8.02(m,1H),6.92(dd,J = 10.38, 16.48 Hz, 1H) , 6.85-6.86 (m, 1H), 6.07-6.12 (m, 1H), 6.05 (d, J =9.77Hz,1H),5.78-5.84(m,1H),3.88(s,3H),3.39-3.75 (m,4H),2.20-2.39(m,2H).

[0195] Example 13: (R)-1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)pyrrolidine-1- il)prop-2-yn-1-one [ka]

[0196] (R)-1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)pyrrolidin-1-yl)prop- 2-yn-1-one was prepared similarly to Example 1. Substances were analyzed by preparative HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-45%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to give (R)-1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1 ,5-a]pyrazin-4-yl)oxy)pyrrolidin-1-yl)prop-2-yn-1-one (18.2 mg, purity 95%, yield 51%) was obtained as a white solid. ESI-MS (M+H)+: 337.0. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.77-8.81 (m, 1H), 8.21-8.26 (m, 1H), 8.00-8.06 (m, 2H), 6.86 (d, J =2.44Hz,1H),5.81-5.91(m,1H), 4.43-4.58(m,1H),3.86-3.91(m,1H),3.86(s,3H),3.40-3.71(m,3H),2.20-2.47(m,2H).

[0197] Example 14: (S)-1-(3-(((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)methyl)piperidine -1-yl)prop-2-en-1-one [ka]

[0198] Synthesis of tert-butyl(3S)-3-[[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxymethyl]piperidine-1-carboxylate [ka] A solution of tert-butyl (3S)-3-(hydroxymethyl)piperidine-1-carboxylate (222 mg, 1.03 mmol) in dry DMF (3 mL) was cooled in an ice bath. Sodium hydride (136 mg, 3.40 mmol, 60% purity) was then added in four portions with stirring. Stirring in the ice bath was continued for 45 minutes, during which time a pale yellow suspension formed. To this mixture, 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (240 mg, 1.03 mmol) was added in one batch, and the mixture instantly turned orangeish. It turned brown. Stirring at room temperature was continued overnight. The mixture was diluted with EtOAc and then water was carefully added. The mixture was transferred to a separatory funnel and the phases were separated. The aqueous phase was extracted one more time with EtOAc and the combined organic phases were washed with brine and Na 2 S.O. 4 dried, filtered and evaporated under vacuum. The residual material was purified with a 10 g Si-SPE column: Rt=0.1, heptane / EtOAc=2 / 1 to give tert-butyl(3S)-3-[[6-(1-methylpyrazol-4-yl)pyrazolo[ 1,5-a]pyrazin-4-yl]oxymethyl]piperidine-1-carboxylate (386 mg, 86% yield, 95% purity) was obtained as an off-white solid. ESI-MS (M+H)+: 413.0.

[0199] Synthesis of 6-(1-methylpyrazol-4-yl)-4-[[(3S)-3-piperidyl]methoxy]pyrazolo[1,5-a]pyrazine [ka] tert-Butyl=(3S)-3-[[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxymethyl]piperidine-1 in DCM (5 mL) -To a solution of carboxylate (404 mg, 978 μmol) was added TFA (2.23 g, 19.6 mmol, 1.50 mL) at room temperature with stirring. Stirring was continued overnight. Dilute the mixture with MeOH and transfer the product to 2M NH on a 10g SCX column. 3 -MeOH and purified by elution with 6-(1-methylpyrazol-4-yl)-4-[[(3S)-3-piperidyl]methoxy]pyrazolo[1,5-a]pyrazine (240 mg, yield 75%, purity 95%) was obtained as a pale yellow sticky gum which upon further drying formed a white foam. ESI-MS (M+H)+: 313.0.

[0200] (S)-1-(3-(((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)methyl)piperidin-1-yl )Synthesis of prop-2-en-1-one [ka] (S)-1-(3-(((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)methyl)piperidin-1-yl ) Prop-2-en-1-one was prepared similarly to Example 2. Substances were analyzed by preparative HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-50%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to produce (S)-1-(3-(((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[ 1,5-a]pyrazin-4-yl)oxy)methyl)piperidin-1-yl)prop-2-en-1-one (10.6 mg, purity 95%, yield 28%) was obtained as a white powder. . ESI-MS (M+H)+: 367.0. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.76 (s, 1H), 8.21 (br s, 1H), 8.03 (d, J =2.44Hz,1H),8.01(s,1H),6.85-6.92(m,1H),6.77-6.84(m ,1H),5.96-6.10(m,1H),5.54-5.67(m,1H),4.41-4.50(m,2H),3.90-4.13(m,1H),3.89(s,3H),2.89-3.29 (m,3H),1.88-2.07(m,2H),1.73(s,1H),1.35-1.57(m,2H).

[0201] Example 15: (S)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl)piperidin-3-yl)methoxy)pyrazolo[1,5-a] pyrazine [ka]

[0202] (S)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl)piperidin-3-yl)methoxy)pyrazolo[1,5-a]pyrazine, Prepared as in Example 14 except that acryloyl was replaced with 2-chloro-ethane-sulfonyl chloride. Substances were analyzed by preparative HPLC (Waters SunFire Prep C18, 5 μm, OBD19 mm x 100 mm column, mobile phase H 2 Purified with O(A) and MeCN(B) and gradient 5-55%B (0.1%TFA final v / v% modifier, flow rate 30mL / min) to (S)-6-(1-methyl -1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl)piperidin-3-yl)methoxy)pyrazolo[1,5-a]pyrazine (8.0 mg, purity 95%, yield 19%) was obtained as a beige solid. ESI-MS (M+H)+: 403.0. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.77 (s, 1H), 8.21 (s, 1H), 8.03 (d, J =2.44Hz,1H),8.01(s,1H),6.84(d,J = 3.05 Hz, 1H), 6.76-6.84 (m, 1H), 6.13 (d, J =9.77Hz,1H),6.09(d,J = 16.48 Hz, 1H), 4.42-4.52 (m, 2H), 3.89 (s, 3H), 3.63 (br dd , J =3.66,11.60Hz,1H),3.38-3.55(m,2H),2.59-2.74(m,1H),2.12-2.28(m,1H),1.84-1.95(m,1H),1.79(td ,J = 3.66, 13.43 Hz, 1H), 1.50-1.64 (m, 1H), 1.18-1.38 (m, 1H).

[0203] Example 16: (S)-1-(3-(((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)methyl)piperidine -1-yl)prop-2-yn-1-one [ka]

[0204] (S)-1-(3-(((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)methyl)piperidin-1-yl ) Prop-2-yn-1-one was prepared similarly to Example 1. Substances were analyzed by preparative HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-55%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to produce (S)-1-(3-(((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[ 1,5-a]pyrazin-4-yl)oxy)methyl)piperidin-1-yl)prop-2-yn-1-one (24.8 mg, purity 95%, yield 68%) was obtained as a white solid. . ESI-MS (M+H)+: 365.0. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.74-8.78 (m, 1H), 8.21 (s, 1H), 7.96-8.07 (m, 2H), 6.78-6.90 (m, 1H), 4.52-4.55 (m, 1H), 4.27-4.51 (m , 2H), 4.01-4.17 (m, 1H), 3.89 (s, 3H), 3.22-3.32 (m, 1H), 2.78-2.98 (m, 2H), 1.98-2.21 (m, 1H), 1.88-1.95 (m, 1H), 1.67-1.83 (m, 1H), 1.28-1.55 (m, 2H).

[0205] Example 17: (R,E)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(prop-1-en-1-ylsulfonyl)piperidin-3-yl) Oxy)pyrazolo[1,5-a]pyrazine [ka]

[0206] 1.(R,E)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(prop-1-en-1-ylsulfonyl)piperidin-3-yl)oxy) Synthesis of pyrazolo[1,5-a]pyrazine [ka] In a vial, 6-(1-methylpyrazol-4-yl)-4-[[(3R)-3-piperidyl]oxy]pyrazolo[1,5-a]pyrazine (125 mg, 419 μmol), DCM (2.1 mL) , N-ethyl-N-isopropyl-propan-2-amine (162 mg, 1.26 mmol, 220 μL) and (E)-prop-1-ene-1-sulfonyl chloride (88 mg, 628 μmol, 66 μL) were added in this order. . The vial was stirred at room temperature overnight. The reaction was diluted with water, passed through a phase separator, and concentrated. The material was dissolved in 2.5 mL of DMSO and passed through a syringe filter. The material was analyzed by reverse-phase HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-60%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to give 6-(1-methylpyrazol-4-yl)-4-[[(3R)-1-[(E)-propanol. -1-enyl]sulfonyl-3-piperidyl]oxy]pyrazolo[1,5-a]pyrazine (55 mg, yield: 30%) was obtained as an off-white solid. ESI-MS (M+H) + : 403.1. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.78 (s, 1H), 8.21 (s, 1H), 7.99-8.06 (m, 1H), 6.84 (dd, J =1.22,2.44Hz,1H),6.61(brd, J = 6.71 Hz, 1H) , 6.46-6.54 (m, 1H), 5.38 (td, J =3.89,7.48Hz,1H),3.88(s,3H),3.72(brdd,J = 3.36, 11.90 Hz, 1H), 3.12-3.28 (m , 2H), 3.05 (ddd, J =3.36,8.09,11.75Hz,1H),2.02-2.08(m,1H),1.90-1.98(m,2H),1.85(dd,J = 1.83, 6.71 Hz, 3H ), 1.71 (ddd, J =4.58,8.55,13.12Hz,2H).

[0207] Example 18: 1-(4-(((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)amino)methyl)piperidin-1-yl )prop-2-en-1-one [ka]

[0208] 1.tert-butyl=4-(((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)amino)methyl)piperidine-1-carboxylate synthesis of [ka] 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (500mg, 2.14mmol) and tert-butyl4-(aminomethyl)piperidine in DMF (7.13mL) To a suspension of -1-carboxylate (504 mg, 2.35 mmol, 500 μL) was added Hunig's base (553 mg, 4.28 mmol, 750 μL). The reaction was warmed to 70°C and stirred overnight. The reaction was concentrated and purified by column chromatography (40 g silica column, 0-100% EtOAc:heptane gradient elution) to give tert-butyl 4-[[6-(1-methylpyrazol-4-yl). ) Pyrazolo[1,5-a]pyrazin-4-yl]amino]methyl]piperidine-1-carboxylate (398 mg, yield: 45%) was obtained as a brown solid. ESI-MS (M+H) + : 412.2.

[0209] 2.Synthesis of 6-(1-methyl-1H-pyrazol-4-yl)-N-(piperidin-4-ylmethyl)pyrazolo[1,5-a]pyrazin-4-amine [ka] tert-Butyl 4-[[[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]amino]methyl]piperidine-1-carboxylate (397mg, 965μmol) was dissolved in DCM (4.8 mL). TFA (1.10 g, 9.65 mmol, 738 μL) was added and the reaction was stirred at room temperature overnight. The reaction was concentrated, diluted with DCM, and carefully quenched with saturated sodium bicarbonate solution. The aqueous layer was washed twice with DCM, then diluted with saturated ammonium hydroxide solution and extracted twice with ethyl acetate. The combined ethyl acetate layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated to give 6-(1-methylpyrazol-4-yl)-N-(4-piperidylmethyl)pyrazolo[1,5 -a]pyrazin-4-amine (300 mg, yield: 100%) was obtained as a pale yellow oily solid. ESI-MS (M+H) + : 312.1.

[0210] 3.1-(4-(((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)amino)methyl)piperidin-1-yl)prop-2 -Synthesis of en-1-one [ka] A vial containing 6-(1-methylpyrazol-4-yl)-N-(4-piperidylmethyl)pyrazolo[1,5-a]pyrazin-4-amine (75 mg, 241 μmol) was added with DCM (2.4 mL) and TEA (73 mg, 725 μmol, 100 μL) was added, which was then placed on a dry ice / acetone bath for 10 minutes. Acryloyl chloride (28 mg, 313 μmol, 26 μL) was added dropwise to this solution. The reaction was stirred for 10 minutes. The reaction was diluted with water and passed through a phase separator. The aqueous layer was extracted with DCM, the combined organic layers were concentrated, dissolved in DMSO, and reversed phase HPLC (Waters XSelect CSH C18, 5 μm, 19 mm × 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-35%B(0.2%NH 4 1-[4-[[[[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine] -4-yl]amino]methyl]-1-piperidyl]prop-2-en-1-one (35 mg, yield: 39%) was obtained as a yellow solid. ESI-MS (M+H) + : 366.2. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.27 (s, 1H), 8.09 (s, 1H), 7.92 (s, 1H), 7.84 (d, J =2.44Hz,1H),7.64(brt, J = 5.49 Hz, 1H), 6.93-6.97 (m, 1H), 6.80 (br dd, J =10.68,16.79Hz,1H),6.07(br dd,J = 2.44, 17.09 Hz, 1H), 5.61-5.68 (m, 1H), 4.42 (br d, J =12.21Hz,1H),4.06(brd, J = 12.82 Hz, 1H), 3.87 (s, 3H), 3.40-3.50 (m, 1H), 2.97-3.10 (m, 1H), 2.59-2.67 (m, 1H), 1.99 (ddd, J =3.97,7.17,10.83Hz,2H),1.81(brd, J = 13.43 Hz, 2H), 1.06-1.22 (m, 2H).

[0211] Example 19: 6-(1-Methyl-1H-pyrazol-4-yl)-N-((1-(vinylsulfonyl)piperidin-4-yl)methyl)pyrazolo[1,5-a]pyrazine-4- amine [ka]

[0212] 1.Synthesis of 6-(1-methyl-1H-pyrazol-4-yl)-N-((1-(vinylsulfonyl)piperidin-4-yl)methyl)pyrazolo[1,5-a]pyrazin-4-amine [ka] DCM (2.4 mL) was added to a vial containing 6-(1-methylpyrazol-4-yl)-N-(4-piperidylmethyl)pyrazolo[1,5-a]pyrazin-4-amine (75 mg, 241 μmol), DMF (200 μL) and TEA (73 mg, 725 μmol, 100 μL) were added, which was then placed on a dry ice / acetone bath for 10 minutes. Ethenesulfonyl chloride (40 mg, 313 μmol, 28 μL) was added dropwise to this solution. The reaction was allowed to warm to room temperature and stirred overnight. The reaction was diluted with water and passed through a phase separator. The aqueous layer was extracted with DCM, the combined organic layers were concentrated, dissolved in DMSO, and reversed phase HPLC (Waters XSelect CSH C18, 5 μm, 19 mm × 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-40%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to produce 6-(1-methylpyrazol-4-yl)-N-[(1-vinylsulfonyl-4-piperidyl)methyl]pyrazolo -[1,5-a]pyrazin-4-amine (19 mg, yield: 20%) was obtained as a yellow solid. ESI-MS (M+H) + : 402.2. 1 H NMR (500 MHz, DMSO-d 6) δ 8.27 (s, 1H), 8.09 (s, 1H), 7.92 (s, 1H), 7.82-7.86 (m, 1H), 7.66 (br t, J =5.80Hz,1H),6.93-6.96(m ,1H),6.78(dd,J = 9.77, 16.48 Hz, 1H), 6.06-6.15 (m, 2H), 3.87 (s, 3H), 3.55 (br d, J =11.60Hz,2H),2.57-2.65 (m,4H),1.85(brd, J = 11.60 Hz, 3H), 1.25-1.35 (m, 2H).

[0213] Example 20: N-[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl]prop-2-enamide [ka]

[0214] Synthesis of tert-butyl N-[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl]carbamate [ka] A solution of 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (300 mg, 1.28 mmol) in t-BuOH (5.1 mL) was added with N-ethyl-N- Isopropyl-propan-2-amine (249 mg, 1.93 mmol, 336 μL) and tert-butyl N-(3-piperidyl) carbamate (264 mg, 1.32 mmol) were added in this order. The reaction mixture was stirred at 80°C overnight. The material was concentrated and carried forward as crude (100% expected yield). LCMS m / z = 398.0. (M+H)+.

[0215] Synthesis of 1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]piperidin-3-amine hydrochloride [ka] tert-Butyl N-[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl]carbamate ( To a solution of 509 mg, 1.28 mmol) was added HCl (4M, 1.92 mL). The mixture was stirred at room temperature overnight. A solid precipitated out, was filtered off and washed with EtOAc. The solid was air dried to give 1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]piperidin-3-amine hydrochloride (500 mg, 94% yield). ) was obtained as a brown solid. The solid was estimated to have 80% purity.

[0216] Synthesis of N-[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl]prop-2-enamide [ka] A solution of 1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]piperidin-3-amine hydrochloride (75mg, 180μmol) in DCM (1.8mL) To this, N-ethyl-N-isopropyl-propan-2-amine (93 mg, 719 μmol, 126 μL) and prop-2-enoyl chloride (18 mg, 198 μmol, 16 μL) were added in this order. The reaction mixture was stirred at room temperature overnight. The material was concentrated and purified by reverse phase purification (column: Waters , 30.5 mg (yield 49%) was obtained. LCMS m / z = 352.2 (M+H)+. 1 H NMR (500 MHz, DMSO-d 6 ) δ ppm 1.19 - 1.30 (m, 1 H) 1.53 - 1.69 (m, 2 H) 1.81 - 2.01 (m, 2 H) 3.06 (dd, J =12.82,9.77Hz,1 H) 3.23 - 3.27 (m, 1 H) 3.87 (s, 3 H) 3.91 - 3.97 (m, 1 H) 4.22 - 4.47 (m, 2 H) 5.57 - 5.66 (m, 1 H) 6.18 (s, 1 H) 6.23 - 6.34 (m, 1 H) 7.06 (d, J =2.44Hz,1 H) 7.89 - 8.03 (m, 1 H) 8.19 - 8.27 (m, 2 H) 8.40 - 8.53 (m, 1 H).

[0217] Example 21: N-[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl]prop-2-ynamide [ka]

[0218] Synthesis of N-[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl]prop-2-ynamide [ka] A solution of 1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]piperidin-3-amine hydrochloride (75mg, 180μmol) in DCM (1.5mL) To this, N-ethyl-N-isopropyl-propan-2-amine (86 mg, 669 μmol, 117 μL) and HATU (68 mg, 178 μmol) were added in this order. The reaction mixture was stirred for 15 minutes, then prop-2-ynoic acid (15 mg, 216 μmol, 13 μL) was added to it and the resulting mixture was stirred at room temperature overnight. The material was concentrated and purified by reverse phase purification (column: Waters , 14.8 mg (yield 24%) was obtained. LCMS m / z = 350.1 (M+H)+. 1 H NMR (500 MHz, DMSO-d 6 ) δ ppm 1.22 - 1.43 (m, 1 H) 1.51 - 1.68 (m, 2 H) 1.78 - 1.99 (m, 2 H) 3.04 (dd, J =12.82,9.16Hz,1 H) 3.18 - 3.26 (m, 1 H) 3.87 (s, 3 H) 3.90 - 3.99 (m, 1 H) 4.22 - 4.41 (m, 2 H) 6.96 (d, J =1.83Hz,1 H) 7.90 - 8.07 (m, 1 H) 8.20 (s, 1 H) 8.44 - 8.56 (m, 1 H) 8.92 (d, J =7.32Hz,1 H).One proton signal is masked by residual water in the deuterated solvent.

[0219] Example 22: 4-chloro-N-[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl]but-2-enamide [ka]

[0220] Synthesis of 4-chloro-N-[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl]but-2-enamide [ka] A solution of 1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]piperidin-3-amine hydrochloride (75mg, 180μmol) in DCM (1.5mL) To this, N-ethyl-N-isopropyl-propan-2-amine (86 mg, 669 μmol, 117 μL) and HATU (68 mg, 178 μmol) were added in this order. The reaction mixture was stirred for 15 minutes, then 4-chlorobut-2-enoic acid (26 mg, 216 μmol) was added to it and the resulting mixture was stirred at room temperature overnight. The material was concentrated and purified by reverse phase purification (column: Waters , 5.7 mg (yield 8%) was obtained. LCMS m / z = 400.2 (M+H)+. 1 H NMR (500MHz, DMSO-d 6 ) δ: 8.51 - 8.43 (m, 1H), 8.30 (d, J = 7.3 Hz, 1H), 8.25 - 8.17 (m, 1H), 8.02 - 7.89 (m, 1H), 7.09 - 6.98 (m, 1H) , 6.75 (td, J = 6.1, 14.6 Hz, 1H), 6.31 - 6.19 (m, 1H), 4.37 (dd, J = 1.2, 6.1 Hz, 3H), 4.32 - 4.19 (m, 1H), 4.02 - 3.91 (m, 1H), 3.87 (s, 3H), 3.31 - 3.22 (m, 1H), 3.15 - 3.00 (m, 1H), 2.03 - 1.90 (m, 1H), 1.86 (br d, J = 3.1 Hz, 1H), 1.70 - 1.54 (m, 2H), 1.33 - 1.17 (m, 1H).

[0221] Example 23: N-Methyl-N-[1-[7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl]-3-piperidyl]prop-2-ynamide [ka]

[0222] Synthesis of tert-butyl=N-methyl-N-[1-[7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl]-3-piperidyl]carbamate [ka] A solution of 5-chloro-7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidine (1.00 g, 4.28 mmol) in t-BuOH (8.6 mL) was added with N-ethyl-N -Isopropyl-propan-2-amine (830 mg, 6.42 mmol, 1.1 mL) and tert-butyl N-methyl-N-(3-piperidyl) carbamate (945 mg, 4.41 mmol) were added in this order. The reaction mixture was stirred at 80°C overnight. The material was concentrated and carried forward as crude (100% expected yield). LCMS m / z = 412.0 (M+H)+.

[0223] Synthesis of N-methyl-1-[7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl]piperidin-3-amine hydrochloride [ka] tert-Butyl N-methyl-N-[1-[7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl]-3- in dioxane (8.56 mL) To a solution of piperidyl]carbamate (1.76 g, 4.28 mmol) was added HCl (4M, 6.42 mL). The mixture was stirred at room temperature overnight. A solid precipitated out overnight, was filtered off and washed with EtOAc. The solid was air dried to give N-methyl-1-[7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl]piperidin-3-amine hydrochloride (1.94 g , 3.90 mmol, 91% yield) as an off-white solid. The solid was estimated to have a purity of 70%. LCMS m / z = 312.1 (M+H)+.

[0224] Synthesis of N-methyl-N-[1-[7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl]-3-piperidyl]prop-2-ynamide [ka] N-Methyl-1-[7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl]piperidin-3-amine hydrochloride (100 mg, 201 μmol) in DCM (1 mL) ), N-ethyl-N-isopropyl-propan-2-amine (130 mg, 1.01 mmol, 176 μL) and prop-2-ynoic acid (18 mg, 262 μmol, 16 μL) were added in this order. HATU (100 mg, 262 μmol) was then added to the vial and the resulting mixture was stirred at room temperature overnight. The material was concentrated and purified by reverse phase purification (column: Waters , 33.4 mg (yield 46%) was obtained. LCMS m / z = 364.3 (M+H)+.

[0225] Example 24: N-Methyl-N-[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl]prop-2-ynamide [ka]

[0226] Synthesis of tert-butyl N-methyl-N-[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl]carbamate [ka] A solution of 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (400 mg, 1.71 mmol) in t-BuOH (3.42 mL) was added with N-ethyl-N- Isopropyl-propan-2-amine (332 mg, 2.57 mmol, 448 μL) and tert-butyl N-methyl-N-(3-piperidyl) carbamate (378 mg, 1.76 mmol) were added in this order. The vial was stirred at 80°C overnight. The material was concentrated and carried forward as crude (100% expected yield). LCMS m / z = 412.1 (M+H)+.

[0227] Synthesis of N-methyl-1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]piperidin-3-amine hydrochloride [ka] tert-Butyl=N-methyl-N-[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3- in dioxane (8.6 mL) To a solution of piperidyl]carbamate (704 mg, 1.71 mmol) was added HCl (4M, 2.57 mL). The mixture was stirred at room temperature overnight. A solid precipitated out overnight, was filtered off and washed with EtOAc. The solid was air dried to give N-methyl-1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]piperidin-3-amine hydrochloride (651 mg, Yield 88%) was obtained as an off-white solid. The solid was estimated to have 80% purity. LCMS m / z = 312.1 (M+H)+.

[0228] Synthesis of N-methyl-N-[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl]prop-2-ynamide [ka] 1N-Methyl-1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]piperidin-3-amine hydrochloride (100mg, 230μmol) in DCM (1mL) ), prop-2-ynoic acid (21 mg, 299 μmol, 18 μL), N-ethyl-N-isopropyl-propan-2-amine (86 mg, 669 μmol, 117 μL) and HATU (114 mg, 299 μmol) were added in this order. added. The reaction mixture was stirred at room temperature overnight. The material was concentrated and purified by reverse phase purification (Column: Waters , 1.9 mg (yield 2%) was obtained. LCMS m / z = 364.2 (M+H)+. 1 H NMR (500 MHz, DMSO-d 6 ) δ ppm 1.59 - 1.75 (m, 1 H) 1.78 - 2.05 (m, 4 H) 2.90 (s, 2 H), 2.99 - 3.11 (m, 1 H) 3.14 - 3.18 (m, 1 H) 3.87 (d , J =1.83Hz,3 H) 4.29 - 4.56 (m, 4 H) 6.95 (d, J =2.44Hz,1 H) 7.90 - 8.04 (m, 2 H) 8.17 (d, J =17.70Hz,1 H ) 8.46 - 8.59 (m, 1 H).

[0229] Example 25: N-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-3-yl)methyl)propiol Amide [ka]

[0230] Synthesis of tert-butyl=N-[[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl]methyl]carbamate [ka] tert-Butyl N-(3-piperidylmethyl)carbamate (229 mg, 1.07 mmol), 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a] in isopropanol (4 mL) A suspension of pyrazine (250 mg, 1.07 mmol) and DIPEA (277 mg, 2.14 mmol, 374 μL) was heated under reflux for 17 hours. The reaction mixture was cooled to room temperature and concentrated under vacuum. The residue was taken up in EtOAc and washed with water and brine. Dry the organic layer (MgSO 4 ), filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (0-100% EtOAc / heptane). tert-Butyl N-[[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl]methyl]carbamate (379 mg, yield 86%) was obtained as a pale yellow solid. LCMS: m / z = 412.3 (M+H)+. 1H NMR (500 MHz, Chloroform-d)δ ppm 8.09 (s, 1 H), 7.82 - 7.96 (m, 3 H), 6.69 (br s, 1 H), 4.81 (br s, 1 H), 4.38 ( br d, J =13.4Hz,2 H), 3.98 (s, 3 H), 3.29 (br t, J =11.0Hz,1 H), 3.15 (br s, 2 H), 3.09 (br dd, J = 12.8,9.8Hz,1 H), 1.95 (br d, J =12.2Hz,2 H), 1.87 (dt, J =13.4,3.7Hz,1 H), 1.68 - 1.78 (m, 1 H), 1.45 - 1.53 (m,9 H), 1.33 - 1.42 (m,1 H).

[0231] Synthesis of [1-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-3-piperidyl]methanamine (hydrochloride) [ka] tert-Butyl N-[[1-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl in dry methanol (1 mL) A solution of ]-3-piperidyl]methyl]carbamate (150 mg, 365 μmol) was treated with hydrochloric acid (4M solution in dioxane, 1 mL). The resulting mixture was stirred at room temperature for 1 hour and concentrated under vacuum. [1-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-3-piperidyl]methanamine hydrochloride as an off-white Obtained as a solid. LCMS: m / z = 312.3 (M+H)+.

[0232] Synthesis of N-[[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl]methyl]prop-2-ynamide [ka] Crude [1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl] in dry DMF (1 mL) at 0 °C under nitrogen atmosphere. A suspension of methanamine hydrochloride (50 mg, 161 μmol) was added with DIPEA (62 mg, 482 μmol, 84 μL), followed by prop-2-ynoic acid (17 mg, 241 μmol, 15 μL) and T3P (204 mg, 321 μmol, 217 μL, in DMF). 50%) was added. The resulting solution was stirred at room temperature for 1 h, quenched with saturated sodium bicarbonate solution, and extracted with EtOAc. The organic layer was washed with water and brine, dried (MgSO 4 ), filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (0-10% MeOH / DCM). N-[[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3-piperidyl]methyl]prop-2-ynamide (42.8 mg, yield 66%, purity 90%) as an orange oil. LCMS: m / z = 364.2 (M+H)+. 1 H NMR (500 MHz, Chloroform-d)δ ppm 8.07 (s, 1 H), 7.83 - 7.88 (m, 2 H), 7.79 - 7.83 (m, 1 H), 6.65 (d, J =2.4Hz,1 H), 6.45 (br s, 1 H), 4.16 - 4.25 (m, 2 H), 3.94 - 3.98 (m, 3 H), 3.44 - 3.52 (m, 1 H), 3.35 - 3.44 (m, 1 H) ), 3.28 - 3.35 (m, 1 H), 3.20 - 3.27 (m, 1 H), 2.80 - 2.84 (m, 1 H), 2.08 (quind, J =9.0,9.0,9.0,9.0,3.7Hz,1 H), 1.91 - 2.00 (m, 1 H), 1.78 - 1.86 (m, 1 H), 1.61 - 1.78 (m,1 H), 1.38 - 1.50 (m, 1 H).

[0233] Example 26: (S)-N-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-2-yl) methyl)propiolamide and (R)-N-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidine-2- yl)methyl)propiolamide [ka]

[0234] Synthesis of tert-butyl N-[[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2-piperidyl]methyl]carbamate [ka] tert-Butyl N-(2-piperidylmethyl)carbamate (302 mg, 1.41 mmol), 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a] in dioxane (5 mL) A suspension of pyrazine (300 mg, 1.28 mmol) and cesium carbonate (1.25 g, 3.84 mmol) was sparged with nitrogen for 5 minutes. RuPhos (119mg, 256μmol) and Pd 2 (dba) 3 (117 mg, 128 μmol) was added and the resulting mixture was heated under reflux overnight. Additional tert-butyl N-(2-piperidylmethyl)carbamate (302 mg, 1.41 mmol), RuPhos (119 mg, 256 μmol) and Pd 2 (dba) 3 (117 mg, 128 μmol) was added and heating continued for a further 24 hours. The reaction mixture was then cooled to room temperature, filtered through Celite, rinsed with EtOAc, and the filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (0-100% EtOAc / heptane). tert-Butyl N-[[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2-piperidyl]methyl]carbamate (267 mg, yield 51%) was obtained as a yellow foam. LCMS: m / z = 412.3 (M+H)+. 1 H NMR (400 MHz, Chloroform-d)δ ppm 8.09 (s, 1 H), 7.82 - 7.95 (m, 3 H), 6.69 (br s, 1 H), 5.96 (br s, 1 H), 4.90 ( br s, 1 H), 4.29 - 4.42 (m, 1 H), 3.99 (s, 3 H), 3.85 (br t, J =11.8Hz,1 H), 3.35 (br d, J =13.6Hz,2 H), 1.71 - 1.92 (m, 6 H), 1.35 (s,9 H).

[0235] Synthesis of [1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2-piperidyl]methanamine (hydrochloride) [ka] tert-Butyl=N-[[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2-piperidyl]methyl in dry methanol (1 mL) ] A suspension of carbamate (150 mg, 365 μmol) was treated with hydrochloric acid (4M solution in dioxane, 1 mL) and the resulting solution was stirred at room temperature for 2 hours. A solid formed and the reaction mixture was concentrated under vacuum and the residue was used directly. [1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2-piperidyl]methanamine hydrochloride was obtained as a pale yellow solid. Quantitative yield assumed. LCMS: m / z = 312.2 (M+H)+.

[0236] Synthesis of N-[[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2-piperidyl]methyl]prop-2-ynamide [ka] Crude [1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2-piperidyl]methanamine in dry DMF (1 mL) at 0 °C under nitrogen. A suspension of hydrochloride (50 mg, 161 μmol) was added with DIPEA (62 mg, 482 μmol, 84 μL) followed by prop-2-ynoic acid (17 mg, 241 μmol, 15 μL) and T3P (204 mg, 321 μmol, 217 μL, 50 μL in DMF. %) was added. The resulting solution was stirred at room temperature for 1 h, quenched with saturated sodium bicarbonate solution, and extracted with EtOAc. The organic layer was washed with water and brine, dried (MgSO 4 ), filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (0-10% MeOH / DCM) and the product was further purified by preparative TLC (7% MeOH / DCM). N-[[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2-piperidyl]methyl]prop-2-ynamide (20 mg, yield 33%, purity 95%) was obtained as a brown solid. LCMS: m / z = 364.2 (M+H)+. 1H NMR (400 MHz, Chloroform-d)δ ppm 8.56 (br s, 1 H), 8.07 - 8.14 (m, 1 H), 7.89 (d, J =2.3Hz,1 H), 7.84 (s, 2 H) ), 6.67 (d, J =2.0Hz,1 H), 4.90 - 5.02 (m, 1 H), 4.31 (br d, J =13.8Hz,1 H), 4.05 - 4.19 (m, 1 H), 3.92 - 4.00 (m, 3 H), 3.42 - 3.52 (m, 1 H), 3.36 (br s, 1 H), 2.54 (s, 1 H), 1.73 - 1.96 (m,6 H).

[0237] Chiral SFC purification (CHIRALPAK AD-H 30×250mm, 5um column; Method: 30% MeOH (no modifier) / CO 2 (flow rate: 100 mL / min, ABPR 120 bar, MBPR 40 psi, column temperature 40° C.) to give enantiomer E1 (first eluting peak, 7.9 mg, 100% ee). Rf=3.76 min and enantiomer E2 (second eluting peak, 7.8 mg, 95.90%ee). Rf=4.43 minutes.

[0238] Example 27: N-[[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2-piperidyl]methyl]prop-2-enamide [ka]

[0239] Crude [1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2-piperidyl]methanamine in dry THF (1 mL) at 0 °C under nitrogen. To a suspension of hydrochloride (60 mg, 193 μmol) was added DIPEA (75 mg, 578 μmol, 101 μL) followed by prop-2-enoyl chloride (26 mg, 289 μmol, 24 μL). The resulting suspension was stirred at 0° C. for 10 min, quenched with saturated sodium bicarbonate solution, and extracted with EtOAc. The organic layer was washed with brine and dried (MgSO 4 ), filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (0-10% MeOH / DCM) and further purified by preparative TLC (93:7DCM / MeOH). N-[[1-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2-piperidyl]methyl]prop-2-enamide (13.2 mg, yield 18%, purity 95%) as a brownish foam. LCMS: m / z = 366.1 (M+H)+. 1 H NMR (400 MHz, Chloroform-d)δ ppm 8.09 (s, 1 H), 7.86 - 7.90 (m, 1 H), 7.83 - 7.86 (m, 1 H), 7.78 (s, 1 H), 7.70- 7.90 (br s, 1H), 6.67 (d, J =2.0Hz,1 H), 6.08 (dd, J =17.1,1.3Hz,1 H), 5.79 (dd, J =17.1,10.3Hz,1 H) , 5.43 (dd, J =10.4,1.4Hz,1 H), 4.98 - 5.08 (m, 1 H), 4.27 - 4.40 (m, 1 H), 4.08 - 4.22 (m, 1 H), 3.93 - 4.00 ( m,3 H), 3.44 - 3.53 (m,1 H), 3.28 - 3.44 (m, 1 H), 1.72 - 1.96 (m,6 H).

[0240] Example 28: (R)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl)azepan-4-yl)oxy)pyrazolo[1,5-a] pyrazine [ka]

[0241] 1.tert-butyl=(R)-4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxy Synthesis of Lato [ka] A solution of tert-butyl 4-hydroxyazepane-1-carboxylate (710 mg, 3.30 mmol) in dry DMF (10 mL) was cooled in an ice bath. Sodium hydride (396 mg, 9.90 mmol, 60% purity) was then added in four portions with stirring. Stirring in the ice bath was continued for 45 minutes, during which time a pale yellow suspension formed. To this mixture was added 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (700 mg, 3.00 mmol) in one portion. Stirring was continued overnight at room temperature. The mixture was diluted with ethyl acetate and then water was carefully added. The mixture was transferred to a separatory funnel and the phases were separated. The aqueous phase was extracted one more time with ethyl acetate and the combined organic phases were washed with brine and Na 2 S.O. 4 dried, filtered and concentrated. The residual material was purified on a 10 g silica column with 50% heptane / ethyl acetate to give tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4 -yl]oxyazepan-1-carboxylate (1.30 g, yield: 95%) was obtained as a sticky pale yellow gum. Chiral SFC purification of racemic substances (CHIRALPAK AD-H 30×250mm, 5um, 25%IPA+0.1%DEA / CO 2 (S)-tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1, 5-a]pyrazin-4-yl]oxyazepane-1-carboxylate (first eluting peak) (389 mg, yield: 63%) and (R)-tert-butyl 4-[6-(1-methyl Pyrazol-4-yl) pyrazolo[1,5-a]pyrazin-4-yl]oxyazepan-1-carboxylate (second eluting peak) (407 mg, yield: 66%) as an off-white solid. Obtained. The absolute stereochemistry of the products in these two peaks was later confirmed using commercially available chiral tert-butyl(4S)-hydroxyazepane-1-carboxylate, and the analytical data showed that the first A compound matching the eluting peak was synthesized. ESI-MS (M+H) + : 413.2.

[0242] 2. Synthesis of (R)-4-(azepan-4-yloxy)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine [ka] tert-Butyl (4R)-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxylate (407 mg, 987 μmol) in DCM (3 mL). TFA (2.25 g, 19.7 mmol, 1.51 mL) was added to the solution of ) at room temperature with stirring. After stirring overnight, dissolve the mixture in MeOH and transfer the desired product to 2M NH on a 5g SCX column. 3 -MeOH and purified by elution with 4-(azepan-4-yloxy)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (250 mg, yield: 77% yield). ) was obtained as a white solid. ESI-MS (M+H) + : 313.2.

[0243] 3.(R)-6-(1-methyl-1H-pyrazol-4-yl)-N-((1-(vinylsulfonyl)piperidin-4-yl)methyl)pyrazolo[1,5-a]pyrazine- Synthesis of 4-amine [ka] A solution of (4R)-(azepan-4-yloxy)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (30 mg, 96 μmol) in THF (1 mL) was added with 2-chloroethane. When sulfonyl chloride (31 mg, 192 μmol, 20 μL) was added, precipitation occurred instantly. TEA (39 mg, 384 μmol, 53 μL) was then added at room temperature with stirring. After stirring overnight, the volatiles were removed, the residual material was redissolved in DMSO, and the remaining material was redissolved in reverse phase HPLC (Waters XSelect CSH C18, 5 μm, 19 mm × 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-60%B(0.2%NH 4 (R)-6-(1-methylpyrazol-4-yl)-4-(1-vinylsulfonylazepane-4- yl)oxy-pyrazolo[1,5-a]pyrazine (11 mg, yield: 26%) was obtained as a yellow oil. ESI-MS (M+H) + : 403.2. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.74 (s, 1H), 8.19 (s, 1H), 7.98-8.03 (m, 1H), 6.79-6.94 (m, 2H), 6.05-6.11 (m, 2H), 5.57 (tt, J =3.66 ,7.63Hz,1H),3.88(s,3H),3.40-3.67(m,2H),3.33-3.38(m,2H),3.21-3.31(m,1H),2.17-2.27(m,1H), 1.99-2.10(m,3H),1.89-1.99(m,1H),1.68-1.83(m,1H).

[0244] Example 29: (R)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1- il)prop-2-en-1-one [ka]

[0245] 1.(R)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl) Synthesis of prop-2-en-1-one [ka] A solution of (4R)-(azepan-4-yloxy)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (30 mg, 96 μmol) in THF (1 mL) was - Upon addition of enoyl chloride (17 mg, 192 μmol, 16 μL), precipitation occurred instantly. TEA (19 mg, 192 μmol, 27 μL) was then added at room temperature with stirring. After stirring overnight, the volatiles were removed, the residual material was redissolved in DMSO, and the remaining material was redissolved in reverse phase HPLC (Waters XSelect CSH C18, 5 μm, 19 mm × 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-50%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to give (R)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1 ,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2-en-1-one (9 mg, yield: 23%) was obtained as a clear oil. ESI-MS (M+H) + : 367.2. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.73 (s, 1H), 8.18 (d, J =18.92Hz,1H),7.98-8.03(m,1H),6.76-6.87(m,2H),6.18(ddd,J = 2.44, 3.66, 16.48 Hz, 1H), 5.65-5.75 (m, 1H), 5.45-5.58 (m, 1H), 3.88 (d, J =1.83Hz,3H),3.56-3.79(m,4H),2.71-2.92(m, 1H),2.17-2.26(m,1H),1.99-2.10(m,2H),1.84-1.98(m,2H),1.63-1.82(m,1H).

[0246] Example 30: (R)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1- il)prop-2-yn-1-one [ka]

[0247] 1.(R)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl) Synthesis of prop-2-yn-1-one [ka] A solution of (4R)-(azepan-4-yloxy)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (30 mg, 96 μmol) in DMF (1 mL) was added with propiolic acid. (13 mg, 192 μmol, 12 μL) followed by DIPEA (25 mg, 192 μmol, 34 μL) at room temperature with stirring. After stirring at room temperature for 5 minutes, T3P (122 mg, 192 μmol, purity 50%) was added dropwise with stirring. After stirring for a further 3 hours at room temperature, the mixture was diluted with ethyl acetate and washed with water. The organic phase was dried over sodium sulphate, filtered and evaporated. The residual white solid was redissolved in DMSO and subjected to reverse phase HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-55%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to give (R)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1 ,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2-yn-1-one (24 mg, yield: 48%) was obtained as a white solid. ESI-MS (M+H) + : 365.2. 1 H NMR (500 MHz, DMSO-d 6 )δ8.70-8.81(m,1H),8.19(d,J = 3.66 Hz, 1H), 7.95-8.08 (m, 2H), 6.74-6.88 (m, 1H), 5.45-5.63 (m, 1H) , 3.88 (s, 3H), 3.75-3.84 (m, 2H), 3.48-3.66 (m, 2H), 2.19-2.29 (m, 1H), 2.10-2.20 (m, 1H), 1.85-2.09 (m, 4H), 1.67-1.84 (m, 1H).

[0248] Example 31: (S)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1- il)prop-2-yn-1-one [ka]

[0249] 1. Synthesis of (S)-4-(azepan-4-yloxy)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine [ka] tert-Butyl (4S)-4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxylate ( TFA (2.15 g, 18.9 mmol, 1.44 mL) was added to a solution of 389 mg, 944 μmol) at room temperature with stirring. After stirring overnight, dissolve the mixture in MeOH and transfer the desired product to 2M NH on a 5g SCX column. 3 -MeOH and purified by elution with 4-[(4S)-azepan-4-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (170 mg, yield :55%) was obtained as a white solid. ESI-MS (M+H) + : 313.2.

[0250] 2.(S)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl) Synthesis of prop-2-yn-1-one [ka] Propiolic acid (13 mg, 192 μmol, 12 μL) followed by DIPEA (25 mg, 192 μmol, 34 μL) at room temperature with stirring. After stirring at room temperature for 5 minutes, T3P (122 mg, 192 μmol, purity 50%) was added dropwise with stirring. After stirring for a further 3 hours at room temperature, the mixture was diluted with ethyl acetate and washed with water. The organic phase was dried over sodium sulphate, filtered and evaporated. The residual white solid was redissolved in DMSO and subjected to reverse phase HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-55%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to give (S)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1 ,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2-yn-1-one (18 mg, yield: 48%) was obtained as a yellow solid. ESI-MS (M+H) + : 365.2. 1 H NMR (500 MHz, DMSO-d 6 )δ8.74(d,J = 3.05 Hz, 1H), 8.19 (d, J = 3.66 Hz, 1H), 7.98-8.05 (m, 2H), 6.79-6.87 (m, 1H), 5.46-5.64 (m , 1H), 3.88 (s, 3H), 3.75-3.84 (m, 2H), 3.50-3.67 (m, 2H), 2.12-2.29 (m, 2H), 1.87-2.11 (m, 4H), 1.67-1.84 (m, 1H).

[0251] Example 32: (S)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1- il)prop-2-en-1-one [ka]

[0252] 1.(S)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl) Synthesis of prop-2-en-1-one [ka] A solution of (S)-4-(azepan-4-yloxy)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (30 mg, 96 μmol) in THF (1 mL) was When -2-enoyl chloride (17 mg, 192 μmol, 16 μL) was added, precipitation occurred instantly. TEA (19 mg, 192 μmol, 27 μL) was then added at room temperature with stirring. After stirring overnight, the volatiles were removed, the residual material was redissolved in DMSO, and the remaining material was redissolved in reverse phase HPLC (Waters XSelect CSH C18, 5 μm, 19 mm × 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-50%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to give (S)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1 ,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2-en-1-one (25 mg, yield: 67%) was obtained as a clear oil. ESI-MS (M+H) + : 367.2. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.73 (d, J =1.22Hz,1H),8.18(d,J = 18.92 Hz, 1H), 7.96-8.02 (m, 2H), 6.76-6.87 (m, 2H), 6.18 (ddd, J = 2.44,3.66,16.48Hz,1H),5.66-5.72(m,1H),5.45-5.58(m,1H),3.88(d,J = 1.83 Hz, 3H), 3.55-3.79 (m, 4H), 2.18 -2.25 (m, 1H), 1.99-2.07 (m, 2H), 1.85-1.98 (m, 2H), 1.69-1.79 (m, 1H).

[0253] Example 33: (S)-6-(1-methyl-1H-pyrazol-4-yl)-4-((1-(vinylsulfonyl)azepan-4-yl)oxy)pyrazolo[1,5-a] pyrazine [ka]

[0254] (S)-6-(1-methyl-1H-pyrazol-4-yl)-N-((1-(vinylsulfonyl)piperidin-4-yl)methyl)pyrazolo[1,5-a]pyrazine-4- Synthesis of amines [ka]

[0255] 2-chloroethanesulfonyl chloride was added to a solution of 4-(azepan-4-yloxy)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (30 mg, 96 μmol) in THF (1 mL). When (31 mg, 192 μmol, 20 μL) was added, precipitation occurred instantly. TEA (39 mg, 384 μmol, 53 μL) was then added at room temperature with stirring. After stirring overnight, the volatiles were removed, the residual material was redissolved in DMSO, and the remaining material was redissolved in reverse phase HPLC (Waters XSelect CSH C18, 5 μm, 19 mm × 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-60%B(0.2%NH 4 (S)-6-(1-methylpyrazol-4-yl)-4-(1-vinylsulfonylazepane-4- yl)oxy-pyrazolo[1,5-a]pyrazine (7 mg, yield: 16%) was obtained as a yellow oil. ESI-MS (M+H) + : 403.2. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.74 (s, 1H), 8.19 (s, 1H), 7.98-8.04 (m, 2H), 6.82-6.91 (m, 2H), 6.09 (d, J =16.48Hz,1H),6.06(d, J = 10.38 Hz, 1H), 5.57 (tt, J =3.66,7.63Hz,1H),3.88(s,3H),3.43-3.52(m,1H),2.17-2.25(m,1H),2.00-2.09 (m,4H),1.88-1.98(m,2H),1.69-1.82(m,2H).

[0256] Example 34: (S) or (R)-1-(4-((7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)oxy) azepan-1-yl)prop-2-en-1-one [ka]

[0257] 1.tert-butyl=(R) and (S)-4-((7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)oxy)azepane Synthesis of -1-carboxylate [ka] A solution of tert-butyl 4-hydroxyazepane-1-carboxylate (355 mg, 1.65 mmol) in dry DMF (5 mL) was cooled in an ice bath. Sodium hydride (198 mg, 4.95 mmol, 60% purity) was then added in four portions with stirring. Stirring in the ice bath was continued for 45 minutes, during which time a pale yellow suspension formed. To this mixture was added 5-chloro-7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidine (350 mg, 1.50 mmol) in one portion. Stirring at room temperature was continued overnight. The mixture was diluted with ethyl acetate and then water was carefully added. The mixture was transferred to a separatory funnel and the phases were separated. The aqueous phase was extracted one more time with ethyl acetate and the combined organic phases were washed with brine and Na 2 S.O. 4 dried, filtered and concentrated. The residual material was purified on a 10 g silica column with 50% heptane / ethyl acetate to give tert-butyl 4-[7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidine-5 -yl]oxyazepan-1-carboxylate (520 mg, yield: 84%) was obtained as a sticky pale yellow gum. 450mg of racemic substance was purified by chiral SFC (CHIRALPAK AD-H 30×250mm, 5um, 30%IPA+0.1%DEA / CO 2 , flow rate: 100 mL / min, ABPR 120 bar, MBPR 60 psi, column temperature 40 °C), the two products were first eluted (E1), peak 1 (172 mg, yield: 76%) and 2. The second eluting peak (E2) was obtained as peak 2 (171 mg, yield: 76%) as an off-white solid. ESI-MS (M+H) + : 413.3.The absolute stereochemistry of the products in each peak was not assigned.

[0258] 2. Synthesis of (R) or (S)-5-(azepan-4-yloxy)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidine [ka] tert-Butyl (4R) or (4S)-4-[7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl]oxyazepane of E2 in DCM (3 mL) TFA (949 mg, 8.33 mmol, 637 μL) was added to a solution of -1-carboxylate (172 mg, 416 μmol) at room temperature with stirring. After stirring overnight, dissolve the reaction in MeOH and transfer the desired product to 2M NH on a 10g SCX column. 3 Purified by elution with -MeOH, 5-[(4R) or (4S)-azepan-4-yl]oxy-7-(1-methylpyrazol-4-yl)imidazo[1,2-c] Pyrimidine (95 mg, yield: 69%) was obtained as a white solid. ESI-MS (M+H) + : 313.2.

[0259] 3.(R) or (S)-1-(4-((7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)oxy)azepan- Synthesis of 1-yl)prop-2-en-1-one [ka] 5-(4R) or (4S)-(azepan-4-yloxy)-7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidine (30 mg, When prop-2-enoyl chloride (17 mg, 192 μmol, 16 μL) was added to a solution of 96 μmol) (single enantiomer; chirality was arbitrarily assigned), precipitation occurred instantly. TEA (19 mg, 192 μmol, 27 μL) was then added at room temperature with stirring. After stirring overnight, the volatiles were removed, the residual material was redissolved in DMSO, and the remaining material was redissolved in reverse phase HPLC (Waters XSelect CSH C18, 5 μm, 19 mm × 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-35%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to produce (R)- or (S)-1-(4-((7-(1-methyl-1H-pyrazole-4- yl)imidazo[1,2-c]pyrimidin-5-yl)oxy)azepan-1-yl)prop-2-en-1-one (17 mg, yield: 45%) was obtained as a clear oil. . ESI-MS (M+H) + : 367.2.1 H NMR (500 MHz, DMSO-d 6 ) δ 8.25 (d, J =12.82Hz,1H),8.04(d,J = 3.66 Hz, 1H), 7.70 (s, 1H), 7.50 (t, J =1.53Hz,1H),7.44(s,1H ),6.82(ddd,J = 8.55, 10.38, 16.48 Hz, 1H), 6.17 (dd, J =2.44,16.48Hz,1H),5.69(dt,J = 2.44, 10.38 Hz, 1H), 5.50-5.64 ( m, 1H), 3.89 (d, J =1.22Hz,3H),3.75-3.84(m,1H),3.59-3.72(m,3H),2.21(dq,J = 3.05, 7.32 Hz, 1H), 2.06 -2.17 (m, 2H), 1.87-2.01 (m, 2H), 1.70-1.82 (m, 1H).

[0260] Example 35: (S) or (R)-1-(4-((7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)oxy) azepan-1-yl)prop-2-yn-1-one [ka]

[0261] (R) or (S)1-(4-((7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)oxy)azepan-1-yl ) Synthesis of prop-2-yn-1-one [ka] 5-(4R)- or (4S)-(azepan-4-yloxy)-7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidine (30 mg) of E3 in DMF (1 mL) , 96 μmol) was added at room temperature with stirring, propiolic acid (13 mg, 192 μmol, 12 μL) followed by DIPEA (25 mg, 192 μmol, 34 μL). After stirring at room temperature for 5 minutes, T3P (122 mg, 192 μmol, purity 50%) was added dropwise with stirring. After stirring for a further 3 hours at room temperature, the mixture was diluted with ethyl acetate and washed with water. organic phase with Na 2 S.O. 4 dried, filtered and concentrated. The residual white solid was redissolved in DMSO and subjected to reverse phase HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-40%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to produce (R) or (S)-1-(4-((7-(1-methyl-1H-pyrazol-4-yl) ) imidazo[1,2-c]pyrimidin-5-yl)oxy)azepan-1-yl)prop-2-yn-1-one (2 mg, yield: 5%) was obtained as a yellow oil. ESI-MS (M+H) + : 365.2. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.26 (d, J =2.44Hz,1H),8.05(d,J = 4.27 Hz, 1H), 7.73 (d, J =11.60Hz,1H),7.52(t,J = 1.53 Hz, 1H), 7.46 (d, J =2.44Hz,1H),5.55-5.67(m,1H),4.53(d,J = 17.70 Hz, 1H), 3.89 (s, 3H), 3.78-3.82 (m, 1H), 3.53 -3.72 (m, 2H), 3.40-3.52 (m, 1H), 2.21-2.28 (m, 1H), 2.07-2.19 (m, 2H), 1.91-2.06 (m, 2H), 1.72-1.89 (m, 1H).

[0262] Example 36: (R)- or (S)-7-(1-methyl-1H-pyrazol-4-yl)-5-((1-(vinylsulfonyl)azepan-4-yl)oxy)imidazo[1 ,2-c]pyrimidine [ka]

[0263] (R)- or (S)-7-(1-methyl-1H-pyrazol-4-yl)-5-((1-(vinylsulfonyl)azepan-4-yl)oxy)imidazo[1,2-c ]Synthesis of pyrimidine [ka] 5-(4R)- or (4S)-(azepan-4-yloxy)-7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidine (30 mg) of E3 in THF (1 mL) When 2-chloroethanesulfonyl chloride (31 mg, 192 μmol, 20 μL) was added to a solution of 2-chloroethanesulfonyl chloride (31 mg, 192 μmol, 20 μL), precipitation occurred instantly. TEA (39 mg, 384 μmol, 53 μL) was then added at room temperature with stirring. After stirring overnight, the volatiles were removed, the residual material was redissolved in DMSO, and the remaining material was redissolved in reverse phase HPLC (Waters XSelect CSH C18, 5 μm, 19 mm × 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-40%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to produce (R)- or (S)-7-(1-methyl-1H-pyrazol-4-yl)-5-(( 1-(vinylsulfonyl)azepan-4-yl)oxy)imidazo[1,2-c]pyrimidine (2 mg, yield: 4%) was obtained as a yellow solid. ESI-MS (M+H) + : 403.2.

[0264] Example 37: (R)- or (S)-1-(4-((7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)oxy )Azepan-1-yl)Prop-2-yn-1-one [ka]

[0265] 1. Synthesis of (R) or (S)-5-(azepan-4-yloxy)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidine [ka] tert-Butyl (4R) or (4S)-4-[7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl]oxyazepane of E1 in DCM (3 mL) To a solution of -1-carboxylate (172 mg, 416 μmol) was added TFA (949 mg, 8.33 mmol, 637 μL) at room temperature with stirring. After stirring overnight, dissolve the reaction in MeOH and transfer the desired product to 2M NH on a 10g SCX column. 3 Purified by elution with -MeOH, 5-[(4R) or (4S)-azepan-4-yl]oxy-7-(1-methylpyrazol-4-yl)imidazo[1,2-c] Pyrimidine (95 mg, yield: 69%) was obtained as a white solid. ESI-MS (M+H) + : 313.2.

[0266] 2.(R) or (S)-1-(4-((7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)oxy)azepan- Synthesis of 1-yl)prop-2-yn-1-one [ka] 5-[(4R)- or (4S)-azepan-4-yl]oxy-7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidine ( Propiolic acid (13 mg, 192 μmol, 12 μL) followed by DIPEA (25 mg, 192 μmol, 34 μL) was added at room temperature with stirring. After stirring at room temperature for 5 minutes, T3P (122 mg, 192 μmol, purity 50%) was added dropwise with stirring. After stirring for a further 3 hours at room temperature, the mixture was diluted with ethyl acetate and washed with water. organic phase with Na 2 S.O. 4 dried, filtered and concentrated. The residual white solid was redissolved in DMSO and subjected to reverse phase HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-40%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to produce (R)- or (S)-1-(4-((7-(1-methyl-1H-pyrazole-4- yl)imidazo[1,2-c]pyrimidin-5-yl)oxy)azepan-1-yl)prop-2-yn-1-one (1 mg, yield: 3%) was obtained as a clear oil. . ESI-MS (M+H) + : 365.2.

[0267] Example 38: (R)- or (S)-1-(4-((7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)oxy )Azepan-1-yl)Prop-2-en-1-one [ka]

[0268] 1.(R)- or (S)-1-(4-((7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)oxy)azepane Synthesis of -1-yl)prop-2-en-1-one [ka] 5-[(4R)- or (4S)-azepan-4-yl]oxy-7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidine ( When prop-2-enoyl chloride (19 mg, 207 μmol, 17 μL) was added to a solution of 32 mg, 104 μmol), precipitation occurred instantly. TEA (21 mg, 207 μmol, 29 μL) was then added at room temperature with stirring. After stirring overnight, the volatiles were removed, the residual material was redissolved in DMSO, and the remaining material was redissolved in reverse phase HPLC (Waters XSelect CSH C18, 5 μm, 19 mm × 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-35%B(0.2%NH 4 OH final v / v% modifier), flow rate 30 mL / min) to produce (R)- or (S)-1-(4-((7-(1-methyl-1H-pyrazole-4- yl)imidazo[1,2-c]pyrimidin-5-yl)oxy)azepan-1-yl)prop-2-en-1-one (11 mg, yield: 27%) was obtained as a yellow oil. . ESI-MS (M+H) + : 367.2. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.26 (d, J =12.82Hz,1H),8.04(d,J = 3.05 Hz, 1H), 7.70 (s, 1H), 7.51 (t, J =1.53Hz,1H),7.44(s,1H) ),6.82(ddd,J = 8.55, 10.38, 16.48 Hz, 1H), 6.17 (dd, J =2.14,16.18Hz,1H),5.69(dt,J = 2.44, 10.38 Hz, 1H), 5.53-5.64 ( m, 1H), 3.89 (s, 3H), 3.75-3.83 (m, 1H), 3.50-3.71 (m, 3H), 2.18-2.26 (m, 1H), 2.06-2.17 (m, 2H), 1.91- 2.02 (m, 2H), 1.69-1.82 (m, 1H).

[0269] Example 39: (R)-1-(3-((7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)oxy)pyrrolidine-1- il)prop-2-yn-1-one [ka]

[0270] tert-Butyl=(R)-3-((7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)oxy)pyrrolidine-1-carboxylate synthesis [ka] In a vial, 5-chloro-7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidine (250 mg, 1.07 mmol), DMF (5.4 mL), sodium hydride (64 mg, 1.61 mmol, (60% suspension in mineral oil) and tert-butyl (3R)-3-hydroxypyrrolidine-1-carboxylate (200 mg, 1.07 mmol) were added. The vial was stirred at 80°C overnight. The mixture was then diluted with MeOH and concentrated, and the residue was then purified by silica gel column chromatography (10-100% [3:1 EtOAc:EtOH] / heptane) to give tert-butyl (3R)-3 -[7-(1-Methylpyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl]oxypyrrolidine-1-carboxylate (310 mg, 75% yield) was mixed with the starting aryl chloride. was obtained as a mixture of and used without further purification. LCMS m / z = 385.1 (M+H)+.

[0271] Synthesis of (R)-7-(1-methyl-1H-pyrazol-4-yl)-5-(pyrrolidin-3-yloxy)imidazo[1,2-c]pyrimidine hydrochloride [ka] tert-Butyl (3R)-3-[7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl]oxypyrrolidine-1-carboxylate in methanol (4 mL) A solution of (310 mg, 806 μmol) was treated with HCl (4M in dioxane, 2.0 mL) and the resulting mixture was stirred at room temperature for 1 h. The mixture was then concentrated under vacuum and the solid residue was used without further purification. LCMS m / z = 285.0 (M+H)+.

[0272] (R)-1-(3-((7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)oxy)pyrrolidin-1-yl)prop- Synthesis of 2-yn-1-one [ka] In a vial were added 7-(1-methylpyrazol-4-yl)-5-[(3R)-pyrrolidin-3-yl]oxy-imidazo[1,2-c]pyrimidine hydrochloride (114 mg, 355 μmol), DCM ( 3.6 mL), N-ethyl-N-isopropyl-propan-2-amine (310 μL, 1.78 mmol), then prop-2-ynoic acid (33 μL, 533 μmol) were added. The vial was stirred at room temperature for 16 hours. The mixture was then concentrated and the residue was purified by silica gel column chromatography (10-100% [3:1 EtOAc:EtOH] / heptane). Fractions were combined, concentrated, and then subjected to preparative HPLC (Waters SunFire Prep, C18 5 μm, OBD 30 × 50 mm, 10-70% MeCN:H 2 1-[(3R)-3-[7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidine-5 -yl]oxypyrrolidin-1-yl]prop-2-yn-1-one (27.3 mg, 23% yield) was obtained as a solid. LCMS m / z = 337.0 (M+H)+. 1 H NMR (500 MHz, MeOD-d 4 )δ:8.46(d,J = 4.3 Hz, 1H), 8.23 ​​(d, J =2.4Hz,1H),8.12-8.07(m,1H),7.92(d,J = 2.4 Hz, 1H), 7.65 ( d, J =4.9Hz,1H),6.21-6.09(m,1H),4.33-4.22(m,1H),4.16-4.07(m,1H),4.01(d,J = 1.2 Hz, 5H), 3.92 -3.68 (m, 1H), 2.66-2.47 (m, 2H).

[0273] Examples 40-53. The compounds in the table below are prepared from 5-chloro-7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidine and the appropriate alcohol and carboxylic acid according to the steps described in Example 39. did: [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4]

[0274] Example 54: (S)-1-(6-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)-1,4 -Oxazepan-4-yl)prop-2-en-1-one [ka]

[0275] tert-Butyl (6S)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy-1,4-oxazepane-4-carboxylate synthesis [ka] A flask containing tert-butyl (6S)-6-hydroxy-1,4-oxazepane-4-carboxylate (247 mg, 1.14 mmol) in anhydrous THF (2 mL) was cooled in an ice-water bath and then cooled. To the mixture was carefully added sodium tert-butoxide (168 mg, 1.74 mmol) in portions. After 10 minutes, 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (235 mg, 1.01 mmol) was carefully added in portions to the cooled heterogeneous mixture. added. Once the addition of 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine was complete, the mixture was warmed to 23° C. and monitored by LCMS. After 18 hours, the reaction was carefully quenched by slowly adding water, then the biphasic mixture was extracted three times with ethyl acetate. The organics were pooled and then dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (30-100% ethyl acetate / heptane). The desired fractions were pooled and then concentrated under reduced pressure to give the white solid tert-butyl(6S)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a] obtained as pyrazin-4-yl]oxy-1,4-oxazepane-4-carboxylate (319 mg, 76% yield), which was used without further purification. LCMS m / z = 415.1(M+H) + . 1 HNMR(500MHz,DMSO-d 6 )d=8.77(s,1H),8.29-8.17(m,1H),8.11-7.91(m,2H),6.85-6.75(m,1H),5.62-5.53(m,1H),4.28-3.94( m,3H),3.93-3.74(m,4H),3.47-3.36(m,1H),3.73-3.32(m,3H),1.76-0.98(m,9H).

[0276] Synthesis of (6S)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy-1,4-oxazepane [ka] tert-Butyl=(6S)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy-1,4- in anhydrous dichloromethane (2 mL) The vial containing oxazepane-4-carboxylate (319 mg, 769 μmol) was cooled in an ice-water bath, then trifluoroacetic acid (1 mL, 13 mmol) was carefully added dropwise to the chilled mixture. Once the TFA addition was complete, the mixture was warmed to 23°C and monitored by LCMS. After 1 h, the reaction was carefully concentrated under reduced pressure to give a light yellow film of (6S)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine- 4-yl]oxy-1,4-oxazepane (345 mg, TFA salt), which was used without further purification. LCMS m / z = 315.0(M+H) + .

[0277] 1-[(6S)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy-1,4-oxazepan-4-yl]prop- Synthesis of 2-en-1-one [ka] (6S)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy-1,4-oxazepane (329 mg, Hunig's base (0.7 mL, 4.02 mmol) was carefully added dropwise at −25° C. to a vial containing 769 μmol, TFA salt). After 5 minutes, acryloyl chloride (0.2 mL, 2.46 mmol) was carefully added dropwise to the cooled homogeneous solution. Once the acryloyl chloride addition was complete, the reaction was warmed to 23°C and monitored by LCMS and TLC. After 3 minutes, the reaction was carefully quenched by slowly adding saturated aqueous sodium bicarbonate solution. The biphasic mixture was loaded onto a silica gel column and purified (15-75% [3:1 ethyl acetate:ethanol] / heptane). The desired fractions were pooled and then concentrated under reduced pressure to yield a white solid, 1-[(6S)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine. Obtained as -4-yl]oxy-1,4-oxazepan-4-yl]prop-2-en-1-one (226 mg, yield 76%). 1 H NMR (500MHz, DMSO-d 6 )d= 8.82 - 8.74 (m, 1H), 8.27 - 8.19 (m, 1H), 8.13 - 7.96 (m, 2H), 6.92 - 6.73 (m, 2H), 6.19 (dd, J =2.4,16.5Hz, 1H),5.76- 5.60 (m, 2H), 4.53 - 4.05 (m, 3H), 4.03 - 3.84 (m, 5H), 3.76 - 3.50 (m, 3H).LCMS m / z = 369.1(M+H) + .

[0278] Example 55: (S)-1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1- il)prop-2-en-1-one [ka] Synthesis of tert-butyl(3S)-3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxylate [ka] A vial containing tert-butyl (3S)-3-hydroxyazepane-1-carboxylate (464 mg, 2.16 mmol) in anhydrous THF (8 mL) was cooled in an ice-water bath, and then the chilled mixture was added to Sodium tert-butoxide (314 mg, 3.27 mmol) was carefully added in portions. After 15 minutes, 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (495 mg, 2.12 mmol) was carefully added in portions to the cooled heterogeneous mixture. added. Once the addition of 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine was complete, the mixture was warmed to 23° C. and monitored by LCMS. After 2.5 hours, the reaction was carefully quenched by slowly adding water. The biphasic mixture was extracted three times with ethyl acetate and then dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (0-30% [3:1 ethyl acetate:ethanol] / heptane). The desired fractions were pooled and then concentrated under reduced pressure to give a yellow film of tert-butyl(3S)-3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a ]pyrazin-4-yl]oxyazepane-1-carboxylate, which was used without further purification. LCMS m / z = 413.2(M+H) + .

[0279] Synthesis of 4-[(3S)-azepan-3-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine [ka] tert-Butyl (3S)-3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxylate in anhydrous methanol (2 mL) The vial containing (787 mg, 1.91 mmol) was cooled in an ice-water bath, then HCl (1.25 M in methanol, 4 mL) was carefully added dropwise to the chilled mixture. Once the addition of 1.25M HCl in methanol was complete, the mixture was warmed to 23°C and monitored by LCMS. After 6 days, the reaction was carefully concentrated under reduced pressure to give a light yellow film of 4-[(3S)-azepan-3-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[1 ,5-a]pyrazine hydrochloride (672 mg, crude), which was used without further purification. LCMS: m / z = 313.2(M+H) + .

[0280] 1-[(3S)-3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepan-1-yl]prop-2-en-1- synthesis of on [ka] 4-[(3S)-azepan-3-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine hydrochloride (288 mg, 824 μmol) in anhydrous dichloromethane (2 mL) Hunig's base (0.7 mL, 4.02 mmol) was carefully added dropwise to the vial at -25°C. After 5 minutes, acryloyl chloride (0.15 mL, 1.85 mmol) was carefully added dropwise to the cooled homogeneous solution. Once the acryloyl chloride addition was complete, the reaction was warmed to 23°C and monitored by LCMS and TLC. After 3 minutes, the reaction was carefully quenched by slowly adding saturated aqueous sodium bicarbonate solution. The biphasic mixture was loaded onto a silica gel column and purified (15-75% [3:1 ethyl acetate:ethanol] / heptane). The desired fractions were pooled and then concentrated under reduced pressure to yield a white solid, 1-[(3S)-3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine. Obtained as -4-yl]oxyazepan-1-yl]prop-2-en-1-one (73 mg, yield 23%). 1H NMR (500MHz, DMSO-d 6 )d= 8.76 (d, J =6.1Hz,1H),8.29- 8.18 (m, 1H), 8.06 - 7.99 (m, 1H), 6.88 - 6.68 (m, 2H), 6.16 (dt, J =2.4, 16.8Hz,1H),5.74- 5.51 (m, 2H), 4.33 (br dd, J =5.5,13.4Hz,1H),4.01- 3.91 (m, 1H), 3.90 - 3.64 (m, 3H), 3.64 - 3.43 (m, 2H), 2.13 - 2.00 (m, 1H), 2.00 - 1.62 (m, 4H), 1.62 - 1.37 (m, 2H).LCMS m / z = 367.1(M+H) + .

[0281] Example 56: (R)-1-(3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1- il)prop-2-en-1-one [ka]

[0282] Synthesis of tert-butyl(3R)-3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxylate [ka] A vial containing tert-butyl (3R)-3-hydroxyazepane-1-carboxylate (550 mg, 2.56 mmol) in anhydrous THF (9 mL) was cooled in an ice-water bath, and then the chilled mixture was added to Sodium tert-butoxide (338 mg, 3.52 mmol) was carefully added in portions. After 15 minutes, 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (537 mg, 2.30 mmol) was carefully added in portions to the cooled heterogeneous mixture. added. Once the addition of 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine was complete, the mixture was warmed to 23° C. and monitored by LCMS. After 2 hours, the reaction was carefully quenched by slowly adding water. The biphasic mixture was extracted three times with ethyl acetate and then dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (20-65% ethyl acetate / heptane). The desired fractions were pooled and then concentrated under reduced pressure to give a yellow film of tert-butyl(3R)-3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a ]pyrazin-4-yl]oxyazepane-1-carboxylate (905.5 mg, 96% yield), which was used without further purification. LCMS: m / z = 413.2(M+H) + . 1 H NMR (500MHz, DMSO-d 6 )d= 8.79 - 8.72 (m, 1H), 8.28 - 8.18 (m, 1H), 8.11 - 7.97 (m, 2H), 6.78 (dd, J = 1.2, 18.3 Hz, 1H), 5.58 - 5.47 (m, 1H), 4.09 - 4.02 (m, 1H), 4.01 - 3.87 (m, 3H), 3.61 - 3.19 (m, 4H), 1.97 - 1.78 (m, 3H), 1.78 - 1.62 (m, 2H), 1.41 ( s, 3H), 1.46 - 1.05 (m, 6H).

[0283] Synthesis of 4-[(3R)-azepan-3-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine [ka] tert-Butyl (3R)-3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxylate in anhydrous dichloromethane (2 mL) The vial containing (905.5 mg, 2.20 mmol) was cooled in an ice water bath, then trifluoroacetic acid (2 mL, 26.1 mmol) was carefully added dropwise to the chilled mixture. Once the TFA addition was complete, the mixture was warmed to 23°C and monitored by LCMS. After 1 h, the reaction was carefully concentrated under reduced pressure to give a light yellow film of 4-[(3R)-azepan-3-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[ 1,5-a]pyrazine (941.1 mg, 100% yield, TFA salt), which was used without further purification. LCMS m / z = 313.1(M+H) + .

[0284] 1-[(3R)-3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepan-1-yl]prop-2-en-1- on synthesis [ka] 4-[(3R)-Azepan-3-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (191 mg, 612 mmol, TFA salt) in anhydrous dichloromethane (2 mL) ) was carefully added dropwise at −25° C. to the vial containing Hunig's base (0.5 mL, 2.87 mmol). After 5 minutes, acryloyl chloride (0.1 mL, 1.23 mmol) was carefully added dropwise to the cooled homogeneous solution. Once the acryloyl chloride addition was complete, the reaction was warmed to 23°C and monitored by LCMS and TLC. After 3 minutes, the reaction was carefully quenched by slowly adding saturated aqueous sodium bicarbonate solution. The biphasic mixture was loaded onto a silica gel column and purified (15-75% [3:1 ethyl acetate:ethanol] / heptane). The desired fractions were pooled and then concentrated under reduced pressure to yield a white solid, 1-[(3R)-3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine. Obtained as -4-yl]oxyazepan-1-yl]prop-2-en-1-one. 1 H NMR (500MHz, DMSO-d 6 )d= 8.76 (d, J =5.5Hz,1H),8.29- 8.18 (m, 1H), 8.06 - 8.01 (m, 1H), 6.88 - 6.71 (m, 2H), 6.16 (dt, J =2.1, 16.9Hz,1H),5.74- 5.51 (m, 2H), 4.33 (br dd, J =5.5,14.0Hz,1H),3.99- 3.91 (m, 1H), 3.90 - 3.68 (m, 3H), 3.59 - 3.43 (m, 2H), 2.06 (ddd, J =4.3,8.9,13.7Hz,1H),1.98- 1.66 (m, 4H), 1.65 - 1.42 (m, 2H).LCMS m / z = 367.1(M+ H) + .

[0285] Example 57: 1-(4-((6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)oxy) azepan-1-yl)prop-2-en-1-one [ka]

[0286] Synthesis of tert-butyl 4-((6-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)oxy)azepane-1-carboxylate [ka] A flask containing tert-butyl 4-hydroxyazepane-1-carboxylate (659 mg, 3.06 mmol) in anhydrous THF (10 mL) was cooled in an ice-water bath, and the chilled mixture was then charged with sodium tert-butoxide ( 454 mg, 4.72 mmol) was carefully added in several portions. After 15 minutes, 6,8-dibromo-[1,2,4]triazolo[1,5-a]pyrazine (850 mg, 3.06 mmol) was carefully added in portions to the cooled heterogeneous mixture. Once the addition of 6,8-dibromo-[1,2,4]triazolo[1,5-a]pyrazine was complete, the mixture was warmed to 23°C and monitored by LCMS. After 2.5 hours, the reaction was carefully quenched by slowly adding water. The biphasic mixture was extracted three times with ethyl acetate and then dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (20-45% ethyl acetate / heptane). The desired fractions were pooled and then concentrated under reduced pressure to yield a faintly yellow film of tert-butyl 4-((6-bromo-[1,2,4]triazolo[1,5-a]pyrazine). -8-yl)oxy)azepane-1-carboxylate (952.3 mg, 76% yield), which was used without further purification. LCMS: m / z = 412.0(M+H) + . 1 H NMR (500MHz, DMSO-d 6 )d= 9.03 (s, 1H), 8.60 (s, 1H), 5.35 - 5.29 (m, 1H), 3.48 - 3.39 (m, 3H), 3.34 - 3.25 (m, 1H), 2.24 - 2.10 (m, 1H), 1.98 - 1.83 (m, 4H), 1.68 (br dd, J= 4.9, 9.2 Hz, 1H), 1.42 (s, 9H).

[0287] tert-Butyl 4-((6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)oxy)azepan-1 -Synthesis of carboxylates [ka] tert-Butyl 4-((6-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)oxy)azepane-1-carboxylate (952 mg, 2.31 mmol), 1- Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (971 mg, 4.67 mmol), Pd(dppf)Cl 2 The flask containing the dichloromethane adduct (300 mg, 367 μmol) and potassium carbonate (961 mg, 6.95 mmol) was evacuated and then backfilled with nitrogen. Dioxane (6 mL) was added to the mixture followed by water (0.6 mL). Once the water addition was complete, the reaction was heated to 90°C and monitored by LCMS. After 2.5 hours, the reaction was carefully quenched by slowly adding water. The biphasic mixture was extracted three times with ethyl acetate and then dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (25-100% ethyl acetate / heptane). The desired fractions were pooled and then concentrated under reduced pressure to remove the sticky yellow foam from tert-butyl 4-((6-(1-methyl-1H-pyrazol-4-yl)-[ Obtained as 1,2,4]triazolo[1,5-a]pyrazin-8-yl)oxy)azepane-1-carboxylate (707.6 mg, 74% yield), which was used without further purification. 1 H NMR (500MHz, DMSO-d 6 )d= 8.97 (s, 1H), 8.55 (s, 1H), 8.25 (br d, J= 15.3 Hz, 1H), 8.04 (d, J= 9.8 Hz, 1H), 5.52 - 5.45 (m, 1H) , 3.59 - 3.42 (m, 3H), 3.41 - 3.35 (m, 1H), 3.35 - 3.25 (m, 4H), 2.26 - 2.19 (m, 1H), 2.05 - 1.85 (m, 4H), 1.73 (br dd , J = 4.6, 8.9 Hz, 2H), 1.43 (d, J = 6.7 Hz, 7H).LCMS m / z = 414.2(M+H) + .

[0288] Synthesis of 8-(azepan-4-yloxy)-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazine [ka] tert-Butyl 4-((6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazine-8- The vial containing yl)oxy)azepane-1-carboxylate (708 mg, 1.71 mmol) was cooled in an ice-water bath, and then trifluoroacetic acid (1 mL, 13.1 mmol) was carefully added dropwise to the chilled mixture. Once the TFA addition was complete, the mixture was warmed to 23°C and monitored by LCMS. After 1 h, the reaction was carefully concentrated under reduced pressure to give a pale yellow film of 8-(azepan-4-yloxy)-6-(1-methyl-1H-pyrazol-4-yl)-[1, Obtained as 2,4]triazolo[1,5-a]pyrazine (301 mg, TFA salt), which was used without further purification. LCMS m / z = 314.1(M+H) + .

[0289] 1-(4-((6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)oxy)azepan-1- Synthesis of prop-2-en-1-one [ka] 8-(azepan-4-yloxy)-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazine ( Hunig's base (0.5 mL, 2.87 mmol) was carefully added dropwise at −25° C. to a vial containing 301 mg, 704.5 μmol, TFA salt). After 5 minutes, acryloyl chloride (0.1 mL, 1.23 mmol) was carefully added dropwise to the cooled homogeneous solution. Once the acryloyl chloride addition was complete, the reaction was warmed to 23°C and monitored by LCMS and TLC. After 3 minutes, the reaction was carefully quenched by slowly adding saturated aqueous sodium bicarbonate solution. The biphasic mixture was loaded onto a silica gel column and purified (20-85% [3:1 ethyl acetate:ethanol] / heptane). The desired fractions were pooled and then concentrated under reduced pressure to give the white solid 1-(4-((6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo Obtained as [1,5-a]pyrazin-8-yl)oxy)azepan-1-yl)prop-2-en-1-one (96 mg, yield 35%). 1 H NMR (500MHz, DMSO-d 6 )d= 8.97 (s, 1H), 8.55 (d, J =1.2Hz,1H),8.28- 8.21 (m, 1H), 8.04 (d, J =7.3Hz,1H),6.82(ddd,J = 10.4 , 12.2, 16.5 Hz, 1H), 6.18 (td, J =2.2,16.9Hz,1H),5.70(dd,J = 2.4, 10.4 Hz, 1H), 5.53 -5.44(m,1H),3.90(d, J = 1.8 Hz, 3H), 3.88 -3.61(m,3H),3.59- 3.49 (m, 2H), 2.31 - 2.21 (m, 1H), 2.06 - 1.97 (m, 3H), 1.83 - 1.71 (m, 1H).LCMS m / z = 368.1(M+H) + .

[0290] Example 58: (R)-1-(6-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)-1,4 -Oxazepan-4-yl)prop-2-en-1-one [ka]

[0291] tert-Butyl=(6R)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy-1,4-oxazepane-4-carboxylate synthesis [ka]

[0292] A flask containing tert-butyl (6R)-6-hydroxy-1,4-oxazepane-4-carboxylate (496 mg, 2.28 mmol) in anhydrous THF (4 mL) was cooled in an ice-water bath and then cooled. To the mixture was carefully added sodium tert-butoxide (308 mg, 3.20 mmol) in portions. After 10 minutes, 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (465 mg, 1.99 mmol) was carefully added in portions to the cooled heterogeneous mixture. added. Once the addition of 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine was complete, the mixture was warmed to 23° C. and monitored by LCMS. After 2 hours, the reaction was carefully quenched by slowly adding water, and then the biphasic mixture was extracted three times with ethyl acetate. The organics were pooled and then dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (30-100% ethyl acetate / heptane). The desired fractions were pooled and then concentrated under reduced pressure to give the white solid tert-butyl=(6R)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a] obtained as pyrazin-4-yl]oxy-1,4-oxazepane-4-carboxylate (757.9 mg, 92% yield), which was used without further purification. 1 H NMR (500MHz, DMSO-d 6 )d=8.77(s,1H),8.27-8.19(m,1H),8.08-7.95(m,2H),6.82-6.76(m,1H),5.58(brd,J = 3.7 Hz, 1H), 4.14 -3.92(m,3H),3.88(s,3H),3.85- 3.80 (m, 1H), 3.79 - 3.57 (m, 3H), 3.45 - 3.37 (m, 1H), 1.46 - 1.04 (m, 9H) .LCMS m / z = 415.1(M+H) + .

[0293] Synthesis of (6R)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy-1,4-oxazepane [ka] tert-Butyl=(6R)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy-1,4- in anhydrous dichloromethane (2 mL) The vial containing oxazepane-4-carboxylate (758 mg, 1.83 mmol) was cooled in an ice-water bath, then trifluoroacetic acid (2 mL, 26.1 mmol) was carefully added dropwise to the chilled mixture. Once the TFA addition was complete, the mixture was warmed to 23°C and monitored by LCMS. After 18 hours, the reaction was carefully concentrated under reduced pressure to give a light yellow film of (6R)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine- 4-yl]oxy-1,4-oxazepane (783.3 mg, crude, TFA salt), which was used without further purification. LCMS m / z = 315.0(M+H) + .

[0294] 1-[(6R)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy-1,4-oxazepan-4-yl]prop- Synthesis of 2-en-1-one [ka] (6R)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy-1,4-oxazepane (253 mg, Hunig's base (0.5 mL, 2.87 mmol) was carefully added dropwise at -25 °C to a vial containing 591 μmol, TFA salt). After 5 minutes, acryloyl chloride (0.1 mL, 1.23 mmol) was carefully added dropwise to the cooled homogeneous solution. Once the acryloyl chloride addition was complete, the reaction was warmed to 23°C and monitored by LCMS and TLC. After 3 minutes, the reaction was carefully quenched by slowly adding saturated aqueous sodium bicarbonate solution. The biphasic mixture was loaded onto a silica gel column and purified (15-100% [3:1 ethyl acetate:ethanol] / heptane). The desired fractions were pooled and then concentrated under reduced pressure to yield a white solid, 1-[(6R)-6-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine. -4-yl]oxy-1,4-oxazepan-4-yl]prop-2-en-1-one. LCMS: m / z = 369.1(M+H) + . 1 H NMR (500MHz, DMSO-d 6 )d= 8.80 - 8.73 (m, 1H), 8.28 - 8.19 (m, 1H), 8.13 - 7.99 (m, 2H), 6.92 - 6.73 (m, 2H), 6.19 (dd, J =2.1,16.8Hz, 1H),5.90- 5.59 (m, 3H), 4.56 - 4.42 (m, 1H), 4.18 - 4.09 (m, 1H), 4.03 - 3.92 (m, 2H), 3.90 - 3.84 (m, 3H), 3.78 - 3.54 (m, 3H).

[0295] Example 59: (R)-4-((1-acryloylazepan-4-yl)oxy)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine- 3-carbonitrile [ka]

[0296] Synthesis of 4-chloro-3-iodo-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine [ka] A vial containing 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (477 mg, 2.04 mmol) in anhydrous DMF (5 mL) was cooled in an ice-water bath and N-iodosuccinimide (1.23 g, 5.48 mmol) was then carefully added in portions to the cooled mixture. After 15 minutes, the cloudy yellow mixture was carefully heated to 50° C. and monitored by LCMS. After 2 hours, the reaction was cooled to 23°C and stirred overnight. After 19 hours, the heterogeneous mixture was filtered. The off-white solid was identified as 4-chloro-3-iodo-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine and was used without purification. 1 H NMR (500MHz, DMSO-d 6 )δ= 9.29 (s, 1H), 8.31 (s, 1H), 8.27 (s, 1H), 8.06 - 8.00 (m, 1H), 3.95 - 3.84 (m, 3H).LCMS m / z = 359.9(M +H) + .

[0297] Synthesis of tert-butyl(4R)-4-[3-iodo-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxylate [ka] A vial containing tert-butyl (4R)-4-hydroxyazepane-1-carboxylate (113 mg, 525 μmol) in anhydrous THF (2 mL) was cooled in an ice-water bath, and the chilled mixture was then added with sodium chloride. Tert-butoxide (79.5 mg, 827 μmol) was carefully added in portions. After 10 minutes, 4-chloro-3-iodo-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (181 mg, 504 μmol) was added in portions to the cooled heterogeneous mixture. I added it carefully. Once the addition of 4-chloro-3-iodo-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine was complete, the mixture was warmed to 23° C. and monitored by LCMS. After 18 hours, the heterogeneous reaction was carefully concentrated under reduced pressure. The residue was diluted with ethyl acetate and then washed with saturated aqueous sodium chloride solution. The organic layer was dried with anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (20-65% ethyl acetate / heptane). The desired fractions were pooled and then concentrated under reduced pressure to give a colorless sticky film of tert-butyl(4R)-4-[3-iodo-6-(1-methylpyrazol-4-yl) Obtained as pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxylate (99.3 mg, 36% yield), which was used without further purification. 1 H NMR (400MHz, DMSO-d 6 )δ= 8.78 (s, 1H), 8.19 (d, J = 6.0 Hz, 1H), 8.09 (s, 1H), 7.99 (d, J = 2.5 Hz, 1H), 5.59 (br s, 1H), 3.88 (s, 3H), 3.72 - 3.38 (m, 4H), 2.09 - 1.97 (m, 3H), 1.83 - 1.71 (m, 2H), 1.55 - 1.46 (m, 1H), 1.42 (d, J = 5.0 Hz , 9H).LCMS m / z = 539.0(M+H) + .

[0298] Synthesis of tert-butyl=(4R)-4-[3-cyano-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxylate [ka] tert-Butyl (4R)-4-[3-iodo-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4- in dioxane (1 mL) and water (1 mL) yl]oxyazepane-1-carboxylate (106 mg, 196 μmol), potassium hexacyanoferrate(II) trihydrate (44 mg, 104 μmol), dicyclohexyl-[2-(2,4,6-triisopropylphenyl)phenyl]phosphane (Xphos) (10mg, 21μmol), [2-(2-aminophenyl)phenyl]-methylsulfonyloxy-palladium;dicyclohexyl-[2-(2,4,6-triisopropylphenyl)phenyl]phosphane (Xphos G3) (17 mg, 20 μmol) and potassium acetate (40 mg, 408 μmol) were evacuated and backfilled with nitrogen. (Evacuation and backfilling with nitrogen was repeated three times.) The white, heterogeneous reaction mixture was carefully heated to 90° C. and monitored by LCMS. After 18 hours, the heterogeneous reaction was cooled to room temperature and then carefully partitioned between water and ethyl acetate. The aqueous layer was extracted two more times with ethyl acetate. The organic extracts were pooled and then washed once with saturated aqueous sodium chloride solution, then the organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (25-80% ethyl acetate / heptane). The desired fractions were pooled and then concentrated under reduced pressure to give a colorless sticky film of tert-butyl(4R)-4-[3-cyano-6-(1-methylpyrazol-4-yl) Obtained as pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxylate (10.2 mg, 12% yield), which was used without further purification. LCMS m / z = 460.1(M+Na) + .

[0299] Synthesis of 4-[(4R)-azepan-4-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carbonitrile [ka] tert-Butyl (4R)-4-[3-cyano-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane in anhydrous dichloromethane (0.5 mL) The vial containing -1-carboxylate (10 mg, 23 μmol) was cooled in an ice-water bath, and then TFA (0.05 mL, 653 μmol) was carefully added dropwise to the chilled mixture. Once the TFA addition was complete, the mixture was warmed to 23°C and monitored by LCMS. After 15 minutes, the reaction was carefully concentrated under reduced pressure to give a light yellow film of 4-[(4R)-azepan-4-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[ 1,5-a]pyrazine-3-carbonitrile (11 mg, trifluoroacetate), which was used without purification. LCMS m / z = 338.1(M+H) + .

[0300] Synthesis of 6-(1-methylpyrazol-4-yl)-4-[(4R)-1-prop-2-enoylazepan-4-yl]oxy-pyrazolo[1,5-a]pyrazine-3-carbonitrile [ka] 4-[(4R)-azepan-4-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carbonitrile ( Hunig's base (0.1 mL 574 μmol) was carefully added dropwise at −25° C. to a vial containing 11 mg, 24.4 μmol, trifluoroacetate). After 5 minutes, acryloyl chloride (0.01 mL, 123 μmol) was carefully added dropwise to the cooled homogeneous solution. Once the acryloyl chloride addition was complete, the reaction was warmed to 23°C and monitored by LCMS and TLC. After 3 minutes, the reaction was carefully quenched by slowly adding saturated aqueous sodium bicarbonate solution. The biphasic mixture was loaded onto a silica gel column and purified (25-85% [3:1 ethyl acetate:ethanol] / heptane). The desired fractions were pooled and then concentrated under reduced pressure to yield a colorless film of 6-(1-methylpyrazol-4-yl)-4-[(4R)-1-prop-2-enoylazepan-4- yl]oxy-pyrazolo[1,5-a]pyrazine-3-carbonitrile. 1 H NMR (400MHz, dichloromethane-d 2 )δ= 8.30 - 8.16 (m, 2H), 7.96 - 7.89 (m, 1H), 7.88 - 7.87 (m, 1H), 6.75 - 6.61 (m, 1H), 6.33 - 6.25 (m, 1H), 5.71 - 5.64 (m, 2H), 4.16 - 3.95 (m, 4H), 3.86 - 3.54 (m, 3H), 3.49 - 3.34 (m, 1H), 2.35 - 2.13 (m, 4H), 1.96 (br d, J = 11.5 Hz, 1H).LCMS m / z = 392.1(M+H) + .

[0301] Example 60: N-Methyl-N-((trans)-3-((3-methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4- yl)oxy)cyclobutyl)acrylamide [ka]

[0302] tert-butyl=((trans)-3-((3-iodo-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl) Synthesis of (methyl)carbamate [ka] A vial containing racemic trans tert-butyl N-(3-hydroxycyclobutyl)-N-methyl-carbamate (406 mg, 2.0 mmol) in anhydrous THF (6 mL) was cooled in an ice-water bath and then cooled. To the mixture was carefully added sodium tert-butoxide (333 mg, 3.47 mmol) in portions. After 10 minutes, 4-chloro-3-iodo-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (593 mg, 1.65 mmol) was carefully added to the cold mixture. Once the addition of 4-chloro-3-iodo-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine was complete, the mixture was warmed to 23°C. After 1 hour, the reaction was carefully quenched by slowly adding saturated aqueous sodium bicarbonate solution, and then the biphasic mixture was extracted three times with ethyl acetate. The organics were pooled and then dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (15-70% ethyl acetate / heptane). The desired fractions were pooled and then concentrated under reduced pressure to give the white solid tert-butyl ((trans)-3-((3-iodo-6-(1-methyl-1H-pyrazol-4-yl). ) pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)(methyl)carbamate (698.5 mg, crude), which was used without further purification. 1 H NMR (500MHz, DMSO-d 6 )δ= 8.79 (s, 1H), 8.16 (s, 1H), 8.11 (s, 1H), 7.98 (s, 1H), 5.45 (br t, J= 6.7 Hz, 1H), 4.89 (br s, 1H) ), 3.88 (s, 3H), 2.89 - 2.84 (m, 3H), 2.79 - 2.72 (m, 2H), 2.48 - 2.42 (m, 2H), 1.41 (s, 9H).LCMS: m / z = 525.0 (M+H) + .

[0303] tert-Butyl=methyl((trans)-3-((3-methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl ) Synthesis of carbamate [ka]

[0304] tert-Butyl=((trans)-3-((3-iodo-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4- yl)oxy)cyclobutyl)(methyl)carbamate (204mg, 389μmol), methylboronic acid (81mg, 1.35mmol), tricyclohexylphosphane (29mg, 105μmol), Pd 2 (dba) 3 (36mg, 39μmol), Pd(dppf)Cl 2 ·CH 2 Cl 2 (68 mg, 84 μmol) and tripotassium phosphate (1.0 M solution, 1.2 mL) were evacuated and backfilled with nitrogen. Evacuation and nitrogen refilling were repeated three times. The heterogeneous reaction mixture was carefully heated to 90°C. After 18 hours, the heterogeneous reaction was cooled to room temperature and then carefully partitioned between water and ethyl acetate. The aqueous layer was extracted two more times with ethyl acetate. The organic extracts were pooled and then washed once with saturated aqueous sodium chloride solution, then the organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (30-90% ethyl acetate / heptane). The desired fractions were pooled and then concentrated under reduced pressure to give a deep yellow film of tert-butyl methyl ((trans)-3-((3-methyl-6-(1-methyl-1H-pyrazole- 4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)carbamate (125.7 mg, 78% yield), which was used without further purification. LCMS m / z = 413.2(M+H) + .

[0305] (trans)-N-methyl-3-((3-methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutane-1 -Synthesis of amines [ka]

[0306] tert-Butyl methyl((trans)-3-((3-methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine- The vial containing 4-yl)oxy)cyclobutyl)carbamate (125.7 mg, 305 μmol) was cooled in an ice-water bath, and then trifluoroacetic acid (0.23 mL, 3 mmol) was carefully added dropwise to the chilled mixture. Once the TFA addition was complete, the mixture was warmed to 23°C. After 1.5 h, the reaction was carefully concentrated under reduced pressure to give a light yellow film of (trans)-N-methyl-3-((3-methyl-6-(1-methyl-1H-pyrazole-4- yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutan-1-amine trifluoroacetate (133.9 mg, crude), which was used without purification. LCMS m / z = 313.1(M+H) + .

[0307] N-Methyl-N-((trans)-3-((3-methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy) Synthesis of cyclobutyl)acrylamide [ka] (trans)-N-Methyl-3-((3-methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4- Hunig's base (1 mL, 5.74 mmol) was carefully added dropwise to a vial containing yl)oxy)cyclobutan-1-amine trifluoroacetate (133.9 mg, 314 μmol) at -25°C. After 5 minutes, acryloyl chloride (0.05 mL, 615 μmol) was carefully added dropwise to the cooled homogeneous solution. Once the acryloyl chloride addition was complete, the reaction was warmed to 23°C and monitored by LCMS and TLC. After 3 minutes, the reaction was carefully quenched by slowly adding saturated aqueous sodium bicarbonate solution. The mixture was stirred at 23°C for 1 hour, then the biphasic mixture was extracted three times with ethyl acetate. The organics were pooled and washed once with saturated aqueous sodium bicarbonate. The organic layer was separated and then dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (15-65% [3:1 ethyl acetate:ethanol] / heptane). The desired fractions were pooled and then concentrated under reduced pressure to give a white foam, diluted with DMSO and then filtered. The homogeneous mixture was purified by reverse phase mass spectrometry coupled HPLC purification. (Liquid chromatography was performed using Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-60%B(0.2%NH 4 OH final v / v% modifier), using a flow rate of 30 mL / min. ) Fractions containing the desired product are pooled and then concentrated to yield a colorless film of N-methyl-N-((trans)-3-((3-methyl-6-(1-methyl-1H -pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)-acrylamide. 1 H NMR (500MHz, DMSO-d 6 ) δ = 8.62 (s, 1H), 8.14 (s, 1H), 7.97 (s, 1H), 7.84 (s, 1H), 6.76 (br dd, J= 11.0, 16.5 Hz, 1H), 6.09 (br s , 1H), 5.68 (br s, 1H), 5.49 (br s, 1H), 5.35 - 4.90 (m, 1H), 3.88 (s, 3H), 3.15 - 2.77 (m, 5H), 2.67 - 2.52 (m , 2H), 2.47 (s, 3H).LCMS m / z = 367.2(M+H) + .

[0308] Example 61: 1-[(4R)-4-[3-fluoro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepan-1-yl] Prop-2-en-1-one [ka]

[0309] Synthesis of tert-butyl(4R)-4-[3-fluoro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxylate [ka] tert-Butyl=(4R)-4-[3-iodo-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1 in THF (3 mL) A solution of -carboxylate (224 mg, 416 μmol) was cooled to −78° C., butyllithium (2.5 M, 200 μL) was added, and stirred for 20 minutes. N-fluorobenzenesulfonimide (157 mg, 499 μmol) in THF was then added and the reaction mixture was stirred for 1 h. N.H. 4 The reaction was quenched by adding aqueous Cl solution. The reaction was diluted with EtOAc, the layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layer was diluted with Na 2 S.O. 4 The residue was dried with (SiO 2 , 0-70% EtOAc / DCM) to give tert-butyl(4R)-4-[3-fluoro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine. -4-yl]oxyazepane-1-carboxylate (25.3 mg, 14% yield) was obtained as an amorphous solid. LCMS: Rt = 0.93 min, m / z 431.2. 1 H NMR (400 MHz, chloroform-d)δ7.99 (d, J= 1.51 Hz, 1H), 7.83 (s, 1H), 7.74-7.83 (m, 1H), 7.70 (d, J= 3.76 Hz, 1H ), 5.52-5.61 (m, 1H), 3.97 (s, 3H), 3.51-3.82 (m, 2H), 3.25-3.48 (m, 2H), 2.07-2.17 (m, 3H), 1.98 (br d, J= 12.05 Hz, 2H), 1.78 (br d, J = 5.02 Hz, 1H), 1.49 (s, 9H). 19 F NMR (376 MHz, chloroform-d)δ-174.27 (s, 1F).

[0310] Synthesis of 4-[(4R)-azepan-4-yl]oxy-3-fluoro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine [ka] tert-Butyl=(4R)-4-[3-fluoro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepan-1 in DCM (1 mL) -To a solution of carboxylate (25 mg, 59 μmol) was added TFA (1.49 g, 13.1 mmol, 1 mL) and stirred at room temperature for 1 hour. After concentration, the crude residue 4-[(4R)-azepan-4-yl]oxy-3-fluoro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine was directly purified as follows. used for steps. LCMS: Rt = 0.63 min, m / z 183.2.

[0311] 1-[(4R)-4-[3-fluoro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepan-1-yl]prop-2- Synthesis of en-1-one [ka] 4-[(4R)-azepan-4-yl]oxy-3-fluoro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (48 mg, 146 μmol) in DCM (4 mL) TEA (30 mg, 292 μmol, 41 μL) was added to the solution of ) and the reaction was stirred for 5 minutes. After cooling to 0° C., acryloyl chloride (16 mg, 175 μmol, 14 μL) was added and stirred for 3 minutes. Saturate the reactants with NaHCO 3 Quenched with aqueous solution and extracted with DCM. organic layer with Na 2 S.O. 4 The concentrated residue was chromatographed on silica gel (EtOAc / MeOH 0-30%) to give 1-[(4R)-4-[3-fluoro-6-(1-methylpyrazole-4- yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepan-1-yl]prop-2-en-1-one (12.6 mg, yield 21%, purity 95%) was obtained. LCMS: Rt = 0.70 min, m / z 385.0. 1 H NMR (400 MHz, chloroform-d)δ8.01 (d, J= 1.51 Hz, 1H), 7.85 (br s, 1H), 7.76 (s, 1H), 7.71 (d, J = 3.76 Hz, 1H) , 6.58-6.68 (m, 1H), 6.35-6.44 (m, 1H), 5.73 (br d, J = 10.54 Hz, 1H), 5.62 (br s, 1H), 3.99 (br d, J = 2.51 Hz, 3H), 3.79 (br dd, J = 6.78, 13.55 Hz, 1H), 3.62-3.73 (m, 1H), 3.52-3.61 (m, 1H), 3.41-3.51 (m, 1H), 2.16-2.29 (m , 4H), 1.74-2.00 (m, 2H). 19 F NMR (376 MHz, chloroform-d)δ-174.12 (br d, J= 58.58 Hz, 1F).

[0312] Example 62: 1-[(4R)-4-[6-(1-methylpyrazol-4-yl)-3-(trifluoromethyl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepan- 1-yl]prop-2-en-1-one [ka]

[0313] tert-Butyl=(4R)-4-[6-(1-methylpyrazol-4-yl)-3-(trifluoromethyl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxy Synthesis of Lato [ka] tert-Butyl=(4R)-4-[3-iodo-6-(1-methylpyrazol-4-yl)pyrazolo[1, Methyl fluorosulfonyl difluoroacetate (223 mg, 1.16 mmol, 148 μL) and copper(I) iodide (66 mg, 348 μmol) were added to a solution of 5-a]pyrazin-4-yl]oxyazepane-1-carboxylate (125 mg, 232 μmol). was added and degassed. The mixture was heated at 80°C overnight. The cooled mixture was diluted with EtOAc and NH 4 Wash with aqueous Cl solution, filter through Celite, and remove Na 2 S.O. 4 It was dried with. The concentrated residue was chromatographed on silica gel (heptane / EtOAc 0-70%) to give tert-butyl=(4R)-4-[6-(1-methylpyrazol-4-yl)-3-(tri-butyl). Fluoromethyl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxylate (18 mg, yield 15%, purity 95%) was obtained. LCMS: Rt = 1.03 min, m / z 481.2.381.2.

[0314] Synthesis of 4-[(4R)-azepan-4-yl]oxy-6-(1-methylpyrazol-4-yl)-3-(trifluoromethyl)pyrazolo[1,5-a]pyrazine [ka] tert-Butyl=(4R)-4-[6-(1-methylpyrazol-4-yl)-3-(trifluoromethyl)pyrazolo[1,5-a]pyrazin-4-yl in DCM (1 mL) ] To a solution of oxyazepane-1-carboxylate (18 mg, 37 μmol) was added TFA (1.49 g, 13.1 mmol, 1 mL) and the reaction mixture was stirred at room temperature for 1 h. The crude product was concentrated to give 4-[(4R)-azepan-4-yl]oxy-6-(1-methylpyrazol-4-yl)-3-(trifluoromethyl)pyrazolo[1,5-a] Pyrazine (19.0 mg, crude, trifluoroacetic acid) was obtained as a residue and used as is for the next step. LCMS: Rt = 0.64 min, m / z 381.2.

[0315] 1-[(4R)-4-[6-(1-methylpyrazol-4-yl)-3-(trifluoromethyl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepan-1-yl] Synthesis of prop-2-en-1-one [ka] 4-[(4R)-Azepan-4-yl]oxy-6-(1-methylpyrazol-4-yl)-3-(trifluoromethyl)-pyrazolo[1,5-a] in DCM (2 mL) TEA (7.8 mg, 77 μmol, 11 μL) was added to a solution of pyrazine (19 mg, 38 μmol, trifluoroacetic acid) and the reaction mixture was stirred for 5 minutes. After cooling to 0° C., acryloyl chloride (4.2 mg, 46 μmol, 3.8 μL) was added and the reaction mixture was stirred for 3 minutes. Saturate the reactants with NaHCO 3 Quenched with aqueous solution and extracted with DCM. organic layer with Na 2 S.O. 4 The concentrated residue was chromatographed on silica gel (EtOAc / MeOH 0-30%) to give 1-[(4R)-4-[6-(1-methylpyrazol-4-yl)-3 -(trifluoromethyl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepan-1-yl]prop-2-en-1-one (9 mg, yield 51%, purity 95%) was obtained. . LCMS: Rt = 0.80 min, m / z 457.1 [M+Na] + . 1 H NMR (400 MHz, chloroform-d)δ8.24 (s, 1H), 8.11 (s, 1H), 7.88 (s, 1H), 7.78-7.87 (m, 1H), 6.58-6.70 (m, 1H) , 6.39 (br t, J= 15.18 Hz, 1H), 5.73 (br d, J = 10.54 Hz, 1H), 5.67 (br s, 1H), 4.11-4.22 (m, 1H), 4.00 (s, 3H) , 3.73-3.83 (m, 1H), 3.52-3.70 (m, 1H), 3.37 (br dd, J = 5.52, 14.31 Hz, 1H), 2.18-2.38 (m, 4H), 1.86-1.95 (m, 2H) ). 19 F NMR (376 MHz, chloroform-d)d-54.80 (d, J = 5.45 Hz, 3F).

[0316] Example 63: N-((cis)-3-((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy) Cyclobutyl)-N-methylacrylamide [ka]

[0317] tert-butyl = ((cis)-3-((3-iodo-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl) Synthesis of (methyl)carbamate [ka] A vial containing tert-butyl ((cis)-3-hydroxycyclobutyl)(methyl)carbamate (175 mg, 868 μmol) in anhydrous THF (10 mL) was cooled in an ice-water bath, and then the chilled mixture was added to Sodium tert-butoxide (132 mg, 1.37 mmol) was carefully added in portions. After 10 min, 4-chloro-3-iodo-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (300 mg, 834 μmol) was added in portions to the cooled heterogeneous mixture. I added it carefully. Once the addition of 4-chloro-3-iodo-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine was complete, the mixture was warmed to 23° C. and monitored by LCMS. After 18 hours, the residue was diluted with ethyl acetate and filtered through Celite. The concentrated residue was loaded onto a silica gel column and purified with (20-65% ethyl acetate / heptane) to give tert-butyl=((cis)-3-((3-iodo-6-(1-methyl-1H -pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)(methyl)carbamate (252 mg, yield 58%) was obtained. LCMS: Rt = 1.00 min, m / z 525.2.

[0318] tert-butyl=((cis)-3-((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl) Synthesis of (methyl)carbamate [ka] tert-Butyl=((cis)-3-((3-iodo-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4- A solution of yl)oxy)cyclobutyl)(methyl)carbamate (292 mg, 557 μmol) was cooled to −78° C., butyllithium (2.5 M, 267.30 μL) was added, and the reaction mixture was stirred for 20 minutes. N-fluorobenzenesulfonimide (211 mg, 668 μmol) in THF (1 mL) was then added and the reaction mixture was kept stirring for 1 h. N.H. 4 The reaction was quenched by adding aqueous Cl solution. The reaction was diluted with EtOAc, the layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layer was diluted with Na 2 S.O. 4 The residue was dried and concentrated (FCC, SiO 2 , 0-70% EtOAc / DCM) to give tert-butyl((cis)-3-((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1, 5-a]pyrazin-4-yl)oxy)cyclobutyl)(methyl)-carbamate (75.5 mg, 33% yield) was obtained as an amorphous solid. LCMS, Rt = 0.92 min, m / z 439.2, 317.1. 19 F NMR (376 MHz, chloroform-d)δ-174.02 (br s, 1F).

[0319] (cis)-3-((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)-N-methylcyclobutane-1 -Synthesis of amines [ka]

[0320] tert-Butyl=((cis)-3-((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4- TFA (1.49 g, 13.1 mmol, 1 mL) was added to a solution of yl)oxy)cyclobutyl)(methyl)carbamate (76 mg, 181 μmol) and the reaction mixture was stirred at room temperature for 1 hour. The crude product was concentrated to give (cis)-3-((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)- N-Methylcyclobutan-1-amine (166 mg, crude, trifluoroacetic acid) was obtained as a residue and used as is for the next step. LCMS: Rt = 0.57 min, m / z 317.1.

[0321] N-((cis)-3-((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)-N -Synthesis of methylacrylamide [ka] (cis)-3-((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)- in DCM (5 mL) TEA (78 mg, 771 μmol, 108 μL) was added to a solution of N-methylcyclobutan-1-amine (166 mg, 386 μmol, trifluoroacetic acid) and the reaction mixture was stirred for 5 minutes. After cooling to 0° C., acryloyl chloride (42 mg, 463 μmol, 38 μL) was added and stirring was continued for 3 minutes. Saturate the reactants with NaHCO 3 Quenched with aqueous solution and extracted with DCM. organic layer with Na 2 S.O. 4 The dried and concentrated residue was chromatographed on silica gel (EtOAc / MeOH 0-30%) to give a residue. This was preparative HPLC (10-90%H 2 N-((cis)-3-((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine- 4-yl)oxy)cyclobutyl)-N-methylacrylamide (30.1 mg, yield 15%, purity 95%, trifluoroacetic acid) was obtained. LCMS: Rt = 0.70 min, m / z 371.2 [M+H] + , 393.2 [M+Na] + . 1 H NMR (400 MHz, chloroform-d)δ8.06 (d, J = 1.76 Hz, 1H), 7.91 (br s, 1H), 7.84 (br s, 1H), 7.75 (br d, J = 3.51 Hz, 1H), 6.58 (br dd, J = 10.92, 16.69 Hz, 1H), 6.35 (br d, J= 19.07 Hz, 1H), 5.79 (br d, J = 10.79 Hz, 1H), 5.17-5.25 (m, 1H), 4.82 (br s, 1H), 4.03 (s, 3H), 3.11 (br s, 3H), 3.00 (br s, 2H), 2.59 (br s, 1H), 2.43 (br s, 1H). 19 F NMR (376 MHz, chloroform-d)δ-75.97 (s, 3F), -173.35 (br s, 1F).

[0322] Example 64: N-((trans)-3-((3-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,4-a]pyrazin-4-yl )oxy)cyclobutyl-N-methacrylamide [ka]

[0323] tert-Butyl=methyl((trans)-3-((6-(1-methyl-1H-pyrazol-4-yl)-3-vinylpyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl) Synthesis of carbamate [ka]

[0324] tert-Butyl = ((trans)-3-((3-iodo-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl) in a microwave vial) oxy)cyclobutyl)(methyl)carbamate (135mg, 257μmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (79mg, 515μmol, 87μL), di-tert-butyl( Cyclopentyl)phosphane; dichloropalladium; iron (34 mg, 51 μmol) and potassium carbonate (100 mg, 721 μmol) were added, and N 2 I put it down. Cap the vial, add dioxane (1.2 mL) and water (0.3 mL) via syringe, and purify the red mixture again with N. 2 I lowered it (2 cycles). After stirring at room temperature for 5 minutes, the mixture was heated to 90° C. and stirred at that temperature for 5 hours. After cooling to room temperature, the mixture was diluted with EtOAc and filtered. The filtrate was evaporated under vacuum and the residual material was purified with 10 g Si-SPE: Rf=0.27, heptane / EtOAc=5 / 1 to give tert-butyl=methyl((trans)-3-((6-(1 -Methyl-1H-pyrazol-4-yl)-3-vinylpyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)carbamate (110 mg, yield 91%, purity 90%) as a yellow gum. I got it as a thing.

[0325] tert-butyl=((trans)-3-((3-formyl-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl) Synthesis of (methyl)carbamate [ka] tert-butyl=methyl ((trans)-3-((6-(1-methyl-1H-pyrazol-4-yl)-3-vinylpyrazolo[1,5-a]pyrazin-4-yl)oxy) in a vial Cyclobutyl) carbamate (110 mg, 259 μmol), water (0.5 mL) and THF (1.5 mL) were added and cooled in an ice bath. Osmium tetroxide (132 mg, 26 μmol, 5% purity; resin bound) and 4-methyl-4-oxide-morpholin-4-ium (30 mg, 259 μmol) were then added and stirring in the ice bath was continued for 1 h. . Sodium (meta)periodate (111 mg, 518 μmol) was then added and stirring continued in the water bath while the reaction mixture was allowed to warm to room temperature overnight. Then saturated Na 2 S 2 O 3 , followed by the addition of DCM. The mixture was filtered, the organic phase was separated, dried and evaporated under vacuum to give a dark green sticky gum. This material was carried forward without further purification. ESI-MS (M+Na) + : 449.4.

[0326] tert-Butyl=((trans)-3-((3-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy ) Synthesis of cyclobutyl)(methyl)carbamate [ka] tert-butyl=((trans)-3-((3-formyl-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy) in a vial Add cyclobutyl)(methyl)carbamate (90 mg, 211 μmol) and DCM (2 mL), N 2 Lower and cool in an ice bath. Then, N-ethyl-N-(trifluoro-sulfanyl)ethanamine (68 mg, 422 μmol, 56 μL) was added dropwise with stirring. Stirring was continued overnight, during which time the mixture gradually warmed to room temperature. The mixture was diluted with DCM and silica gel was added. The volatiles were evaporated under vacuum and the residual material was purified with 5g Si-SPE:Rf=0.5, EtOAc to give tert-butyl=((trans)-3-((3-(difluoromethyl)-6- (1-Methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)(methyl)carbamate (45 mg, yield 43%, purity 90%) in pale yellow It was obtained as a sticky gum. ESI-MS (M+H) + : 449.5.

[0327] (trans)-3-((3-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)-N-methyl Synthesis of cyclobutan-1-amine [ka] tert-Butyl ((trans)-3-((3-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine) in DCM (2 mL) To a solution of -4-yl)oxy)cyclobutyl)(methyl)carbamate (40 mg, 89 μmol) was added TFA (102 mg, 892 μmol, 68 μL) at room temperature with stirring. After stirring overnight, the mixture was diluted with MeOH and the product was transferred to 2M NH on a 2g SCX column. 3 After purification and removal of volatiles by elution with -MeOH, (trans)-3-((3-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1 ,5-a]pyrazin-4-yl)oxy)-N-methylcyclobutan-1-amine (28 mg, 81% yield, 90% purity) was obtained as a yellow gum.

[0328] N-((trans)-3-((3-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl )-N-Methylacrylamide synthesis [ka] (trans)-3-((3-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)-N -Methylcyclobutan-1-amine (28 mg, 80 μmol) and THF (1 mL) were charged. Acryloyl chloride (7.2 mg, 80 μmol) was then added, and a precipitate instantly formed. TEA (12 mg, 121 μmol, 17 μL) was then added and stirring at room temperature was continued for 1 hour. The volatiles were evaporated under vacuum and the remaining material was purified by basic preparative HPLC (Waters XSelect CSH C18, 5 μm, 30 mm × 50 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-60%B(0.2%NH 4 N-((trans)-3-((3-(difluoromethyl)-6-(1- Methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)-N-methylacrylamide (6.8 mg, yield 19%, purity 90%) as a white solid. Obtained. ESI-MS (M+H) + : 403.4. 1 H NMR (chloroform-d, 400MHz): δ = 10.39-10.44 (m, 1H), 8.45-8.47 (m, 1H), 8.30 (s, 1H), 7.9 (m, 1H), 7.82 (m, 1H) , 6.50-6.66 (m, 1H), 6.31 (br d, J= 15.8 Hz, 1H), 5.72 (br d, J = 10.3 Hz, 1H), 5.63 (br s, 1H), 5.07 (br s, 1H) ), 4.01 (s, 3H), 3.12 (s, 3H), 2.80-2.90 (m, 2H), 2.70-2.78 (m, 1H), 2.64-2.84 (m, 2H).

[0329] Example 65: 1-[(4R)-4-[7-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridin-5-yl]oxyazepan-1-yl]prop-2- en-1-one [ka]

[0330] Synthesis of tert-butyl(4R)-4-(7-iodoimidazo[1,2-a]pyridin-5-yl)oxyazepane-1-carboxylate [ka] A vial containing 5-chloro-7-iodo-imidazo[1,2-a]pyridine (155 mg, 557 μmol) in anhydrous THF (2 mL) was cooled in an ice-water bath, then the chilled mixture was added with sodium tert. -butoxide (93 mg, 970 μmol) was carefully added in several portions. After 15 minutes, tert-butyl (4R)-4-hydroxyazepane-1-carboxylate (142 mg, 661 μmol) was carefully added in portions to the cooled heterogeneous mixture. Once the addition of 5-chloro-7-iodo-imidazo[1,2-a]pyridine was complete, the mixture was warmed to 23° C. and monitored by LCMS. After 19 hours, the reaction was carefully quenched by slowly adding water, then the biphasic mixture was extracted three times with ethyl acetate. The organics were pooled and then dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (20-65% ethyl acetate / heptane). The desired fractions were pooled and then concentrated under reduced pressure to yield a pale yellow oil. Obtained as oxyazepane-1-carboxylate (119 mg, 47% yield), which was used without further purification. LCMS m / z = 458.0(M+H) + .

[0331] Synthesis of tert-butyl(4R)-4-[7-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridin-5-yl]oxyazepane-1-carboxylate [ka] tert-Butyl (4R)-4-(7-iodoimidazo[1,2-a]pyridin-5-yl)oxyazepane-1-carboxylate (119 mg, 260 μmol), 1-methyl- in dioxane (1 mL). 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (111 mg, 534 μmol), tricyclohexylphosphane (19.4 mg, 69 μmol), tris(dibenzylideneacetone) A vial containing dipalladium (25.4 mg, 28 μmol) and tripotassium phosphate (1 M, 0.8 mL) was evacuated and then backfilled with nitrogen. After evacuation and backfilling with nitrogen (x3), the reaction was heated to 90°C and monitored by LCMS. After 2 hours, the reaction was carefully quenched by slowly adding water. The biphasic mixture was extracted three times with ethyl acetate and then dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (20-100% [3:1 ethyl acetate:ethanol] / heptane). The desired fractions were pooled and then concentrated under reduced pressure to give a yellow film of tert-butyl(4R)-4-[7-(1-methylpyrazol-4-yl)imidazo[1,2-a ]pyridin-5-yl]oxyazepane-1-carboxylate (75.9 mg, 71% yield), which was used without further purification. LCMS m / z =412.1(M+H) + . Synthesis of 5-[(4R)-azepan-4-yl]oxy-7-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridine [ka] tert-Butyl (4R)-4-[7-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridin-5-yl]oxyazepane-1-carboxy in anhydrous dichloromethane (0.5 mL) The vial containing Lato (76 mg, 184 μmol) was cooled in an ice-water bath, and then trifluoroacetic acid (149 mg, 1.31 mmol, 0.1 mL) was carefully added dropwise to the chilled mixture. Once the TFA addition was complete, the mixture was warmed to 23°C and monitored by LCMS. After 19 hours, the reaction was carefully concentrated under reduced pressure to give a light yellow film of 5-[(4R)-azepan-4-yl]oxy-7-(1-methylpyrazol-4-yl)imidazo[ 1,2-a]pyridine (crude, trifluoroacetic acid), which was used without purification. LCMS m / z =312.0(M+H) + .

[0332] 1-[(4R)-4-[7-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridin-5-yl]oxyazepan-1-yl]prop-2-en-1- synthesis of on [ka] 5-[(4R)-azepan-4-yl]oxy-7-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridine (79 mg, 254 μmol, trifluoro Hunig's base (445 mg, 3.44 mmol, 0.6 mL) was carefully added to the vial containing acetic acid) at -25 °C. After 4 minutes, acryloyl chloride (45 mg, 492 μmol, 0.04 mL) was carefully added dropwise to the cooled homogeneous solution. Once the acryloyl chloride addition was complete, the reaction was warmed to 23°C and monitored by LCMS and TLC. After 3 minutes, the reaction was carefully quenched by slowly adding saturated aqueous sodium bicarbonate solution. The biphasic mixture was loaded onto a silica gel column and purified (40-100% [3:1 ethyl acetate:ethanol] / heptane, then flush with 20% methanol / dichloromethane). The desired fractions were pooled and then concentrated under reduced pressure to yield 67 mg of a colorless film, which was subjected to mass spectrometry coupled reverse phase HPLC (Waters XSelect CSH C18, 5 μm, 19 mm x 100 mm column, mobile phase H 2 O(A) and MeCN(B) and gradient 5-50%B(0.2%NH 4 It was further purified by OH final v / v% modifier), flow rate 30 mL / min). The fractions containing the desired product were concentrated to give a colorless film of 1-[(4R)-4-[7-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridine-5 -yl]oxyazepan-1-yl]prop-2-en-1-one (1.6 mg, yield 2%). 1 H NMR (500MHz, DMSO-d6) δ = 8.52 - 8.12 (m, 2H), 8.02 - 7.64 (m, 2H), 7.47 (s, 1H), 6.96 - 6.77 (m, 2H), 6.23 - 6.13 (m , 1H), 5.75 - 5.65 (m, 1H), 5.28 - 5.16 (m, 1H), 3.96 - 3.85 (m, 3H), 3.84 - 3.46 (m, 6H), 2.12 - 2.07 (m, 1H), 1.99 - 1.91 (m, 2H), 1.83 - 1.72 (m, 1H).LCMS: m / z = 366.1 (M+H)+.

[0333] Example 66: 1-[(4R)-4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]oxyazepan-1-yl]prop-2- En-1-one [ka]

[0334] Synthesis of tert-butyl(4R)-4-(6-bromopyrazolo[1,5-a]pyridin-4-yl)oxyazepane-1-carboxylate [ka] tert-Butyl(4S)-4-hydroxyazepan-1-carboxylate (303 mg, 1.41 mmol), 6-bromopyrazolo[1,5-a]pyridin-4-ol (300 mg, 1.41 mmol) in THF (5 mL) DIAD (342 mg, 1.69 mmol, 333 μL) was added to a solution of triphenylphosphine (554 mg, 2.11 mmol) and stirred at room temperature for 16 hours. The concentrated crude was chromatographed on silica gel (heptane / EtOAc 0-60%) to give tert-butyl (4R)-4-(6-bromopyrazolo[1,5-a]pyridin-4-yl). Oxyazepane-1-carboxylate (255 mg, 42% yield, 95% purity) was obtained as a colorless oil. LCMS: Rt = 1.00 min, m / z 356.1, 412.1 (M+H) + .

[0335] Synthesis of tert-butyl(4R)-4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]oxyazepane-1-carboxylate [ka] 1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (194 mg, 932 μmol) in dioxane (3 mL) and water (0.5 mL), Pd (dppf)Cl 2 DCM (51mg, 62μmol) and K 2 C.O. 3 A solution of (258 mg, 1.86 mmol) was degassed and heated to 95 °C for 16 h. After cooling to room temperature, the mixture was filtered through Celite and concentrated. The residue was chromatographed on silica gel (heptane / EtOAc 0-100%) to give tert-butyl=(4R)-4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a ]pyridin-4-yl]oxyazepane-1-carboxylate (192 mg, 71% yield, 95% purity) was obtained as a yellow gel. LCMS: Rt = 0.87 min, m / z 412.3 (M+H) + .

[0336] Synthesis of 4-[(4R)-azepan-4-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridine [ka] tert-Butyl (4R)-4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]oxyazepane-1-carboxylate ( TFA (1.49 g, 13.1 mmol, 1 mL) was added to a solution of 192 mg, 467 μmol), and the reaction mixture was stirred at room temperature for 1 hour. The crude material was concentrated to give 4-[(4R)-azepan-4-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridine (345 mg, crude, trifluoroacetic acid ), which was used directly in the next step. LCMS: Rt = 0.50 min, m / z 312.1 (M+H) + .

[0337] 1-[(4R)-4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]oxyazepan-1-yl]prop-2-en-1- synthesis of on [ka] 4-[(4R)-Azepan-4-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridine (345 mg, 811 μmol, trifluoroacetic acid) in DCM (10 mL) TEA (164 mg, 1.62 mmol, 226 μL) was added to the solution of ) and the reaction mixture was stirred for 5 minutes. After cooling to 0° C., acryloyl chloride (88 mg, 973 μmol, 79 μL) was added and the reaction mixture was stirred for 3 minutes. Saturate the reactants with NaHCO 3 Quenched with aqueous solution and extracted with DCM. organic layer with Na 2 S.O. 4 The concentrated residue was chromatographed on silica gel (EtOAc / MeOH 0-30%) to give 1-[(4R)-4-[6-(1-methylpyrazol-4-yl)pyrazolo[ 1,5-a]pyridin-4-yl]oxyazepan-1-yl]prop-2-en-1-one (112.1 mg, yield 36%, purity 95%) was obtained. LCMS: Rt = 0.62 min, m / z 366.2 (M+H) + . 1 H NMR (400 MHz, chloroform-d)δ8.25 (s, 1H), 7.84 (t, J = 1.76 Hz, 1H), 7.70 (d, J= 3.26 Hz, 1H), 7.59 (d, J= 6.02 Hz, 1H), 6.55-6.66 (m,2H), 6.44 (d, J= 8.28 Hz, 1H), 6.31-6.41 (m, 1H), 5.68-5.75 (m, 1H), 4.72 (br s, 1H) ), 3.95 (s, 3H), 3.63-3.80 (m, 2H), 3.45-3.61 (m, 2H), 2.07-2.25(m, 4H), 1.88-1.99 (m, 1H), 1.69-1.86 (m , 1H).

[0338] Example 67: 1-[(4R)-4-[2-amino-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepan-1-yl] Prop-2-en-1-one [ka]

[0339] Synthesis of ethyl-4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate [ka] Suspension of ethyl 4-hydroxy-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate (130 mg, 454 μmol) in dry acetonitrile (2 mL) under nitrogen Phosphoryl chloride (1.11 g, 7.27 mmol, 677 μL) was added dropwise to the solution. The resulting mixture was heated to 80°C for 17 hours. After cooling to room temperature, the reaction mixture was diluted with EtOAc and carefully quenched with saturated aqueous sodium bicarbonate. The layers were separated and the organic layer was washed sequentially with saturated bicarbonate solution (2x) and brine. Organic phase (MgSO 4 ) was dried, filtered and concentrated under vacuum. Ethyl 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate was obtained as a white solid and used directly. Quantitative yield assumed. 1 H NMR (500 MHz, chloroform-d) δ ppm 8.50 (d, J = 1.2 Hz, 1 H), 7.94 (s, 1 H), 7.90 (s, 1 H), 7.37 - 7.42 (m, 1 H) , 4.50 (q, J = 6.9 Hz, 2 H), 3.97 - 4.01 (m, 3 H), 1.46 (t, J = 7.0 Hz, 3 H).LCMS: m / z =306.3 [M+H]+ .

[0340] (R)-1-(tert-butoxycarbonyl)azepan-4-yl=4-(((R)-1-(tert-butoxycarbonyl)azepan-4-yl)oxy)-6-(1-methyl- Synthesis of 1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate [ka] To a solution of tert-butyl (4R)-4-hydroxyazepane-1-carboxylate (232 mg, 1.08 mmol) in dry DMF (2 mL) under nitrogen was added NaHMDS (1 M, 1.08 mL) at 20 °C. . The mixture was stirred at 20°C for 15 minutes. A solution of ethyl 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate (150 mg, 491 μmol) in dry DMF (2 mL) was added to obtain the The resulting mixture was stirred at room temperature for 2 hours and then heated with H 2 Quenched with O (1 mL) and diluted with EtOAc. Wash the organic layer with brine (3x) and MgSO 4 dried, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (0-100% EtOAc / heptane) to give [(4R)-1-tert-butoxycarbonylazepan-4-yl]=4-[(4R)-1-tert-butoxy Carbonylazepan-4-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate (136 mg, yield 42%) as a pale yellow foam. I got it as a thing. 1H NMR (500 MHz, chloroform-d) δ ppm 8.23 ​​(s, 1 H), 7.76 - 7.90 (m, 2 H), 5.55 (br s, 1 H), 5.22 - 5.32 (m, 1 H), 3.98 (s, 3 H), 3.58 - 3.72 (m, 2 H), 3.30 - 3.58 (m, 6 H), 2.06 - 2.25 (m, 4 H), 1.89 - 2.06 (m, 6 H), 1.69 - 1.84 (m, 2 H), 1.51 (s, 9 H), 1.49 (s, 9 H).LCMS: m / z = 654.7 [M+H]+.

[0341] (R)-4-((1-(tert-butoxycarbonyl)azepan-4-yl)oxy)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine- Synthesis of 2-carboxylic acid [ka] [(4R)-1-tert-butoxycarbonylazepan-4-yl]=4-[(4R)-1-tert-butoxycarbonylazepan-4-yl]oxy-6-( in methanol (400 μL) To a solution of 1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate (41 mg, 63 μmol) was added sodium hydroxide solution (2 M, 94 μL) and the resulting mixture was stirred at room temperature. Stir for 30 minutes. The reaction mixture was quenched with HCl solution (1M, 188 μL) and diluted with EtOAc and water. Separate the layers and wash the organic layer with water and brine, dry (MgSO 4 ), filtered and concentrated under vacuum. 4-[(4R)-1-tert-butoxycarbonylazepan-4-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylic acid white Obtained as a solid and used directly. Quantitative yield assumed. LCMS: m / z =457.4 [M+H]+.

[0342] tert-Butyl=(R)-4-((2-((tert-butoxycarbonyl)amino)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4 Synthesis of -yl)oxy)azepane-1-carboxylate [ka] 4-[(4R)-1-tert-butoxycarbonylazepan-4-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo in dry DMF (1 mL) and tert-butanol (0.5 mL). Triethylamine (37 mg, 361 μmol, 50 μL) was added dropwise to a solution of [1,5-a]pyrazine-2-carboxylic acid (110 mg, 241 μmol) at room temperature, followed by DPPA (99 mg, 361 μmol, 78 μL). The resulting mixture was stirred at 80° C. for 17 h, cooled to room temperature, diluted with EtOAc, and washed with water and brine (3x). Dry the organic layer (MgSO 4 ), filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (0-5% MeOH / DCM). tert-Butyl=(4R)-4-[2-(tert-butoxycarbonylamino)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepan-1 -carboxylate (38 mg, 30% yield) was obtained as an oil. 1 H NMR (500 MHz, chloroform-d) δ ppm 7.99 (s, 1 H), 7.72 - 7.84 (m, 2 H), 7.33 (br s, 1 H), 6.82 - 7.05 (bs, 1 H), 5.47 - 5.55 (m, 1 H), 3.96 (s, 3 H), 3.58 - 3.76 (m, 2 H), 3.45 - 3.56 (m, 2 H), 1.88 - 2.03 (m, 6 H), 1.50 (s , 9 H), 1.46 (s, 9 H).LCMS: m / z = 528.3 [M+H]+.

[0343] Synthesis of (R)-4-(azepan-4-yloxy)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-2-amine dihydrochloride [ka] tert-Butyl (4R)-4-[2-(tert-butoxycarbonylamino)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine- in methanol (0.6 mL) To a solution of 4-yl]oxyazepane-1-carboxylate (38 mg, 72 μmol) was added HCl (4M in dioxane, 360 μL). The resulting solution was stirred at room temperature for 2 hours and concentrated under vacuum. 4-[(4R)-Azepan-4-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-2-amine (dihydrochloride) as an off-white Obtained as a solid and used directly. Quantitative yield assumed. LCMS: m / z =328.1[M+H]+.

[0344] 1-[(4R)-4-[2-amino-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepan-1-yl]prop-2- Synthesis of en-1-one [ka] Crude 4-[(4R)-azepan-4-yl]oxy-6-(1-methylpyrazol-4-yl)pyrazolo[1, Triethylamine (21 mg, 210 μmol, 29 μL) was added to a suspension of 5-a]pyrazin-2-amine (28 mg, 70 μmol, dihydrochloride), and the resulting suspension was cooled to 0°C. Acryloyl chloride (6 mg, 70 μmol, 6 μL) was added dropwise and the resulting mixture was stirred at 0° C. for 30 minutes. After quenching with saturated sodium bicarbonate solution and diluting with EtOAc, the layers were separated. The organic layer was washed with brine (3x), dried (MgSO 4 ), filtered and concentrated under vacuum. The residue was purified by silica gel chromatography and the desired product was further purified by preparative TLC (96:4 DCM / MeOH). 1-[(4R)-4-[2-amino-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepan-1-yl]prop-2- En-1-one (4.2 mg, 15% yield, 95% purity) was obtained as an off-white solid. 1 H NMR (500 MHz, chloroform-d) δ ppm 7.93 (s, 1 H), 7.79 (s, 1 H), 7.68 - 7.76 (m, 1 H), 6.58 - 6.67 (m, 1 H), 6.36 - 6.43 (m, 1 H), 5.94 (d, J = 4.3 Hz, 1 H), 5.72 (dd, J = 10.4, 2.4 Hz, 1 H), 5.49 - 5.60 (m, 1 H), 4.02 (br s , 2 H), 3.96 (s, 3 H), 3.80 - 3.94 (m, 1 H), 3.55 - 3.77 (m, 3 H), 2.11 - 2.32 (m, 3 H), 1.93 - 2.11 (m, 2 H), 1.77 - 1.90 (m, 1 H).LCMS: m / z = 382.1 [M+H]+.

[0345] Example 68: N-((cis)-3-((2-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy) Cyclobutyl)-N-methylacrylamide [ka]

[0346] (cis)-3-((tert-butoxycarbonyl)(methyl)amino)cyclobutyl=4-((cis)-3-((tert-butoxycarbonyl)(methyl)amino)cyclobutoxy)-6-(1- Synthesis of methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate [ka] Ethyl 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate (300 mg) in dry THF (4 mL) and dry DMSO (1 mL) under nitrogen. , 981 μmol) and tert-butyl ((cis)-3-hydroxycyclobutyl)(methyl)-carbamate (494 mg, 2.45 mmol) was treated with potassium tert-butoxide solution (1 M in THF, 2.45 mL) at 0 °C. added. The mixture was warmed to room temperature, stirred at room temperature for 2 h, and heated with H 2 Quenched with O (1 mL) and diluted with EtOAc. The organic layer was washed with brine (2x), dried over MgSO4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (0-100% EtOAc / heptane) to give (cis)-3-((tert-butoxycarbonyl)(methyl)amino)cyclobutyl 4-((cis)-3-((tert -butoxycarbonyl)(methyl)amino)cyclobutoxy)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate (250 mg, 41% yield) was obtained as a pale yellow foam. 1H NMR (500 MHz, chloroform-d) δ ppm 8.23 ​​(s, 1 H), 7.74 - 7.92 (m, 2 H), 5.55 (br s, 1 H), 5.28 (br s, 1 H), 3.98 ( s, 3 H), 3.59 - 3.74 (m, 2 H), 3.39 - 3.59 (m, 5 H), 3.29 - 3.39 (m, 1 H), 1.89 - 2.32 (m, 10 H), 1.69 - 1.84 ( m, 2 H), 1.48 - 1.53 (m, 18 H).LCMS: m / z = 471.2 [M+H]+.

[0347] 4-((cis)-3-((tert-butoxycarbonyl)(methyl)amino)cyclobutoxy)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine- Synthesis of 2-carboxylic acid [ka] (cis)-3-((tert-butoxycarbonyl)(methyl)amino)cyclobutyl 4-((cis)-3-((tert-butoxycarbonyl)(methyl)amino)cyclobutoxy) in methanol (1 mL) To a solution of -6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate (332 mg, 531 μmol) was added sodium hydroxide solution (2M, 266 μL), The resulting mixture was stirred at room temperature for 30 minutes. After quenching with HCl (1M, 531 μL) and diluting with EtOAc and water, the layers were separated. The organic layer was washed with water and brine, dried (MgSO 4 ), filtered and concentrated under vacuum. 4-((cis)-3-((tert-butoxycarbonyl)(methyl)amino)cyclobutoxy)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine- The 2-carboxylic acid was obtained as a white solid and was used directly. Quantitative yield assumed. 1 H NMR (500 MHz, DMSO-d6) δ ppm 13.26 (br s, 1 H), 8.81 (s, 1 H), 8.27 (s, 1 H), 8.05 (s, 1 H), 7.20 (s, 1 H), 5.05 - 5.16 (m, 1 H), 3.91 (s, 3 H), 2.84 (m, 2 H), 2.80 (s, 3 H), 2.32 - 2.42 (m, 2 H), 1.42 (s , 9 H).LCMS: m / z = 443.1 [M+H]+.

[0348] tert-Butyl=((cis)-3-((2-((tert-butoxycarbonyl)amino)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine- Synthesis of 4-yl)oxy)cyclobutyl)(methyl)carbamate [ka] 4-((cis)-3-((tert-butoxycarbonyl)(methyl)amino)cyclobutoxy)-6-(1-methyl-1H-pyrazole) in dry DMF (1 mL) and tert-butanol (0.5 mL). -4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylic acid (115 mg, 260 μmol) was added with triethylamine (39 mg, 390 μmol, 54 μL) followed by DPPA (107 mg, 390 μmol, 84 μL) at room temperature. dripped. The resulting mixture was stirred at 80° C. for 17 h, cooled to room temperature, diluted with EtOAc, and washed with water and brine (3x). Dry the organic layer (MgSO 4 ), filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (heptane / EtOAc 0-100%). tert-Butyl=((cis)-3-((2-((tert-butoxycarbonyl)amino)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine- 4-yl)oxy)cyclobutyl)(methyl)carbamate (26 mg, 20% yield) was obtained as a white foam. 1 H NMR (500 MHz, Chloroform-d) δ ppm 8.30-8.00 (br s, 1H), 8.10 (s, 1H), 7.81 (s, 1 H), 7.76 (s, 1 H), 6.82 - 7.09 (b s , 1 H), 5.10 (q, J= 7.2 Hz, 1 H), 3.94 - 3.99 (m, 3 H), 2.80 - 2.92 (m, 2 H), 2.86 (s, 3H), 2.33 (m, 2 H),1.55 (s, 9 H),1.49 (s, 9 H).LCMS: m / z = 514.2 [M+H]+.

[0349] tert-butyl = ((cis)-3-((2-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl) (Methyl)carbamate (16 mg, 15% yield) was also isolated as an oil. 1 H NMR (500 MHz, chloroform-d) δ ppm 7.94 (s, 1 H), 7.79 (s, 1 H), 7.72 (s, 1 H), 5.95 (s, 1 H), 5.01 - 5.10 (quin, J = 7.2 Hz, 1 H), 4.01 - 4.09 (b s, 2 H), 3.95 (s, 3 H), 2.83 - 2.93 (m, 2 H), 2.86 (s, 3 H), 2.28 - 2.42 (m , 2 H), 1.48 (s, 9 H).LCMS: m / z = 414.2 [M+H]+.

[0350] Synthesis of 6-(1-methyl-1H-pyrazol-4-yl)-4-((cis)-3-(methylamino)cyclobutoxy)pyrazolo[1,5-a]pyrazin-2-amine [ka] tert-Butyl=((cis)-3-((2-((tert-butoxycarbonyl)amino)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[ A solution of 1,5-a]pyrazin-4-yl)oxy)cyclobutyl)(methyl)carbamate (26 mg, 51 μmol) was treated with HCl (4M in dioxane, 506 μL). The resulting mixture was stirred at room temperature for 1 hour. A solid formed. The mixture was concentrated under vacuum. 6-(1-Methyl-1H-pyrazol-4-yl)-4-((cis)-3-(methylamino)cyclobutoxy)pyrazolo[1,5-a]pyrazin-2-amine (dihydrochloride) was obtained as a white solid, which was used directly. Quantitative yield assumed. LCMS: m / z = 314.5 [M+H]+.

[0351] N-((cis)-3-((2-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)-N -Synthesis of methylacrylamide [ka] Crude 6-(1-methyl-1H-pyrazol-4-yl)-4-((cis)-3-(methylamino)cyclo in dry THF (0.5 mL) and dry DMF (0.5 mL) under nitrogen. Triethylamine (11 mg, 109 μmol, 15 μL) was added to a suspension of butoxy)pyrazolo[1,5-a]pyrazin-2-amine dihydrochloride (14 mg, 36 μmol), and the resulting suspension was cooled to 0°C. did. Acryloyl chloride (3.3 mg, 36 μmol, 3 μL) was added dropwise and the resulting mixture was stirred at 0° C. for 30 minutes. The reaction mixture was quenched with saturated sodium bicarbonate solution and diluted with EtOAc. Separate the layers and wash the organic layer with brine (3x), dry (MgSO 4 ), filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (0-10% MeOH / DCM). N-((cis)-3-((2-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)-N -Methylacrylamide (4.4 mg, 32% yield, 95% purity) was obtained as a white foam. 1 H NMR (500 MHz, chloroform-d) δ ppm 7.94 (s, 1 H), 7.78 (br s, 1 H), 7.73 (br s, 1 H), 6.58 (dd, J = 16.8, 10.7 Hz, 1 H), 6.24 - 6.40 (m, 1 H), 5.95 (s, 1 H), 5.71 (dd, J= 10.4, 1.8 Hz, 1 H), 5.13 (quin, J= 7.2 Hz, 1 H), 4.83 and 4.30 (2 br s, 1 H), 4.02 (b s, 2 H), 3.96 (s, 3 H), 3.06 (br s, 3 H), 2.90 - 2.98 (m, 2 H), 2.51 and 2.36 ( 2br s, 2 H).LCMS: m / z = 368.1 [M+H]+.

[0352] Example 69: (S)-1-(4-((6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan- 1-yl)prop-2-en-1-one and (R)-1-(4-((6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazolo[1,5-a] pyrazin-4-yl)oxy)azepan-1-yl)prop-2-en-1-one [ka]

[0353] Synthesis of tert-butyl-4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)oxyazepane-1-carboxylate [ka] tert-Butyl-4-hydroxyazepane-1-carboxylate (4.0g, 18.6mmol) and 4,6-dichloropyrazolo[1,5-a]pyrazine (3.5g, 18.6mmol) in THF (100mL) To the solution was slowly added a solution of potassium tert-butoxide (1M in THF, 18.6 mL, 18.6 mmol). The flask was stirred at room temperature for 2 hours. The material was concentrated to half volume and taken up in EtOAc and water. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified on an 80 g silica gel column using a 0-60% EtOAc / heptane gradient. The relevant fractions were combined to give tert-butyl-4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)oxyazepan-1-carboxylate (4.32 g, 63% yield) as a yellow oil. obtained as. LCMS m / z = 367.1 (M+H)+. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.36 - 1.47 (m, 9 H) 1.68 (br dd, J =11.7,5.4Hz,1 H) 1.83 (br s, 1 H) 1.90 - 1.98 (m, 3 H) 2.03 - 2.24 (m, 1 H) 3.34 - 3.53 (m, 4 H) 5.22 - 5.44 (m, 1 H) 6.88 - 6.98 (m, 1 H) 8.01 - 8.14 (m, 1 H) 8.65 - 8.76 (m, 1 H)

[0354] Synthesis of tert-butyl-4-[6-(1,3-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxylate [ka] In a microwave vial, tert-butyl-4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)oxyazepane-1-carboxylate (1M, 0.55mL, 0.55mmol), 1,3-dimethyl- 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (145 mg, 0.65 mmol), K 3 P.O. 4 (1M in water, 1.09 mL), Pd-PEPPSI™-IPr (37 mg, 55 μmol) and dioxane (5 mL) were added. The vial was capped and stirred at 60°C overnight. The reaction mixture was concentrated and purified on a 12 g silica gel column using a 40-70% EtOAc / heptane gradient. The relevant fractions were combined to give tert-butyl-4-[6-(1,3-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxylate (136 mg , yield 58%) was obtained as a pale yellow oil. LCMSm / z=427.2(M+H)+.

[0355] Synthesis of 4-[azepan-4-yl]oxy-6-(1,3-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine hydrochloride [ka] tert-butyl-4-[6-(1,3-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepane-1-carboxylate (136 mg, HCl (4M in dioxane, 0.8 mL) was added to a solution of 0.32 mmol). The mixture was stirred at room temperature overnight. Concentrate the material to give 4-[azepan-4-yl]oxy-6-(1,3-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine hydrochloride (115 mg, crude) as an off-white Obtained as a colored solid. LCMS m / z = 327.1 (M+H)+.

[0356] (S)-1-(4-((6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl) Prop-2-en-1-one and (R)-1-(4-((6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4- Synthesis of yl)oxy)azepan-1-yl)prop-2-en-1-one [ka] In a vial was added 4-[azepan-4-yl]oxy-6-(1,3-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine hydrochloride (115 mg, 0.32 mmol) in DCM (4 mL). ), triethylamine (193 mg, 1.9 mmol, 266 μL) and prop-2-enoyl chloride (35 mg, 0.38 mmol, 31 μL) were added in this order. The vial was stirred at room temperature overnight. The reaction mixture was concentrated, taken up in DMSO and passed through a plug. The material was purified by reverse phase purification (column: Waters XSelect CSH Prep C18 5um OBD 19×100mm; conditions: 5-50% acetonitrile / 0.1% v / v ammonium carbonate / water; flow rate: 30 mL / min) to yield 60.6 mg. (50% yield) of the desired product was obtained. LCMS m / z = 381.2 (M+H)+. 1 H NMR (500 MHz, DMSO-d 6 ) δ ppm 1.67 - 1.80 (m, 1 H) 1.86 - 2.10 (m, 4 H) 2.16 - 2.26 (m, 1 H) 2.42 (s, 3 H) 3.56 - 3.78 (m, 4 H) 3.81 (d, J=1.22 Hz, 3 H) 5.42 - 5.56 (m, 1 H) 5.65 - 5.74 (m, 1 H) 6.13 - 6.21 (m, 1 H) 6.75 - 6.87 (m, 2 H) 7.98 - 8.04 (m, 1 H) 8.08 - 8.15 (m, 1 H) 8.42 - 8.49 (m, 1 H).

[0357] The material was purified under the following conditions (Column: CHIRALPAK AD-H 30 x 250 mm, 5 um; Method: 30% MeOH (no modifier) / CO 2 ; flow rate: 100 mL / min; ABPR: 120 bar; MBPR: 40 PSI; column temperature: 40°C) for chiral purification. The first eluting peak E1 was concentrated to yield 11.3 mg of one enantiomer, 1-[-4-[6-(1,3-dimethylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine. -4-yl]oxyazepan-1-yl]prop-2-en-1-one was obtained as a white solid. LCMS m / z = 381.2 (M+H)+.The second eluting peak E2 was concentrated to yield 5.4 mg of the second enantiomer, 1-[4-[6-(1,3-dimethylpyrazole- 4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxyazepan-1-yl]prop-2-en-1-one was obtained as a white solid. LCMS m / z = 381.2 (M+H)+.Stereochemistry of the two isomers could not be assigned.

[0358] Example 70: 1-[(4R)-4-[[6-(1,3-dimethylpyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl ]oxy]azepan-1-yl]prop-2-en-1-one [ka]

[0359] Synthesis of tert-butyl(4R)4-((6-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)oxy)azepane-1-carboxylate [ka] tert-Butyl (4R)-4-hydroxyazepane-1-carboxylate (775 mg, 3.60 mmol) and 6,8-dibromo-[1,2,4]triazolo[1,5- a] To a solution of pyrazine (1 g, 3.60 mmol) was slowly added a solution of potassium tert-butoxide (1M in THF, 3.6 mL, 3.6 mmol). The flask was stirred at room temperature for 1 hour. The material was concentrated to half volume and taken up in EtOAc and water. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified on a 40 g silica gel column using a 10-70% EtOAc / heptane gradient. The relevant fractions were combined to give tert-butyl=(4R)-4-[(6-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)oxy]azepan-1- The carboxylate (1.48 g, 2.79 mmol, 77.5% yield) was obtained as a white foam. LCMS m / z = 414.0 (M+H)+. 1 H NMR (500 MHz, DMSO-d 6 ) δ ppm 1.43 (s, 9 H) 1.69 (br dd, J=8.85, 4.58 Hz, 1 H) 1.81 - 2.04 (m, 4 H) 2.10 - 2.31 (m, 1 H) 3.37 - 3.53 (m, 4 H) 5.27 - 5.39 (m, 1 H) 8.52 - 8.66 (m, 1 H) 8.97 - 9.15 (m, 1 H)

[0360] tert-Butyl=(4R)-4-[[6-(1,3-dimethylpyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]oxy] Synthesis of azepane-1-carboxylate [ka] In a microwave vial, tert-butyl (4R)-4-[(6-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)oxy]azepane-1-carboxylate (230mg, 0.56mmol), 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (149mg, 0.67mmol), K 3 P.O. 4 (1M in water, 1.12 mL), Pd-PEPPSI™-IPr (38 mg, 55.8 μmol) and dioxane (5.00 mL) were added. The vial was capped and stirred at 70°C overnight. The reaction mixture was concentrated and purified on a 12 g silica gel column using a 30-100% EtOAc / heptane gradient. The relevant fractions were combined to give tert-butyl=(4R)-4-[[6-(1,3-dimethylpyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazine. -8-yl]oxy]azepane-1-carboxylate (65 mg, 27% yield) was obtained as a pale yellow oil. LCMS m / z = 428.2 (M+H)+

[0361] Synthesis of 8-[(4R)-azepan-4-yl]oxy-6-(1,3-dimethylpyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazine hydrochloride [ka] tert-Butyl (4R)-4-[[6-(1,3-dimethylpyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazine- in dioxane (5 mL) To a solution of 8-yl]oxy]azepane-1-carboxylate (65 mg, 0.15 mmol) was added HCl (4M in dioxane, 0.38 mL). The mixture was stirred at room temperature overnight. Concentrate the material to give 8-[(4R)-azepan-4-yl]oxy-6-(1,3-dimethylpyrazol-4-yl)-[1,2,4]triazolo[1,5-a ] Pyrazine hydrochloride (55.3 mg, 100% yield) was obtained as an off-white solid. LCMS m / z = 328.1 (M+H)+.

[0362] 1-[(4R)-4-[[6-(1,3-dimethylpyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]oxy]azepane Synthesis of -1-yl]prop-2-en-1-one [ka] In a vial, add 8-[(4R)-azepan-4-yl]oxy-6-(1,3-dimethylpyrazol-4-yl)-[1,2,4]triazolo[1, 5-a] Pyrazine hydrochloride (55.3 mg, 0.15 mmol), triethylamine (93 mg, 0.92 mmol, 128 μL) and prop-2-enoyl chloride (17 mg, 0.18 mmol, 15 μL) were added in this order. The vial was stirred at room temperature overnight. The reaction mixture was concentrated, taken up in DMSO and passed through a plug. The material was purified by reverse phase purification (column: Waters A yield of 45%) of the desired product was obtained. LCMS m / z = 382.3 (M+H)+. 1 H NMR (500 MHz, DMSO-d 6 ) δ ppm 1.69 - 1.81 (m, 1 H) 1.91 - 2.07 (m, 4 H) 2.21 - 2.31 (m, 1 H) 2.44 (d, J=1.22 Hz, 3 H) 3.49 - 3.59 (m, 2 H ) 3.66 - 3.76 (m, 2 H) 3.82 (d, J=1.83 Hz, 3 H) 5.41 - 5.54 (m, 1 H) 5.65 - 5.77 (m, 1 H) 6.11 - 6.22 (m, 1 H) 6.75 - 6.88 (m, 1 H) 8.11 - 8.23 ​​(m, 1 H) 8.52 - 8.61 (m, 1 H) 8.69 - 8.78 (m, 1 H).

[0363] Example 71: (S)-5-(4-((1-acryloylazepan-4-yl)oxy)pyrazolo[1,5-a]pyrazin-6-yl)-1-methylpyridine-2(1H )-one and (R)-5-(4-((1-acryloylazepan-4-yl)oxy)pyrazolo[1,5-a]pyrazin-6-yl)-1-methylpyridine-2(1H )-on [ka]

[0364] tert-Butyl=4-((6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxy Synthesis of Lato [ka] 20 mL scintillation of tert-butyl 4-((6-chloropyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate (200 mg, 0.55 mmol) in dioxane (5.0 mL). To the vial was added 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one (154 mg, 0.64 mmol). . Next, K 3 P.O. 4 Aqueous solution (1M, 1.09 mmol, 1.1 mL) was added to the reaction mixture followed by Pd-PEPPSI™-IPr (37 mg, 55 μmol). N the vial 2 and heated at 100°C overnight. After this time, the reaction mixture was filtered through a Celite® pad and concentrated under reduced pressure to give an amber oil. The crude material was purified by silica gel chromatography (0-25% EtOAc / heptane, then 100% [3:1 EtOAc:EtOH]) to give tert-butyl 4-((6-(1-methyl-6- Oxo-1,6-dihydropyridin-3-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate (155 mg, 65% yield) was obtained as an off-white solid. Ta. LC-MS: m / z = 440.0 (M+H) + .

[0365] Synthesis of 5-(4-(azepan-4-yloxy)pyrazolo[1,5-a]pyrazin-6-yl)-1-methylpyridin-2(1H)-one [ka] tert-Butyl 4-((6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyrazolo[1,5-a]pyrazin-4-yl) in dioxane (1.4 mL) To a solution of oxy)azepane-1-carboxylate (155 mg, 0.35 mmol) was added HCl (4M in dioxane, 883 μL, 3.5 mmol). The reaction mixture became heterogeneous immediately upon addition of the HCl solution, which was stirred at room temperature for 1.5 h. The reaction mixture was directly concentrated under reduced pressure to give the title compound as an orange solid, which was carried forward without further purification (100% expected yield). LC-MS: m / z = 361.9 (M+Na) + .

[0366] (S)-5-(4-((1-acryloylazepan-4-yl)oxy)pyrazolo[1,5-a]pyrazin-6-yl)-1-methylpyridin-2(1H)-one and (R)-5-(4-((1-acryloylazepan-4-yl)oxy)pyrazolo[1,5-a]pyrazin-6-yl)-1-methylpyridin-2(1H)-one synthesis [ka] 5-(4-(azepan-4-yloxy)pyrazolo[1,5-a]pyrazin-6-yl)-1-methylpyridin-2(1H)-one (120 mg, 0.35 mmol) in DCM (1.4 mL) ) was added triethylamine (99 μL, 0.71 mmol) followed by acryloyl chloride (57 μL, 0.71 mmol). Upon addition of acryloyl chloride, the solution became red and homogeneous and was stirred at room temperature for 20 minutes. The reaction mixture was then concentrated under vacuum and loaded onto a silica gel cartridge. The crude material was purified by silica gel chromatography (0-100% EtOAc / heptane, then 0-15% MeOH / heptane) to give 5-(4-((1-acryloylazepan-4-yl)oxy)pyrazolo [1,5-a]pyrazin-6-yl)-1-methylpyridin-2(1H)-one was obtained as a white solid (52.1 mg, 38% over 2 steps). LC-MS: m / z = 393.9 (M+H) + . 1 H NMR (400 MHz, CDCl 3) δ ppm 1.72 (br s, 1 H) 1.74 - 1.91 (m, 2 H) 1.95 - 2.49 (m, 6 H) 3.46 - 3.64 (m, 2 H) 3.65 - 3.73 (m, 4 H) 3.77 - 4.12 (m, 2 H) 5.46 - 5.65 (m, 1 H) 5.69 - 5.75 (m, 1 H) 6.35 - 6.43 (m, 1 H) 6.58 - 6.70 (m, 2 H) 6.73 - 6.78 (m, 1 H ) 7.74 - 7.79 (m, 1 H) 7.91 (dd, J=4.39, 2.38 Hz, 1 H) 7.95 - 8.11 (m, 1 H) 8.23 ​​(d, J=0.75 Hz, 1 H).

[0367] Racemic substances were collected using chiral SFC (Chiralpak AD-H 30 x 250 mm, 5 μm column; 25% MeOH / CO 2 (no modifier); flow rate = 100 mL / min, ABPR 120 bar, MBPR 40 psi, column temperature 40 °C) to separate the enantiomer, the first eluting enantiomer E1 (7.0 mg, 100%ee, Rf = 4.36 min). ) and the second eluting enantiomer E2 (arbitrarily assigned to R, 7.6 mg, 90%ee, Rf=4.77 min) were obtained.

[0368] Example 72: 1-(4-((6-(2-methoxypyridin-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2-ene -1-one (chiral, but absolute chemistry unknown) [ka]

[0369] Synthesis of tert-butyl 4-((6-(2-methoxypyridin-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate [ka] 20 mL scintillation of tert-butyl 4-((6-chloropyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate (200 mg, 0.55 mmol) in dioxane (5.0 mL). To the vial was added 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (100 mg, 0.65 mmol). Then, K 3 P.O. 4 Aqueous solution (1M, 1.09 mmol, 1.09 mL) was added to the reaction mixture followed by Pd-PEPPSI™-IPr (37 mg, 55 μmol). N the vial 2 and heated at 100°C overnight. The reaction mixture was allowed to warm to room temperature and then filtered through a pad of Celite®. Concentration under reduced pressure gave the crude product as an amber oil. The crude material was purified by silica gel chromatography (0-25% EtOAc / heptane) to give tert-butyl 4-((6-(2-methoxypyridin-4-yl)pyrazolo[1,5-a]pyrazine- 4-yl)oxy)azepane-1-carboxylate (184 mg, 77% yield) was obtained as an off-white solid. LC-MS: m / z = 440.0 (M+H) + .

[0370] Synthesis of 4-(azepan-4-yloxy)-6-(2-methoxypyridin-4-yl)pyrazolo[1,5-a]pyrazine [ka] tert-Butyl 4-((6-(2-methoxypyridin-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate( To a solution of 184 mg, 0.42 mmol) was added a HCl solution (4M in dioxane, 1.05 mL, 4.2 mmol). The reaction mixture was stirred at room temperature for 3 h and then concentrated under vacuum to give the crude 4-(azepan-4-yloxy)-6-(2-methoxypyridin-4-yl)pyrazolo[1,5-a ] Pyrazine was obtained as a bright yellow solid. The crude product was used without further purification (100% expected yield). LC-MS: m / z = 340.0 (M+H) + .

[0371] Chiral 1-(4-((6-(2-methoxypyridin-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2-ene-1 -on synthesis [ka] A solution of crude 4-(azepan-4-yloxy)-6-(2-methoxypyridin-4-yl)pyrazolo[1,5-a]pyrazine (142 mg, 0.42 mmol) in DCM (1.7 mL) was added to Triethylamine (0.29 mL, 2.09 mmol) was added at room temperature, followed immediately by acryloyl chloride (68 μL, 0.84 mmol). The reaction mixture became deep red and homogeneous and was stirred at room temperature for 20 minutes. After this, the reaction mixture was saturated with NaHCO 3 Quenched by addition of aqueous solution and diluted with EtOAc. The resulting layers were separated and the aqueous layer was further extracted with EtOAc (3x). The combined organics were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude material was purified by silica gel chromatography (0-100% EtOAc / heptane) to give 1-(4-((6-(2-methoxypyridin-4-yl)pyrazolo[1,5-a]pyrazine-4 -yl)oxy)azepan-1-yl)prop-2-en-1-one (64.5 mg, 39% over 2 steps) was obtained as a colorless oil. LC-MS: m / z = 393.9 (M+H) + . 1 HNMR(400MHz, CDCl 3 )δppm1.81- 1.92 (m, 1 H) 1.97 - 2.13 (m, 2 H) 2.16 - 2.31 (m, 3 H) 3.62 - 3.85 (m, 4 H) 4.01 - 4.04 (m, 3 H) 5.64 - 5.70 (m, 1 H) 5.72 (dd, J=10.29, 2.01 Hz, 1 H) 6.39 (ddd, J=16.75, 7.72, 2.13 Hz, 1 H) 6.57 - 6.68 (m, 1 H) 6.80 (dd, J=4.02, 2.01 Hz, 1 H) 7.31 - 7.39 (m, 2 H) 7.98 (t, J=2.01 Hz, 1 H) 8.24 (d, J=5.27 Hz, 1 H) 8.56 (s, 1 H) .

[0372] Racemic substances were purified using chiral SFC (Chiralpak IB 30 × 250 mm, 5 μm column; 15% MeOH / CO 2 (without modifier; flow rate = 100 mL / min, ABPR 120 bar, MBPR 40 psi, column temperature 40 °C) and the first eluting enantiomer E1 (12.2 mg, 100%ee, Rf = 6.91 min) and 2 The second eluting enantiomer E2 (3.6 mg, 96%ee, Rf=7.45 min) was obtained. The second enantiomer contained an unseparable impurity and was not subjected to further purification.

[0373] Example 73: (R)-1-(4-((6-phenylpyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2-en-1-one [ka]

[0374] tert-Butyl=(R)-4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrazine-4- Synthesis of yl)oxy)azepane-1-carboxylate [ka] tert-Butyl (R)-4-((6-chloropyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate (734 mg, 2.0 mmol) dissolved in dioxane (10 mL). Bis(pinacolato)diboron (610 mg, 2.4 mmol) was added to a 20 mL scintillation vial containing . KOAc (589 mg, 6.0 mmol) was then added to the reaction mixture followed by [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (293 mg, 0.40 mmol). N the vial 2 and then stirred at 95° C. overnight. After this time, the reaction mixture was cooled to room temperature and filtered through a Celite® pad with EtOAc. The crude material was dry loaded onto silica gel and purified by silica gel chromatography (0-40% EtOAc / heptane) to give tert-butyl=(R)-4-((6-(4,4,5,5-tetra Methyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate (744 mg, 81% yield) as a colorless oil. Obtained. LC-MS: m / z = 399.2 (M-86+Na) + .

[0375] Synthesis of tert-butyl(R)-4-((6-phenylpyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate [ka] tert-Butyl=(R)-4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5 -a]pyrazin-4-yl)oxy)azepane-1-carboxylate (248 mg, 0.54 mmol) was placed in a 20 mL scintillation vial containing bromobenzene (38 μL, 0.36 mmol) followed by K 3 P.O. 4 Aqueous solution (0.5M, 1.44mL, 0.72mmol) and Pd-PEPPSI™-IPr (49mg, 72μmol) were added sequentially. The reaction mixture was heated at 95° C. overnight, then cooled to room temperature and directly concentrated under reduced pressure. The crude material was purified by silica gel chromatography (0-100% EtOAc / heptane) to give tert-butyl=(R)-4-((6-phenylpyrazolo[1,5-a]pyrazin-4-yl) Oxy)azepane-1-carboxylate (47.6 mg, 32% yield) was obtained as a yellow oil. LC-MS: m / z = 409.2 (M+H) +.

[0376] Synthesis of (R)-4-(azepan-4-yloxy)-6-phenylpyrazolo[1,5-a]pyrazine [ka] tert-Butyl (R)-4-((6-phenylpyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate (48 mg, 0.12 mmol) in dioxane (1.2 mL) ) was added HCl (4M in dioxane, 1.2 mmol, 291 μL). The reaction mixture immediately became a white slurry upon addition of HCl solution, which was stirred at room temperature for 4 hours. The reaction mixture was directly concentrated under reduced pressure to yield the crude (R)-4-(azepan-4-yloxy)-6-phenylpyrazolo[1,5-a]pyrazine, which was obtained without further purification. Proceeded ahead (estimated yield 100%). LC-MS: m / z = 332.2 (M+Na) + .

[0377] Synthesis of (R)-1-(4-((6-phenylpyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2-en-1-one [ka] A solution of crude (R)-4-(azepan-4-yloxy)-6-phenylpyrazolo[1,5-a]pyrazine (36 mg, 0.12 mmol) in THF (1.2 mL) was added to a dry ice / acetone bath. It was cooled down to -78°C in a chamber. Triethylamine (81 μL, 0.58 mmol) was added via microsyringe with stirring, followed immediately by acryloyl chloride (19 μL, 0.23 mmol). The reaction mixture was removed from the ice bath and slowly warmed to room temperature, turning red in the process. After stirring for 2 h at room temperature, the reaction mixture was diluted with EtOAc and saturated NaHCO 3 Quenched by addition of aqueous solution. The resulting layers were separated and the aqueous layer was further extracted with EtOAc (2x). The combined organic extracts were dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product as a pale yellow oil. The crude material was purified by reverse phase HPLC (column: Waters 4-((6-phenylpyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2-en-1-one (16.7 mg in 2 steps, 40% yield ) was obtained as a yellow film. LC-MS:m / z=363.3(M+H) + . 1 HNMR(500MHz,DMSO-d 6 ) δ ppm1.71-1.80(m,1H)1.87-2.13(m,5 H)2.18-2.30(m,1H)3.52-3.78(m,4H)5.54-5.62(m,1H)5.70(dt,J =10.38, 2.14 Hz, 1H) 6.15 - 6.21 (m, 1 H) 6.77 - 6.88 (m, 2 H) 7.37 - 7.42 (m, 1 H) 7.45 - 7.50 (m, 2 H) 8.07 - 8.11 (m, 3 H) 9.03 (s, 1 H).

[0378] Example 74: (R)-1-(4-((6-(6-methoxypyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)propyl -2-en-1-one [ka]

[0379] Synthesis of tert-butyl (R)-4-((6-(6-methoxypyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate [ka] tert-Butyl=(R)-4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5 -a]pyrazin-4-yl)oxy)azepane-1-carboxylate (138 mg, 0.30 mmol) in a 2-dram scintillation vial was added 4-bromo-6-methoxypyrimidine (38 mg, 0.20 mmol). Then, K 3 P.O. 4 Aqueous solution (0.5M, 0.80mL, 0.40mmol) was added followed by Pd-PEPPSI™-IPr (41mg, 40μmol). The reaction mixture was heated at 95° C. overnight, then cooled to room temperature and directly concentrated under reduced pressure. The crude material was purified by silica gel chromatography (0-50% [3:1 EtOAc:EtOH] / heptane) to give tert-butyl(R)-4-((6-(6-methoxypyrimidin-4-yl) ) Pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate (98.6 mg, yield 75%) was obtained. LC-MS: m / z = 441.2 (M+H) + .

[0380] Synthesis of (R)-4-(azepan-4-yloxy)-6-(6-methoxypyrimidin-4-yl)pyrazolo[1,5-a]pyrazine [ka] tert-Butyl (R)-4-((6-(6-methoxypyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1 in dioxane (2.2 mL) -HCl (4M in dioxane, 2.2 mmol, 0.56 mL) was added to a solution of the -carboxylate (99 mg, 0.22 mmol) and a milky white slurry was formed. After stirring at room temperature for 4 hours, the reaction mixture was directly concentrated under reduced pressure to give the crude (R)-4-(azepan-4-yloxy)-6-(6-methoxypyrimidin-4-yl)pyrazolo[1 ,5-a]pyrazine, which was used without further purification (100% expected yield). LC-MS: m / z = 363.3 (M+Na) + .

[0381] (R)-1-(4-((6-(6-methoxypyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2-ene -1-one synthesis [ka] Crude (R)-4-(azepan-4-yloxy)-6-(6-methoxypyrimidin-4-yl)pyrazolo[1,5-a]pyrazine (76 mg, 0.22 mmol) in THF (2.2 mL) The solution was cooled to -78°C in a dry ice / acetone bath. Triethylamine (156 μL, 1.1 mmol) was added with stirring, followed immediately by acryloyl chloride (36 μL, 0.45 mmol). The reaction mixture was removed from the ice bath and slowly warmed to room temperature, turning red in the process. After stirring for 2 h at room temperature, the reaction mixture was diluted with EtOAc and saturated NaHCO 3 Quenched by addition of aqueous solution. The resulting layers were separated and the aqueous layer was further extracted with EtOAc (2x). The combined organic extracts were dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product as a yellow oil. The crude material was purified by reverse phase HPLC (column: Waters 4-((6-(6-methoxypyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2-en-1-one (22.7 mg , 26% yield over two steps) was obtained as a white solid. LC-MS: m / z = 395.3 (M+H) + . 1 HNMR(500MHz,DMSO-d 6) δ ppm 1.71 - 1.81 (m, 1 H) 1.87 - 1.95 (m, 1 H) 1.97 (br s, 1 H) 1.98 - 2.11 (m, 2 H) 2.20 - 2.30 (m, 1 H) 3.53 - 3.81 (m, 4 H) 3.99 - 4.02 (m, 1 H) 4.00 (s, 1 H) 5.57 - 5.64 (m, 1 H) 5.68 - 5.72 (m, 1 H) 6.18 (dt, J=16.79, 2.59 Hz , 1 H) 6.82 (dt, J=16.48, 10.07 Hz, 1 H) 6.95 - 6.98 (m, 1 H) 7.53 (dd, J=10.99, 1.22 Hz, 1 H) 8.17 - 8.22 (m, 1 H) 8.19 - 8.19 (m, 1 H) 8.19 - 8.20 (m, 1 H) 8.82 - 8.87 (m, 1 H) 8.83 - 9.11 (m, 1 H) 9.09 (s, 1 H).

[0382] Example 75: (R)-1-(4-((6-(4-methyloxazol-2-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)propa -2-en-1-one [ka]

[0383] Synthesis of tert-butyl (R)-4-((6-(4-methyloxazol-2-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate [ka] tert-Butyl=(R)-4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5 -a]pyrazin-4-yl)oxy)azepane-1-carboxylate (138 mg, 0.30 mmol) in a 2-dram scintillation vial was added 2-bromo-4-methyloxazole (32 mg, 0.20 mmol). Next, K 3 P.O. 4 Aqueous solution (0.5M, 0.80mL, 0.40mmol) was added followed by Pd-PEPPSI™-IPr (41mg, 40μmol). The reaction mixture was heated at 95° C. overnight, then cooled to room temperature and directly concentrated under reduced pressure. The crude material was purified by silica gel chromatography (0-50% [3:1 EtOAc:EtOH] / heptane) to give tert-butyl (R)-4-((6-(4-methyloxazol-2-yl) ) Pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate (95.4 mg, yield 77%) was obtained. LC-MS: m / z = 441.2 (M+H) +.

[0384] Synthesis of (R)-2-(4-(azepan-4-yloxy)pyrazolo[1,5-a]pyrazin-6-yl)-4-methyloxazole [ka] tert-Butyl (R)-4-((6-(4-methyloxazol-2-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1 in dioxane (2.3 mL) -HCl (4M in dioxane, 2.3 mmol, 0.58 mL) was added to a solution of the -carboxylate (95 mg, 0.23 mmol) and a bright yellow slurry was formed. After stirring at room temperature for 4 hours, the reaction mixture was directly concentrated under reduced pressure to give the crude (R)-2-(4-(azepan-4-yloxy)pyrazolo[1,5-a]pyrazin-6-yl )-4-methyloxazole was obtained which was used without further purification (100% expected yield). LC-MS: m / z = 314.1 (M+Na) + .

[0385] (R)-1-(4-((6-(4-methyloxazol-2-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2-ene -1-one synthesis [ka] Crude (R)-2-(4-(azepan-4-yloxy)pyrazolo[1,5-a]pyrazin-6-yl)-4-methyloxazole (72 mg, 0.23 mmol) in THF (2.3 mL) The solution was cooled to -78°C in a dry ice / acetone bath. Triethylamine (161 μL, 1.2 mmol) was added with stirring, followed immediately by acryloyl chloride (38 μL, 0.46 mmol). The reaction mixture was removed from the ice bath and slowly warmed to room temperature, turning red in the process. After stirring for 2 h at room temperature, the reaction mixture was diluted with EtOAc and saturated NaHCO 3 Quenched by addition of aqueous solution. The resulting layers were separated and the aqueous layer was further extracted with EtOAc (2x). The combined organic extracts were dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield the crude product as a yellow solid. The crude material was purified by reverse phase HPLC (column: Waters 4-((6-(4-methyloxazol-2-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2-en-1-one (28.2 mg , 22% yield over two steps) was obtained as an off-white solid. LC-MS: m / z = 368.3 (M+H) + . 1 HNMR(500MHz,DMSO-d 6 ) δ ppm 1.67 - 1.79 (m, 1 H) 1.83 - 1.96 (m, 2 H) 2.02 - 2.13 (m, 3 H) 2.18 (d, J=1.22 Hz, 4 H) 3.54 - 3.77 (m, 3 H) ) 5.53 - 5.60 (m, 1 H) 5.69 (ddd, J=10.38, 3.66, 2.44 Hz, 1 H) 6.13 - 6.20 (m, 1 H) 6.80 (ddd, J=16.48, 14.04, 10.38 Hz, 1 H ) 6.95 - 6.98 (m, 1 H) 7.97 (s, 1 H) 8.18 (d, J=1.22 Hz, 1 H) 8.90 (s, 1 H).

[0386] Example 76: (R)-1-(4-((6-(2-methylthiazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)propyl -2-en-1-one [ka]

[0387] Synthesis of tert-butyl (R)-4-((6-(2-methylthiazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate [ka] tert-Butyl=(R)-4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5 -a]pyrazin-4-yl)oxy)azepane-1-carboxylate (193 mg, 0.42 mmol), 4-bromo-2-methyl-thiazole (50 mg, 0.28 mmol), dichlorobis(di-tert-butylphosphinite) A solution of palladium dihydrogen(2-) (7 mg, 14 μmol) and cesium fluoride (128 mg, 0.84 mmol) was stirred in the microwave at 90° C. for 3 hours. The reaction was quenched with water and brine. The biphasic mixture was extracted three times with ethyl acetate, then anhydrous MgSO 4 It was dried with. After filtration and concentration under reduced pressure, the crude tert-butyl(R)-4-((6-(2-methylthiazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy ) azepane-1-carboxylate (110 mg, 91% yield) was carried forward without further purification. LCMS: m / z = 430.0(M+H) + .

[0388] (R)-1-(4-((6-(2-methylthiazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2-ene -1-one synthesis [ka] Step 1. Crude tert-butyl (R)-4-((6-(2-methylthiazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxy Lato (110 mg, 0.26 mmol) was dissolved in HCl solution (1.25 M in MeOH, 1.5 mL). The reaction solution was stirred at 40°C. After 16 hours, saturated NaHCO 3 The reaction was carefully quenched by slowly adding aqueous solution. The biphasic mixture was extracted three times with a mixture of chloroform and isopropanol (5:1), then anhydrous MgSO 4 It was dried with. After filtration and concentration under reduced pressure, the crude (R)-4-(4-(azepan-4-yloxy)pyrazolo[1,5-a]pyrazin-6-yl)-2-methylthiazole (84 mg, assumed (100% yield) was concentrated to dryness and proceeded without purification. LCMS: m / z = 330.0(M+H) + .

[0389] Step 2. 20 mL of crude (R)-4-(4-(azepan-4-yloxy)pyrazolo[1,5-a]pyrazin-6-yl)-2-methylthiazole (84 mg, 0.25 mmol) To the vial was added DCM (1.0 mL) followed by TEA (129 mg, 1.27 mmol, 178 μL). The reaction mixture was stirred at room temperature for 5 minutes, then cooled to 0°C. Acryloyl chloride (35 mg, 0.38 mmol, 31 μL) was added dropwise. The solution was stirred at 0°C. After 1 hour, saturated NH 4 The reaction mixture was carefully quenched by slowly adding aqueous Cl solution. The biphasic mixture was extracted three times with ethyl acetate, then anhydrous MgSO 4 It was dried with. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (25-100% ethyl acetate / heptane). The desired fractions were pooled and then concentrated under reduced pressure to yield (R)-1-(4-((6-(2-methylthiazol-4-yl)pyrazolo[1,5-a]pyrazine-4 -yl)oxy)azepan-1-yl)prop-2-en-1-one (31.2 mg, yield 32%) was obtained. 1 H NMR (500 MHz, DMSO-d 6 ) δ ppm 8.67 (s, 1 H) 8.08 (s, 1 H) 7.96 (s, 1 H) 7.92 (rotamer, s, 1 H) 6.77 - 6.89 (m, 2 H) 6.14 - 6.20 (m, 1 H) 5.69 (ddd, J =10.22,7.48,2.44Hz,1 H) 5.52 - 5.62 (m, 1 H) 3.58 - 3.78 (m, 4 H) 2.74 (d, J =1.22Hz,3 H) 2.23 (ddt, J =10.91,7.25,3.43,3.43Hz,1 H) 1.87 - 2.09 (m, 4 H) 1.71 - 1.82 (m, 1 H).LCMS m / z = 384.0(M+H) + .

[0390] Example 77: (R)-1-(4-((6-(2-methylthiazol-5-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)propyl -2-en-1-one [ka]

[0391] Synthesis of tert-butyl (R)-4-((6-(2-methylthiazol-5-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate [ka] tert-Butyl=(R)-4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5 -a]pyrazin-4-yl)oxy)azepane-1-carboxylate (200 mg, 0.44 mmol), 5-bromo-2-methyl-thiazole (156 mg, 0.87 mmol), dihydrogen dichlorobis(di-tert-butylphosph) A solution of palladium (2-) (22 mg, 44 μmol) and cesium fluoride (199 mg, 1.3 mmol) was stirred at 90°C. After 16 hours, the reaction was quenched with water and brine. The biphasic mixture was extracted three times with ethyl acetate, then anhydrous MgSO 4 It was dried with. After filtration and concentration under reduced pressure, the crude tert-butyl(R)-4-((6-(2-methylthiazol-5-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy ) azepane-1-carboxylate (187 mg, assumed 100% yield) was carried forward without further purification. LCMS: m / z = 430.0(M+H) + .

[0392] (R)-1-(4-((6-(2-methylthiazol-5-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2-ene -1-one synthesis [ka] Step 1. Crude tert-butyl (R)-4-((6-(2-methylthiazol-5-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxy Lato (187 mg, 0.44 mmol) was dissolved in HCl solution (1.25 M in MeOH, 1.7 mL). The reaction solution was stirred at 40°C. After 16 hours, saturated NaHCO 3 The reaction was carefully quenched by slowly adding aqueous solution. The biphasic mixture was extracted three times with a mixture of chloroform and isopropanol (5:1), then anhydrous MgSO 4 It was dried with. After filtration and concentration under reduced pressure, the crude (R)-5-(4-(azepan-4-yloxy)pyrazolo[1,5-a]pyrazin-6-yl)-2-methylthiazole (143 mg, assumed (100% yield) was concentrated to dryness and proceeded without purification. LCMS: m / z = 330.0(M+H) + .

[0393] Step 2. 20 mL of crude (R)-5-(4-(azepan-4-yloxy)pyrazolo[1,5-a]pyrazin-6-yl)-2-methylthiazole (143 mg, 0.44 mmol) To the vial was added DCM (2 mL) followed by TEA (439 mg, 4.34 mmol, 605 μL). The reaction mixture was stirred at room temperature for 5 minutes, then cooled to 0°C. Acryloyl chloride (79 mg, 0.87 mmol, 71 μL) was added dropwise. The solution was stirred at 0°C. After 1 hour, saturated NH 4 The reaction mixture was carefully quenched by slowly adding aqueous Cl solution. The biphasic mixture was extracted three times with ethyl acetate, then anhydrous MgSO 4 It was dried with. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (25-100% ethyl acetate / heptane). The desired fractions were pooled and then concentrated under reduced pressure to yield (R)-1-(4-((6-(2-methylthiazol-5-yl)pyrazolo[1,5-a]pyrazine-4 -yl)oxy)azepan-1-yl)prop-2-en-1-one (29.8 mg, yield 18%) was obtained. 1 H NMR (500 MHz, DMSO-d 6 ) δ ppm 9.02 - 9.04 (m, 1 H) 8.25 (d, J =2.44Hz,1 H) 8.09 (dd, J =2.44,1.22Hz,1 H) 6.89 (d, J =3.05Hz,1 H) 6.81 (ddd, J =16.48,12.82,10.38Hz,1 H) 6.17 (ddd, J =16.63,7.48,2.75Hz,1 H) 5.70 (dt, J =10.38,2.44Hz,1 H) 5.38 - 5.44 ( LCMS m / z = 384.0(M+H) + .

[0394] Example 78: (R)-1-(4-((6-(3-methylisothiazol-5-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl) Prop-2-en-1-one [ka]

[0395] Synthesis of tert-butyl(R)-4-((6-(3-methylisothiazol-5-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepane-1-carboxylate [ka] tert-Butyl=(R)-4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5 -a]pyrazin-4-yl)oxy)azepane-1-carboxylate (80 mg, 175 μmol), 5-bromo-3-methyl-isothiazole (47 mg, 262 μmol), dihydrogen dichlorobis(di-tert-butylphosphinite) ) A solution of palladium(2-) (4.4 mg, 8.7 μmol) and cesium fluoride (80 mg, 524 μmol) was stirred at 90°C. After 16 hours, the reaction was quenched with water and brine. The biphasic mixture was extracted three times with ethyl acetate, then anhydrous MgSO 4 It was dried with. After filtration and concentration under reduced pressure, the crude tert-butyl (R)-4-((6-(3-methylisothiazol-5-yl)pyrazolo[1,5-a]pyrazin-4-yl) Oxy)azepane-1-carboxylate (75 mg, expected 100% yield) was carried forward without further purification. LCMS: m / z = 430.0(M+H) + .

[0396] (R)-1-(4-((6-(3-methylisothiazol-5-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1-yl)prop-2- Synthesis of en-1-one [ka] Step 1. Crude tert-butyl (R)-4-((6-(3-methylisothiazol-5-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)azepan-1- The carboxylate (75 mg, 175 μmol) was dissolved in HCl solution (1.25 M in MeOH, 1.4 mL). The reaction solution was stirred at 40°C. After 16 hours, saturated NaHCO3 The reaction was carefully quenched by slowly adding aqueous solution. The biphasic mixture was extracted three times with a mixture of chloroform and isopropanol (5:1), then anhydrous MgSO 4 It was dried with. After filtration and concentration under reduced pressure, the crude (R)-5-(4-(azepan-4-yloxy)pyrazolo[1,5-a]pyrazin-6-yl)-3-methylisothiazole (58 mg, (Estimated yield: 100%) was concentrated to dryness and proceeded without further purification. LCMS: m / z = 330.0(M+H) + .

[0397] Step 2. 20 mL of crude (R)-5-(4-(azepan-4-yloxy)pyrazolo[1,5-a]pyrazin-6-yl)-3-methylisothiazole (58 mg, 175 μmol) To the vial was added DCM (1.0 mL) followed by TEA (88 mg, 0.87 mmol, 122 μL). The reaction mixture was stirred at room temperature for 5 minutes, then cooled to 0°C. Acryloyl chloride (24 mg, 262 μmol, 21 μL) was added dropwise. The solution was stirred at 0°C. After 1 hour, saturated NH 4 The reaction mixture was carefully quenched by slowly adding aqueous Cl solution. The biphasic mixture was extracted three times with ethyl acetate, then anhydrous MgSO 4 It was dried with. After filtration and concentration under reduced pressure, the residue was loaded onto a silica gel column and purified (25-100% ethyl acetate / heptane). The desired fractions were pooled and then concentrated under reduced pressure to yield (R)-1-(4-((6-(3-methylisothiazol-5-yl)pyrazolo[1,5-a]pyrazine- 4-yl)oxy)azepan-1-yl)prop-2-en-1-one (21.3 mg, yield 32%) was obtained. 1 H NMR (500 MHz, DMSO-d 6 ) δ ppm 9.21 (d, J =1.22Hz,1 H) 8.15 (dd, J =2.44,1.22Hz,1 H) 7.80 (d, J =2.44Hz,1 H) 6.94 (d, J =3.05Hz, 1 H) 6.81 (dt, J =16.63,10.30Hz,1 H) 6.14 - 6.21 (m, 1 H) 5.69 (ddd, J =10.38,5.49,2.44Hz,1 H) 5.34 - 5.43 (m, 1 H ) 3.65 - 3.76 (m, 2 H) 3.53 - 3.64 (m, 2 H) 2.45 (s, 3 H) 2.17 - 2.29 (m, 1 H) 1.95 - 2.12 (m, 3 H) 1.86 - 1.93 (m, 1 H) 1.63 - 1.83 (m, 1 H).LCMS m / z = 384.0(M+H) + .

[0398] Example 79: N-Methyl-N-((1s,3s)-3-methyl-3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine- 4-yl)oxy)cyclobutyl)acrylamide [ka]

[0399] tert-Butyl=methyl((1s,3s)-3-methyl-3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy )Cyclobutyl)carbamate synthesis [ka] In a 100 mL 1-neck round bottom flask under nitrogen atmosphere equipped with a condenser, potassium hexamethyldisilazide (1 M in THF, 2.2 mL) was dissolved in tert-butyl =((1s,3s)-3 in dioxane (7.5 mL). -Hydroxy-3-methylcyclobutyl)carbamate (150 mg, 0.75 mmol) at room temperature. After 5 minutes, a solution of 4,6-dichloropyrazolo[1,5-a]pyrazine (128 mg, 0.68 mmol) in dioxane (2.5 mL) was added dropwise to the deep white suspension. Iodomethane (240 mg, 1.70 mmol, 105 μL) was added to the resulting orange suspension at room temperature and stirring was continued for an additional 30 minutes. The resulting reaction mixture was degassed by purging with nitrogen for 30 min, then a solution of tripotassium phosphate (531 mg, 2.50 mmol) in degassed water (2.5 mL) was added at room temperature. After purging the clear orange reaction mixture with nitrogen for an additional 10 min, 1-methyl-4-(4,4,5,5-tetramethyl-1,3, A solution of 2-dioxaborolan-2-yl)pyrazole (212 mg, 1.02 mmol) was added followed by solid Pd-PEPPSI™-IPr catalyst (93 mg, 0.14 mmol). After purging the reaction mixture with nitrogen for an additional 15 minutes, the reaction mixture was heated under reflux for 3 hours. Ethyl acetate (20 mL) was added to the vigorously stirred reaction mixture followed by water (20 mL). After 30 minutes, the organic phase was separated and the volatiles were removed under reduced pressure. The resulting residue was subjected to column chromatography (40 g silica gel, 0-80% [3:1 EtOAc:EtOH] + 2% NH 4 Purification by OH modifier / heptane) gave the title compound as a pale yellow oil (130 mg, 47% yield). LCMS m / z = 413.1 (M+H)+. 1 H NMR (500 MHz, methanol-d 4 )δppm8.42(s,1H),8.05(s,1H),7.93(s,1H),7.91(d,J=2.44Hz,1H),6.77(d,J=1.22 Hz, 1H), 4.10- 4.45 (m, 1H), 3.95 (s, 3H), 2.82 (s, 3H), 2.74-2.81 (m, 2H), 2.67 (br s, 2H), 1.81 (s, 3H), 1.46 (s, 9H) ).

[0400] (1s,3s)-N,3-dimethyl-3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutane-1 -Synthesis of amines [ka] tert-Butyl=methyl((1s,3s)-3-methyl-3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine) in HFIP (45 mL) To a solution of -4-yl)oxy)cyclobutyl)carbamate (4.05g, 9.82mmol) was added TFA (2.24g, 19.6mmol, 1.5mL) at room temperature. The resulting reaction mixture was stirred overnight. Add ethyl acetate (50 mL) followed by saturated NaHCO 3 Aqueous solution (25 mL) and brine (10 mL) were added. After stirring vigorously for 30 minutes, the organic phase was separated, dried over sodium sulfate, filtered and concentrated. The resulting residue was subjected to column chromatography (24 g silica gel, 80-100% [3:1 EtOAc:EtOH] + 2% NH 4 Purification by OH modifier / heptane) gave the title compound as a pale yellow gum (2.53 g, 82% yield). LCMS m / z = 313.1 (M+H)+. 1 H NMR (500 MHz, methanol-d 4 )δppm8.41(d,J=1.22Hz,1H),8.05(s,1H),7.86-7.97(m,2H),6.72-6.81(m,1H),3.95(s,3H),2.96-3.11 (m,1H),2.76-2.90(m,2H),2.31(s,3H),2.25-2.31(m,2H),2.25-2.31(m,2H),1.80(s,3H).

[0401] N-Methyl-N-((1s,3s)-3-methyl-3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl) Synthesis of oxy)cyclobutyl)acrylamide [ka] N-Methyl-N-((1s,3s)-3-methyl-3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]) in THF (50 mL) Acryloyl chloride (819 mg, 9.04 mmol, 740 μL) was added to a solution of pyrazin-4-yl)oxy)cyclobutyl)acrylamide (4.05 g, 9.82 mmol) and DIPEA (2.81 g, 21.7 mmol, 3.8 mL) at 0 °C. . After 30 min, the reaction mixture was diluted with EtOAc (50 mL) and saturated with NaHCO 3 Aqueous solution (50 mL) was added. The vigorously stirred biphasic mixture was brought to room temperature and stirring was continued for an additional 30 minutes. The organic phase was separated, washed with water (25 mL) and brine (25 mL), and washed with Na 2 S.O. 4 dried, filtered and concentrated. The resulting residue was subjected to column chromatography (80 g silica gel, 0-100% [3:1 EtOAc:EtOH] + 2% NH 4 OH modifier / heptane). The colorless solid was recrystallized from EtOAc / heptane (1 / 3, 45 mL) to give the title compound as a free-flowing crystalline solid (1.8 g, 68% yield). Melting point=137.5℃. LCMS m / z = 389.1.1 (M+Na)+. 1 H NMR (500 MHz, methanol-d 4 )δppm8.44(s,1H),8.06(s,1H),7.85-7.98(m,2H),6.67-6.85(m,2H),6.12-6.26(m,1H),5.74(brd,J= 9.16 Hz, 1H), 4.45-4.77 (m, 1H), 3.95 (s, 3H), 2.94-3.12 (m, 3H), 2.62-2.94 (m, 4H), 1.86 (s, 3H).

[0402] Example 80: N-((1s,3s)-3-((6-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)-3-methylcyclobutyl )-N-methylacrylamide [ka]

[0403] Synthesis of tert-butyl=((1s,3s)-3-((6-chloropyrazolo[1,5-a]pyrazin-4-yl)oxy)-3-methylcyclobutyl)(methyl)carbamate [ka] In a 100 mL 1-neck round bottom flask under a nitrogen atmosphere equipped with a condenser, potassium hexamethyldisilazide (1 M in THF, 6.8 mL) was dissolved in tert-butyl =((1s,3s)-3- in dioxane (25 mL). Added to a solution of hydroxy-3-methylcyclobutyl)carbamate (500 mg, 2.48 mmol) at room temperature. After a further 15 minutes, a solution of 4,6-dichloropyrazolo[1,5-a]pyrazine (425 mg, 2.26 mmol) in dioxane (7.5 mL) was added dropwise to the deep white suspension. After another 30 minutes, iodomethane (240 mg, 1.70 mmol, 105 μL) was added dropwise to the resulting orange suspension at room temperature and stirring was continued for 30 minutes. The reaction mixture was diluted with EtOAc (40 mL) and washed with water (30 mL). The organic phase was separated, concentrated under reduced pressure, and subjected to column chromatography (40 g silica gel, 0-80% [3:1 EtOAc:EtOH] + 2% NH 4 Purification by OH modifier / heptane) gave the title compound as a beige solid (555 mg, 67% yield). LCMS m / z = 367.1 (M+H)+.

[0404] tert-Butyl=4-(4-((1s,3s)-3-((tert-butoxycarbonyl)(methyl)amino)-1-methylcyclobutoxy)pyrazolo[1,5-a]pyrazin-6-yl )-1H-pyrazole-1-carboxylate synthesis [ka] tert-Butyl ((1s,3s)-3-((6-chloropyrazolo[1,5-a]pyrazin-4-yl)oxy)-3-methylcyclobutyl)(methyl)carbamate in dioxane (15 mL) (500 mg, 1.36 mmol) and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole-1-carboxylate (802 mg, 2.73 mmol). To the solution was added sequentially Pd-PEPPSI™-IPr catalyst (186 mg, 0.27 mmol), tripotassium phosphate (579 mg, 2.73 mmol) and water (3 mL). The resulting mixture was degassed by purging with nitrogen for 30 minutes. After heating under reflux for 1 h, the reaction mixture was cooled to room temperature and EtOAc (20 mL) and water (20 mL) were added. After stirring vigorously for 30 min, the organic phase was separated, washed with brine (20 mL), and washed with Na 2 S.O. 4 and concentrated under reduced pressure. Column chromatography (40g silica gel, 0-60%[3:1 EtOAc:EtOH]+2%NH 4 Purification of the crude residue with OH modifier / heptane) gave the title compound as an orange gum (640 mg, 94% yield). LCMS m / z = 499.2 (M+H)+.

[0405] Synthesis of (1s,3s)-3-((6-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)-N,3-dimethylcyclobutan-1-amine [ka]

[0406] tert-Butyl 4-(4-((1s,3s)-3-((tert-butoxycarbonyl)(methyl)amino)-1-methylcyclobutoxy)pyrazolo[1,5-a] in HFIP (5 mL) ]Pyrazin-6-yl)-1H-pyrazole-1-carboxylate (360 mg, 0.72 mmol) was added TFA (374 mg, 3.3 mmol, 250 μL) at room temperature. The resulting reaction mixture was stirred for 2 hours. Ethyl acetate (20 mL) was added at room temperature followed by saturated NaHCO 3 Aqueous solution (10 mL) and brine (10 mL) were added. After stirring vigorously for 30 minutes, the organic phase was separated, dried over sodium sulfate, filtered and concentrated. The resulting residue was subjected to column chromatography (12 g silica gel, 80-100% [3:1 EtOAc:EtOH] + 2% NH 4 Purification by OH modifier / heptane) gave the title compound as a colorless gum (162 mg, 75% yield). LCMS m / z = 299.0 (M+H)+.

[0407] N-((1s,3s)-3-((6-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)-3-methylcyclobutyl)-N- Synthesis of methylacrylamide [ka] (1s,3s)-3-((6-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)-N,3-dimethylcyclobutane in THF (5 mL) Acryloyl chloride (54 mg, 0.60 mmol, 50 μL) was added to a solution of -1-amine (162 mg, 0.54 mmol) and DIPEA (211 mg, 1.63 mmol, 290 μL) at 0°C. After 30 min, the reaction mixture was diluted with EtOAc (20 mL) and saturated with NaHCO 3 Aqueous solution (20 mL) was added. The biphasic mixture was brought to room temperature and vigorous stirring was continued for an additional 30 minutes. The organic phase was separated, washed sequentially with water (10 mL) and brine (10 mL), and washed with Na 2 S.O. 4 dried, filtered and concentrated. The resulting residue was subjected to column chromatography (12 g silica gel, 0-100% [3:1 EtOAc:EtOH] + 2% NH 4 Purification by OH modifier / heptane) gave the title compound as a colorless solid (65 mg, 34% yield). LCMS m / z = 375.1 (M+Na)+. 1 H NMR (500 MHz, methanol-d 4 ) δ ppm 8.39-8.48 (m, 1H), 8.07 (br s, 2H), 7.83-7.95 (m, 1H), 6.62-6.86 (m, 2H), 6.08-6.27 (m, 1H), 5.56-5.83 (m, 1H), 4.03-4.75 (m, 1H), 2.88-3.09 (m, 3H), 2.44-2.88 (m, 4H), 1.83 (m, 3H).

[0408] Example 81.1-(3-(2-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)oxy)ethyl)morpholino)prop-2 -en-1-on [ka]

[0409] 1.Synthesis of tert-butyl 3-(2-((methylsulfonyl)oxy)ethyl)morpholine-4-carboxylate [ka] TEA (1.1 eq.) was added to a solution of 6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-ol (1.0 eq.) in dry DCM (10 mL), Subsequently, mesyl chloride (1.05 eq.) was added and the reaction mixture was stirred for 14 hours. H the mixture 2 Wash with O (10 mL) and Na 2 S.O. 4 , filtered, and concentrated under vacuum to obtain the crude product, which was used directly in the next step.

[0410] 2.tert-butyl=3-(2-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)oxy)ethyl)morpholine-4- Synthesis of carboxylates [ka] 6-(1-Methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-ol (Intermediate C, Step 2, 1.0 eq.), Cs in dry DMF (1 mL) 2 C.O. 3 (1.1 eq.), tert-butyl 3-(2-((methylsulfonyl)oxy)ethyl)morpholine-4-carboxylate (1.0 eq.) was heated at 100° C. under Ar(g) for 16 hours. Reaction mixture with H 2 Diluted with O (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (10 mL) and washed with Na 2 S.O. 4 , filtered and concentrated under vacuum to give the crude product, which was used directly in the next step.

[0411] 3. Synthesis of 3-(2-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)oxy)ethyl)morpholine hydrochloride [ka] tert-Butyl = 3-(2-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)oxy)ethyl) in DCM (10 mL) To a solution of morpholine-4-carboxylate (1 eq.) was added 4M HCl in dioxane (10 eq.) and the resulting solution was stirred at 25° C. for 14 hours. The reaction mixture was concentrated under reduced pressure. The product was collected by filtration, washed with IPA (3 x 10 mL), and then dried under vacuum at 40 °C to give 3-(2-((6-(1-methyl-1H-pyrazol-4-yl). ) pyrazolo[1,5-a]pyridin-4-yl)oxy)ethyl)morpholine hydrochloride was obtained.

[0412] 4.1-(3-(2-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)oxy)ethyl)morpholino)prop-2-ene -1-one synthesis [ka] 3-(2-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)oxy)ethyl)morpholine hydrochloride ( DIPEA (1.1 eq.) was added to a solution of 1 eq.), the mixture was cooled to -10.degree. C., acryloyl chloride (1.05 eq.) was added, and the reaction was stirred at room temperature for 3 hours. The reaction mixture was washed with water (10 mL) and Na 2 S.O. 4 dried, filtered and concentrated under vacuum. The crude product was dissolved in DMSO (0.5 mL) and purified by preparative HPLC (Waters SunFire C18 19*100 5 mkm column) to give 1-(3-(2-((6-(1-methyl- 10.2 mg of 1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)oxy)ethyl)morpholino)prop-2-en-1-one was obtained. LCMS m / z = 382.2 (M+H)+.1H NMR (400 MHz, CDCl 3 ) δ ppm: 8.43 - 8.25 (m, 1H), 7.86 (s, 1H), 7.70 (s, 1H), 7.64 - 7.55 (m, 1H), 6.65 - 6.39 (m, 3H), 6.21 (dd, J =16.7, 1.8 Hz, 1H), 5.68 - 4.43 (m, 2H), 4.30 - 4.03 (m, 2H), 4.01 - 3.83 (m, 5H), 3.72 - 3.01 (m, 3H), 2.55 - 2.45 (m , 1H), 2.32 - 2.25 (m, 2H)

[0413] Example 82.N-(5-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)oxy)bicyclo[2.2.1]heptane- 2-yl)acrylamide [ka]

[0414] Following the steps described in Example 81, 6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-ol (Intermediate C, Step 2) and tert-butyl (5-hydroxybicyclo[2.2.1]heptan-2-yl)carbamate to N-(5-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine) -4-yl)oxy)bicyclo[2.2.1]heptan-2-yl)acrylamide was obtained. LCMS m / z = 378.2 (M+H)+.1H NMR(400 MHz, CDCl 3 ) δ ppm: 8.27 (s, 1H), 7.89 (d, J=2.4 Hz, 1H), 7.72 (s, 1H), 7.59 (s, 1H), 6.58 (d, J=2.5 Hz, 1H), 6.43 (s, 1H), 6.25 (d, J=16.8 Hz, 1H), 6.07 (dd, J=17.0, 10.2 Hz, 1H), 5.83 (d, J=7.3 Hz, 1H), 5.61 (d, J= 10.3 Hz, 1H), 4.91 - 4.83 (m, 1H), 4.47 - 4.38 (m, 1H), 3.98 (s, 3H), 2.78 - 2.72 (m, 1H), 2.72 - 2.65 (m, 1H), 2.07 (t, J=13.3, 13.3 Hz, 2H), 1.73 - 1.59 (m, 4H)

[0415] Example 83. (R)-1-(2,2-dimethyl-6-(((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl )oxy)methyl)morpholino)prop-2-en-1-one [ka]

[0416] Following a method similar to that described in Example 81, tert-butyl=(R)-6-(hydroxymethyl)-2,2-dimethylmorpholine-4-carboxylate and 6-(1-methyl-1H- Pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-ol (Intermediate C, Step 2) to (R)-1-(2,2-dimethyl-6-(((6-( 1-Methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)oxy)methyl)morpholino)prop-2-en-1-one was obtained. LCMS m / z = 396.2 (M+H)+.1H NMR (400 MHz, MeOH-d 4 ) δ ppm: 8.36 (s, 1H), 8.01 (s, 1H), 7.88 (s, 1H), 7.86 (d, J=2.4 Hz, 1H), 6.91 - 6.72 (m, 2H), 6.66 (s, 1H), 6.29 (dd, J=16.9, 8.1 Hz, 1H), 5.81 (dd, J=11.0, 5.6 Hz, 1H), 4.54 (dd, J=142.3, 13.0 Hz, 1H), 4.29 - 4.17 (m , 3.5H), 3.97 - 3.90 (m, 3.5H), 3.28 - 3.08 (m, 1H), 2.86 - 2.69 (m, 1H), 1.32 - 1.23 (m, 6H)

[0417] Examples 84 and 85.1-((1R,5S,6s)-6-(((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-4 -yl)oxy)methyl)-3-azabicyclo[3.1.1]heptan-3-yl)prop-2-en-1-one and 1-((1R,5S,6r)-6-(((3- Fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)oxy)methyl)-3-azabicyclo[3.1.1]heptan-3-yl) Prop-2-en-1-one [ka]

[0418] 1.Synthesis of tert-butyl 6-(((methylsulfonyl)oxy)methyl)-3-azabicyclo[3.1.1]heptane-3-carboxylate [ka] A solution of tert-butyl 6-(hydroxymethyl)-3-azabicyclo[3.1.1]heptane-3-carboxylate (1 g, 4.40 mmol) and TEA (1.34 g, 13.2 mmol) in DCM (20 mL) Methanesulfonyl (0.72g, 6.29mmol) was added and the reaction was stirred at 0°C for 1 hour. Water (10 mL) was added and the mixture was extracted with DCM (20 mL x 3). The combined organics were washed with brine (20 mL) and 2 S.O. 4 dried, filtered and concentrated under vacuum to give tert-butyl 6-(((methylsulfonyl)oxy)methyl)-3-azabicyclo[3.1.1]heptane-3-carboxylate (1.7 g, crude ) was obtained as a yellow oil. 1H NMR: (500MHz, DMSO-d 6 ) δ: 4.45 (d, J = 8.0 Hz, 1H), 4.16 (d, J = 7.5 Hz, 1H), 3.57-3.31 (m, 5H), 3.18 (d, J = 14.5 Hz, 3H), 2.50- 2.35 (m, 2H), 2.31-2.22 (m, 1H), 2.04-1.95 (m, 1H), 1.41 (s, 9H).

[0419] 2.tert-butyl=6-(((6-bromo-3-fluoropyrazolo[1,5-a]pyridin-4-yl)oxy)methyl)-3-azabicyclo[3.1.1]heptane-3- Synthesis of carboxylates [ka] Cs in a solution of 6-bromo-3-fluoropyrazolo[1,5-a]pyridin-4-ol (80 mg, 346 μmol) in DMF (4 mL). 2 C.O. 3(200 mg, 614 μmol) and tert-butyl 6-(((methylsulfonyl)oxy)methyl)-3-azabicyclo[3.1.1]heptane-3-carboxylate (212 mg, 693 μmol) were added, and the reaction mixture was heated to 100°C. The mixture was stirred for 1 hour. The reaction mixture was concentrated under vacuum and the crude product was purified by preparative TLC (PE:EtOAc=3:1) to give tert-butyl 6-(((6-bromo-3-fluoropyrazolo[1 ,5-a]pyridin-4-yl)oxy)methyl)-3-azabicyclo[3.1.1]heptane-3-carboxylate (100 mg, 56% yield) was obtained as a brown oil. LCMS m / z = 384.2 (M+H)+

[0420] 3.tert-butyl=6-(((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)oxy)methyl)-3 -Synthesis of azabicyclo[3.1.1]heptane-3-carboxylate [ka] tert-Butyl 6-(((6-bromo-3-fluoropyrazolo[1,5-a]pyridin-4-yl)oxy)methyl)-3-azabicyclo in dioxane (5 mL) and water (1 mL) [3.1.1]Heptane-3-carboxylate (90mg, 204μmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H- Pyrazole (60mg, 288μmol), K 2 C.O. 3 (85mg, 613μmol) and Pd(dtbpf)Cl 2 (13 mg, 20 μmol) in N 2 was purged for 1 minute and the reaction was stirred at 90° C. for 2 hours. The reaction mixture was concentrated under vacuum and the crude product was purified by Combiflash® eluting with EtOAc / PE from 0% to 100% to give tert-butyl 6-(((3-fluoro-6- (1-Methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)oxy)methyl)-3-azabicyclo[3.1.1]heptane-3-carboxylate (90 mg, 90%) was obtained as a yellow oil. LCMS m / z = 442.3 (M+H)+

[0421] 4.(1R,5S,6s)-6-(((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)oxy) methyl)-3-azabicyclo[3.1.1]heptane and (1R,5S,6r)-6-(((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5 Synthesis of -a]pyridin-4-yl)oxy)methyl)-3-azabicyclo[3.1.1]heptane [ka] tert-Butyl = 6-(((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)oxy) in DCM (2 mL) To a solution of methyl)-3-azabicyclo[3.1.1]heptane-3-carboxylate (85 mg, 193 μmol) was added HCl / EtOAc (4 M, 2 mL) and the reaction was stirred at 20° C. for 30 min. DIPEA (0.5 mL) was added dropwise and the reaction mixture was concentrated under vacuum. The crude product was subjected to preparative HPLC (column: Welch Xtimate C18 150×25mm×5μm; conditions: water (10mM NH 4 HCO 3 )-MeCN, 13-33%B, gradient time (min) 15, flow rate (mL / min) 25. ) to yield: the first eluting peak (E1) of a yellow oil, peak 1 (10 mg, 15% yield). LCMS m / z = 342.1 (M+H)+; and the second eluting peak (E2) of a yellow oil, peak 2 (30 mg, 47% yield). LCMS m / z = 342.1 (M+H)+

[0422] 5. Example 84: 1-((1R,5S,6s) or (1R,5S,6r)-6-(((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo Synthesis of [1,5-a]pyridin-4-yl)oxy)methyl)-3-azabicyclo[3.1.1]heptan-3-yl)prop-2-en-1-one [ka] (1R,5S,6s) or (1R,5R,6r)-6-(((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[ Acryloyl chloride (5.3 mg, 59 μmol) in a mixture of 1,5-a]pyridin-4-yl)oxy)methyl)-3-azabicyclo[3.1.1]heptane (10 mg, 29 μmol) and DIPEA (7.6 mg, 59 μmol) was added at 0° C. and the reaction was stirred for 10 minutes. MeOH (0.5 mL) was added dropwise and the reaction mixture was concentrated under vacuum. The crude product was purified by preparative HPLC (column: Welch Xtimate C18 150×25mm×5μm; conditions: water (10mM NH 4 HCO 3 )-MeCN, 21-41%B, gradient time (min) 10, flow rate (mL / min) 25. ) to purify 1-((1R,5S,6s) or (1R,5S,6r)-6-(((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo [1,5-a]pyridin-4-yl)oxy)methyl)-3-azabicyclo[3.1.1]heptan-3-yl)prop-2-en-1-one (3.0 mg, yield 26%) was obtained as a yellow oil. LCMS m / z = 396.1 (M+H)+.1H NMR (500MHz, MeOH-d 4 ) δ = 8.23 ​​(s, 1H), 8.06 (s, 1H), 7.90 (s, 1H), 7.76 (d, J = 3.5 Hz, 1H), 6.81-6.74 (m, 2H), 6.33-6.28 (m , 1H), 5.76 (dd, J1 = 2.0 Hz, J2 = 10.5 Hz, 1H), 4.28-4.16 (m, 2H), 4.01-3.91 (m, 5H), 3.81-3.73 (m, 2H), 2.97- 2.85 (m, 1H), 2.72 (t, J = 6.0 Hz, 2H), 2.30-2.23 (m, 1H), 1.50 (d, J = 9.5 Hz, 1H).

[0423] 6. Example 85: 1-((1R,5S,6r) or (1R,5S,6s)-6-(((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo Synthesis of [1,5-a]pyridin-4-yl)oxy)methyl)-3-azabicyclo[3.1.1]heptan-3-yl)prop-2-en-1-one [ka] Follow the procedure described in step 5 for (1R,5S,6r) or (1R,5S,6s)-6-(((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)) From pyrazolo[1,5-a]pyridin-4-yl)oxy)methyl)-3-azabicyclo[3.1.1]heptane and acryloyl chloride, 1-((1R,5S,6r) or (1R,5S,6s )-6-(((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)oxy)methyl)-3-azabicyclo[3.1 .1]heptan-3-yl)prop-2-en-1-one was obtained as a yellow oil in a yield of 10.2 mg and 29%. LCMS m / z = 396.2 (M+H)+.1H NMR (500MHz, MeOH-d 4 ) δ = 8.24 (s, 1H), 8.07 (s, 1H), 7.92 (s, 1H), 7.77 (d, J = 3.0 Hz, 1H), 6.90-6.72 (m, 2H), 6.35-6.31 (m , 1H), 5.80 (dd, J1 = 2.0 Hz, J2 = 10.5 Hz, 1H), 4.52 (d, J = 7.5 Hz, 2H), 4.10-3.98 (m, 2H), 3.96 (s, 3H), 3.91 -3.85 (m, 1H), 3.83-3.76 (m, 1H), 2.70-2.64 (m, 1H), 2.61-2.55 (m, 2H), 2.38-2.23 (m, 1H), 1.56-1.47 (m, 1H).

[0424] Example 86: 1-(6-((3-fluoro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)-6-methyl -2-Azaspiro[3.3]heptan-2-yl)but-2-yn-1-one [ka]

[0425] 1.tert-butyl=6-((6-chloro-3-fluoropyrazolo[1,5-a]pyrazin-4-yl)oxy)-6-methyl-2-azaspiro[3.3]heptane-2-carboxy Synthesis of Lato [ka] KOtBu (1.0 M in THF, 352 μL) was added to a solution of tert-butyl 6-hydroxy-6-methyl-2-azaspiro[3.3]heptane-2-carboxylate (80.0 mg, 352 μmol) in THF (3.0 mL). , the mixture was stirred for 5 minutes and then concentrated to dryness. The brown foamy solid was dissolved in THF (3 mL) and 4,6-dichloro-3-fluoro-pyrazolo[1,5-a]pyrazine (72.5 mg, 352 μmol) was added. The mixture was stirred at room temperature for 15 minutes and then at 40° C. for 75 minutes. The reaction mixture was then concentrated to dryness and purified directly by silica gel chromatography (heptane to EtOAc) to give tert-butyl 6-((6-chloro-3-fluoropyrazolo[1,5-a]pyrazine- 4-yl)oxy)-6-methyl-2-azaspiro[...

Claims

1. Compounds represented by formula (I'): 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, Het is phenyl, 5-6 membered heteroaryl or N-(C 1 -C 3 alkyl)pyridonyl, X 0 is N, and X 1 is C and X 2 is N, and X 4 is N or X 0 is CR 0 And X 1 is C and X 2 is N, and X 4 is N or X 0 is CR 0 And X 1 is N, and X 2 is C and X 4 is N or X 0 is CR 0 And X 1 is N, and X 2 is C and X 4 is CH or X 0 is CR 0 And X 1 is C and X 2 is N, and X 4 is CH, R 0 is H, halo, methyl, halomethyl, cyclopropyl, CN or phenyl; R 1 is H or C 1 -C 3 Alkyl, C 1 -C 3 -Alkoxy, C 1 -C 3 haloalkyl or a 4- to 7-membered monocyclic oxygen-containing heterocycle; R 3 is H or halo, X 3 Is, absent, CH 2 , C.H. 2 CH 2 , O, O-CH 2 *, O-CH 2 CH 2 *, NH, N(CH 3 ) - *, CH 2 N (CH 3 )-* or NH-CH 2 *, where "*" is R 2 indicates the point of attachment to X 3 is absent, CH 2 or CH 2 CH 2 If R 2 is connected to the bicyclic core or X via a ring nitrogen atom 3 ("N-linked") 4-12 membered monocyclic or bicyclic nitrogen-containing heterocycle, 3 CH 2 , C.H. 2 CH 2 , O, O-CH 2 *, NH, N(CH 3 ) - *, CH 2 N (CH 3 )-* or NH-CH 2 *, then R 2 is connected to X via a ring carbon atom 3 ("C-linked") 4-12 membered monocyclic or bicyclic nitrogen-containing heterocycle, 4-7 membered monocyclic or bicyclic oxygen-containing heterocycle, 3-12 membered monocyclic or bicyclic carbocyclyl, or 5-6 membered heteroaryl; X 3 is O-CH 2 -CH 2 *, then R 2 is absent, X through a ring carbon atom 3 or a 4-12 membered monocyclic or bicyclic nitrogen-containing heterocycle bonded to ("C-bonded") 1 -C 3 is an alkyl group, 2 If is absent, then X 3 is R 4 It is directly connected to R 2 the N-linked 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle represented by the formula: 1 -C 3 The alkyl group is R 4 and optionally substituted with a group represented by R 10 with the proviso that when said N-linked 4-12 membered monocyclic or bicyclic nitrogen-containing heterocycle contains two ring nitrogen atoms, R 2 The N-linked 4-12 membered monocyclic or bicyclic nitrogen-containing heterocycle represented by 5 and optionally N-substituted with a group represented by R 10 is further substituted with one or two groups represented by The C-linked 4-12 membered monocyclic or bicyclic nitrogen-containing heterocycle is R 5 and optionally N-substituted with a group represented by R 10 is further substituted with 1 to 3 groups represented by R 4 teeth, 【Chemistry 2】 and R 5 teeth, 【Chemistry 3】 and Each R 6 are independently H, CN, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, N(R a ) 2 or CH 2 N (R a ) 2 where each R a are independently H, C 1 -C 3 Alkyl or C 3 -C 6 is cycloalkyl, Each R 6 ' is independently H, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl or C 3 -C 6 is cycloalkyl, Each R 7 are independently H, C 1 -C 2 Alkyl, C 1 -C 2 Fluoroalkyl or C 3 -C 6 is cycloalkyl, R 8 is H or C 1 -C 3 is alkyl, Each R 10 Ha, Haro, C 1 -C 3 Alkyl or C 3 -C 6 is cycloalkyl, R 11 is H or N(R 12 ) 2 and Each R 12 are independently H or C 1 -C 3 is alkyl, R 13 is CN or F, R 14 is a halo, each n is independently 0 or 1; each p is independently 1 or 2; and q is 1 or 2.

2. The compound has the formula (I): 【Chemistry 4】 2. The compound according to claim 1, represented by the formula: R 0 is H, halo, methyl, halomethyl, cyclopropyl or CN; X 3 Is, absent, CH 2 , C.H. 2 CH 2 , O, O-CH 2 *, NH or NH-CH 2 *, where "*" is R 2 indicates the point of attachment to X 3 is absent, CH 2 or CH 2 CH 2 If R 2 is connected to the bicyclic core or X via a ring nitrogen atom 3 ("N-linked") 4-12 membered monocyclic or bicyclic nitrogen-containing heterocycle, 3 CH 2 , C.H. 2 CH 2 , O, O-CH 2 *, NH or NH-CH 2 *, then R 2 is connected to X via a ring carbon atom 3 ("C-linked") 4-12 membered mono- or bicyclic nitrogen-containing heterocycle, 4-7 membered monocyclic oxygen-containing heterocycle, or 3-12 membered mono- or bicyclic carbocyclyl; R 2 The N-linked 4- to 12-membered monocyclic or bicyclic nitrogen-containing heterocycle, the 4- to 7-membered oxygen-containing heterocycle and the 3- to 12-membered monocyclic or bicyclic carbocycle represented by R 4 and optionally substituted with a group represented by R 10 is further substituted with one or two groups represented by The C-linked 4-12 membered monocyclic or bicyclic nitrogen-containing heterocycle is R 5 and optionally N-substituted with a group represented by R 10 is further substituted with one or two groups represented by R 4 teeth, 【Chemistry 5】 and R 5 teeth, 【Chemistry 6】 and Each R 6 are independently H, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, N(R a ) 2 or CH 2 N (R a ) 2 where each R a is independently H or methyl; Each R 6 ' is independently H, C 1 -C 3 Alkyl or C 1 -C 3 is haloalkyl, Each R 7 are independently H, C 1 -C 2 Alkyl or C 1 -C 2 is a fluoroalkyl; Each R 10 is F or methyl).

3. The R 11 is H or NH 2 and (R 1 ) q -Het- is 【Chemistry 7】 3. The compound of claim 1 or 2, or a pharma- ceutically acceptable salt thereof, selected from:

4. The compound has one of the following formulas: 【Chemistry 8-1】 【Chemistry 8-2】 The compound according to any one of claims 1 to 3, represented by: or a pharma- ceutically acceptable salt thereof.

5. (i) X 3 is a bond, and R 2 is a 4-12 membered monocyclic or bicyclic nitrogen-containing heterocycle attached to the bicyclic core via a ring nitrogen atom; R 2 The 4-12 membered monocyclic or bicyclic nitrogen-containing heterocycle represented by R 4 and optionally substituted with a group represented by R 10 and optionally R 2 is a 7-10 membered bicyclic nitrogen-containing heterocycle attached to said bicyclic core via a ring nitrogen atom, said 7-10 membered bicyclic nitrogen-containing heterocycle represented by R 2 is substituted with a group represented by R 4 and optionally further substituted with one or two groups represented by R 10 ; or (ii) The compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, wherein R2 is a 4-7 membered monocyclic nitrogen-containing heterocycle attached to said bicyclic core via a ring nitrogen atom, and said 4-7 membered monocyclic nitrogen-containing heterocycle represented by R2 is substituted with a group represented by R4 and optionally further substituted with a group represented by R10.

6. 6. The compound of any one of claims 1 to 5, wherein the compound is represented by a structural formula selected from the following, or a pharma- ceutically acceptable salt thereof: 【Chemistry 9】 。

7. R 6 But, H, CH 3 or CH 2 The compound according to any one of claims 1 to 6, wherein R 4 is Cl, p is 2, and R 4 is CH 2 NHC(O)C≡CH, CH 2 NHC(O)CH═CH 2 , N(CH 3 )C(O)C≡CH, NHC(O)CH═CH 2 , NHC(O)C≡CH, or NHC(O)CH═CHCH 2 Cl, or a pharma- ceutically acceptable salt thereof.

8. X 3 But O, O-CH 2 *, O-CH 2 CH 2 *, NH, NH-CH 2 *, N(CH 3 ), or C.H. 2 N (CH 3 ) -*, and R 2 is connected to X via a ring carbon atom 3 ("C-bonded") 4-12 membered monocyclic or bicyclic nitrogen-containing heterocycle, said C-bonded 4-12 membered nitrogen-containing heterocycle being R 5 and optionally N-substituted with a group represented by R 10 The compound according to any one of claims 1 to 4, further substituted with 1 to 3 groups represented by:

9. R 2 is a 4-7 membered monocyclic ring, a 6-10 membered fused bicyclic ring, an 8-12 membered spirocyclic ring or a 7-10 membered bridged bicyclic ring, optionally containing one ring oxygen or one ring sulfur atom, and R 2 The C-linked 4-12 membered nitrogen-containing heterocycle represented by R 5 and optionally N-substituted with a group represented by R 10 and optionally (i) said C-linked 4-12 membered nitrogen-containing heterocycle represented by R 2 is further substituted with one or two groups represented by the formula: azatricyclo[4.1.1.03,7]octylene, azatricyclo[3.2.0]heptanylene, azatricyclo[3.1.1]heptanylene, azatricyclo[3.2.1]octanylene, azatricyclo[4.1.1.03,7]octylene, azatricyclo[3.2.0]heptanylene, azatricyclo[2.1.1]heptanylene, azatricyclo[2.1.1]hexanylene, azatricyclo[3.1.0]hexanylene, 2λ2-azaspiro[3.4]octylene or octahydrocyclopenta[c]pyrrolene, R said C-linked 4-12 membered nitrogen-containing heterocycle represented by R 2 is N-substituted with a group represented by R 5 and optionally further substituted with 1 or 2 groups represented by R 10 , or (ii) said C-linked 4-12 membered monocyclic or bicyclic nitrogen-containing heterocycle represented by R 2 is selected from: 【Chemistry 10-1】 【Chemistry 10-2】 9. The compound of any one of claims 1 to 4 and 8, or a pharma- ceutically acceptable salt thereof, wherein "**" indicates the point of attachment to X3 and "***" indicates the point of attachment to R5, and wherein each group represented by R2 is optionally further substituted with 1 to 3 groups represented by R10.

10. X 3 R is bonded to 2 The compound according to any one of claims 1 to 4 and 8 to 9, wherein the stereochemical configuration of the ring carbon atoms in the C-linked 4-12 membered nitrogen-containing heterocycle represented by the formula:

11. R 6 and R 6 ', independently, H, CH 3 or CH 2 Cl, p is 2, and R 5 is SO 2 CH=CH 2 , SO 2 CH=CHCH 3 , SO 2 CH=CHCH 2 Cl, SO 2 C≡CH, SO 2 C≡CCH 3 , SO 2 C≡CCH 2 Cl, COCH=CH 2 , COCH=CHCH 3 , COCH=CHCH 2 Cl, CO-C≡CH, CO-C≡CCH 3 , CO-C≡CCH 2 Cl, COCF=CH 2 , COCF=CHCH 3 , COCF=CHCH 2 Cl, 【Chemistry 11】 11. The compound according to any one of claims 1 to 4 and 8 to 10, wherein:

12. X 3 But O, O-CH 2 *, NH or NH-CH 2 * and R 2 is a 3- to 12-membered monocyclic or bicyclic carbocyclyl, a 4- to 7-membered monocyclic or bicyclic oxygen-containing heterocycle, or a 5- to 6-membered heteroaryl; R 2 The 3- to 12-membered monocyclic or bicyclic carbocycle, the 4- to 7-membered monocyclic or bicyclic oxygen-containing heterocycle and the 5- to 6-membered heteroaryl are represented by R 4 and optionally substituted with a group represented by R 10 and optionally said 4-7 membered monocyclic or bicyclic oxygen-containing heterocycle is oxabicyclo[3.1.1]heptanylene or tetrahydro-2H-pyranylene, each of which is substituted with a group represented by R 4 and optionally further substituted with 1 or 2 groups represented by R 10 ; and said 5-6 membered heteroaryl is pyridinylene substituted with a group represented by R 4 and optionally further substituted with 1-3 groups represented by R 10 , and R 2 is selected from the following: 【Chemistry 12】 (each of which is substituted with a group represented by R 4 and optionally further substituted with one or two groups represented by R 10 ), a compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof.

13. X 3 But O, O-CH 2 *, NH or NH-CH 2 * and R 2 is a 3- to 12-membered monocyclic or bicyclic carbocyclyl; R 2 The 3-12 membered monocyclic or bicyclic carbocyclic ring represented by R 4 and optionally substituted with a group represented by R 10 and optionally R 2 is phenylene, C 3 -C 7 cycloalkylene or C 6 -C 9 bicyclic saturated carbocycle, said phenylene, C 3 -C 7 cycloalkylene and C 6 -C 9 bicyclic saturated carbocycle represented by R 2 is substituted with a group represented by R 4 and optionally further substituted with one or two groups represented by R 10 , or a pharma- ceutically acceptable salt thereof.

14. X 3 is O; R 2 is phenylene, cyclobutylene, cyclohexylene, cyclopentylene, cyclopropylene, bicyclo[3.3.1]heptylene, bicyclo[2.2.1]heptanylene, bicyclo[4.1.0]heptanylene or bicyclo[2.1.1]hexanylene, each of which is substituted with a group represented by R 4 and optionally further substituted with one or two groups represented by R 10 ; and optionally R 2 is 【Chemistry 13】 14. The compound of any one of claims 1 to 4 and 13, or a pharma- ceutically acceptable salt thereof, wherein "**" indicates the point of attachment to X and "***" indicates the point of attachment to R, and the group represented by R is optionally substituted with 1 or 2 groups represented by R.

15. R 6 is H, CN, CH 3 , CH 2 Cl, CF 3 or CH 2 N(R a ) 2 , R a is each independently selected from -CH 3 and cyclopropyl, R 6 ' is H, CN, CH 3 , CH 2 Cl, CF 3 or cyclopropyl, and R 4 is NHC(O)CH═CH 2 , N(CH 3 )C(O)CH═CH 2 , NHC(O)CH═CHCH 3 , N(CH 3 )C(O)CH═CHCH 3 , N(CH 3 )C(O)CH═CHCN, NHC(O)C≡CH, N(CH 3 )C(O)C≡CH, N(H)C(O)C≡CCH 3 , N(CH 3 )C(O)C≡CCH3, N(CH2CH2F)C(O)CH=CH2, N(CH2CH2F)C(O)CH=CHCH3, N(CH2CH2F)C(O)C≡CH, N(CH2CH2 F)C(O)C≡CCH3, CH2N(CH3)C(O)CH=CH2, N(CH2CHF2)C(O)CH=CH2, N(CH3)C(O)CH=CHCH2Cl, NHC(O)CH=CHCF3, N(CH 3) C(O)CH=CHCF 3 , NHC(O)C≡C-cyclopropyl, NHC(O)CH=CHCH 2 N(CH 3 )-cyclobutyl, N(CH2CHF2)C(O)CH=CHCH2N(CH3)2, N(cyclopropyl)C(O)CH=CH2, N(CH3)C(O)CH2Cl, N(CH3)CH2CN, 【Chemistry 14】 15. The compound according to any one of claims 1 to 4 and 13 to 14, wherein the formula is (O)CH=CH 2 , or CH(CH 3 )NHC(O)CH=CH 2 , or a pharma- ceutically acceptable salt thereof.

16. X 3 R is bonded to 2 or a pharma- ceutically acceptable salt thereof.

16. The compound according to any one of claims 1 to 4 and 13 to 15, wherein the stereochemical configuration of the ring carbon atoms in the C-linked 3- to 12-membered carbocyclic ring represented by

17. X 3 and R 4 is in a trans or cis orientation, or a pharma- ceutically acceptable salt thereof.

18. X 3 But O-CH 2 CH 2 * and R 2 But, R 4 and optionally substituted with a group represented by R 10 C further substituted with 1 or 2 groups represented by 1 -C 3 is an alkyl group or R 2 But absent, X 3 But, R 4 and optionally R 2 is selected from **-CH 2 -***, **-CH 2 CH(CH 3 )-***, where "**" represents the point of attachment to X 3 and "***" represents the point of attachment to R 4 , and R 4 is N(CH 3 )C(O)CH═CH 2 , and optionally one or more of the following: (i) R 1 is H or C 1 -C 3 alkyl, C 1 -C 3 fluoroalkyl or a 4-7 membered monocyclic oxygen-containing heterocycle; (ii) R 0 is H, F, CN, CH 3 , CF 3 , cyclopropyl or phenyl; (iii) R 7 is selected from H, CH 3 , CH 2 CH 3 , CH 2 CHF 2 , and cyclopropyl; (iv) R 8 is H or CH 3 ; (v) R 10 is F, Cl, CH 3 or cyclopropyl, and (vi) R 14 is Cl.

19. The compound has the formula (XV): 【Chemistry 15】 2. The compound according to claim 1, represented by the formula: R 0 is H, halo or cyclopropyl; X 3 is O or O-CH 2 * and R 2 is a 4- to 7-membered monocyclic or bicyclic saturated carbocyclyl; R 2 The 4-7 membered monocyclic or bicyclic saturated carbocyclyl represented by R 4 and optionally one or two R 10 or R 2 is connected to X via a ring carbon atom 3 ("C-bonded") 7-9 membered bicyclic nitrogen-containing heterocycle, said C-bonded 7-9 membered bicyclic nitrogen-containing heterocycle being R 5 and optionally one or two R 10 is further substituted with R 4 is N(R 7 )C(O)C≡CCH 3 , N(R 7 )C(O)CH=CH 2 and R 5 is C(O)CH=CH 2 and R 7 is H, C 1 -C 2 Alkyl, or C 1 -C 2 is haloalkyl, R 10 is C 1 -C 3 (alkyl).

20. X 3 20. The compound of claim 19, or a pharma- ceutically acceptable salt thereof, wherein R2 is O; R2 is cyclobutylene, cyclohexylene, cyclopentylene, or bicyclo[2.1.1]hexanylene, each of which is substituted with a group represented by R4 and optionally further substituted with one or two R10; and R7 is H, CH3, or CH2CHF2.

21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 20 or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

22. A pharmaceutical composition for treating a disorder responsive to Bruton's tyrosine kinase inhibition in a subject, comprising an effective amount of a compound according to any one of claims 1 to 20.

23. 23. The method of claim 22, wherein the disorder is an autoimmune disorder, atopic dermatitis, leukemia or lymphoma.

24. 24. The method of claim 23, wherein the autoimmune disorder is rheumatoid arthritis or systemic lupus erythematosus.